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Abstract 
Breast cancer is a global health concern of high prevalence that lacks safe and 
effective therapies for advanced cases.  A targeted enzyme prodrug therapy aims to 
address this issue using an enzyme localized to the tumor to convert a systemically 
administered nontoxic prodrug into a toxic anticancer agent exclusively in the tumor.  
The target of the presented enzyme prodrug systems, phosphatidylserine, exists on 
cancer cells and the cells of the tumor vasculature.  Annexin V binds to 
phosphatidylserine with high affinity and was successfully fused to three enzymes for 
the targeted delivery of the enzyme prodrug systems to the tumor.  Development of the 
purine nucleoside phosphorylase fusion with annexin V is described, and results 
showing strong in vitro binding and promising cytotoxicity are presented.  This system 
is compared in vivo with targeted cytosine deaminase and targeted methioninase 
enzyme prodrug systems.  The methioninase system produced the strongest antitumor 
results showing tumor regression for the duration of treatment.  Further engineering of 
the system resulted in the generation of a mammalian cystathionine-γ-lyase protein with 
methioninase activity to prevent the immune response anticipated against foreign 
methioninase.  Successful transition to immune competent models without incurring an 
immune response led to studies with combination therapies to achieve an enhanced 
therapeutic effect.  Antitumor synergism was observed when the enzyme prodrug 
therapy was combined with rapamycin to address the hypoxic response.  Combination 
with immunostimulatory levels of cyclophosphamide produced an anti-metastatic 
response and enhanced survival.  Combination of the enzyme prodrug therapy with both 
xxii 
rapamycin and cyclophosphamide effectively reduced tumor volumes, inhibited 
metastatic progression, and enhanced survival.
1 
Chapter I: Introduction 
Breast Cancer Landscape and Project Overview 
Impact and Treatment of Breast Cancer 
Despite advancing technologies and enormous public health campaigns, one in 
eight women are still diagnosed with breast cancer [1, 2] and over 40,000 women die 
each year in the United States [3].  Breast tumor metastasis rather than primary tumor 
burden causes mortality in over 90% of cases; therefore, early detection should improve 
survival rates [1, 4].  While there is an inarguable decline in breast cancer death rates in 
recent decades [5], the relevance of these statistics and the standards of care responsible 
are a topic of debate.  A recent study claims 30% of breast cancer patients are 
overdiagnosed and overtreated, resulting in one to three deaths for every one life saved 
[1, 6, 7].  An improved breast cancer landscape depends upon enhanced diagnostic 
abilities as well as the development of revolutionary treatment regimens as safe and 
effective alternatives to the current standards of care. 
Oncologists utilize response rates specific to tumor type and stage to prescribe 
treatment regimens that attempt to find a middle ground between inadequate treatment 
efficacy and overtreatment, both of which have potentially fatal consequences.  Current 
standards of care include surgery, sentinel lymph node biopsy and surgery, radiation 
therapy, chemotherapy, hormone therapy, and targeted therapy [8].  Surgical options 
range from lumpectomy to radical mastectomy and are often dependent on lymph node 
biopsy. Surgical procedures are frequently preceded by neoadjuvant chemotherapy or 
followed by adjuvant radiation therapy, chemotherapy, or hormone therapy.  Difficulty 
in removing every cancer cell and recurrence limits the success of surgical resection [9, 
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10].  Radiation therapy uses high-energy radiation from either internal or external 
sources to kill cancer cells.  Chemotherapy drugs kill cancer cells or inhibit growth, 
either through systemic or regional administration.  The FDA has approved dozens of 
chemotherapeutic agents and drug combinations for the treatment of breast cancer [8].  
Tumor access, drug sensitivity, local and systemic toxicities, and development of 
resistance constrain chemotherapy and radiotherapy efficacies [11-13].  Targeted 
therapies attempt to identify and attack cancer cells without impacting normal cells.  
Exploitation of the hormone dependence of a subset of breast cancers, specifically 
estrogen dependence, has led to the development of hormone therapies including 
tamoxifen and aromatase inhibitors [8].  Other targeted approaches for breast cancer 
treatment include monoclonal antibodies, tyrosine kinase inhibitors, and poly(ADP 
ribose) polymerase (PARP) inhibitors.  Most FDA approved targeted drugs for breast 
cancer (Trastuzumab, Pertuzumab, Ado-trastuzumab emtansine, Lapatinib) are only 
indicated for HER2-positive breast cancer (20% of cases) [5, 8].  Recent approval of 
mTOR-targeted Everolimus expands targeted breast cancer treatment to HER2-negative 
breast cancer, though it is only indicated in advanced hormone receptor-positive breast 
cancer in combination with exemestane and after failed responses to letrozole or 
anastrozole [8].   
 
Directed Enzyme Prodrug Strategy 
As research continues to unravel the “molecular circuitry” behind cancers and 
identifies more specific targets, targeted therapies will likely enhance the duration and 
quality of life of cancer patients beyond the current achievable levels with creative 
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approaches including toxic payload delivery, signaling attenuation, immune stimulation, 
and combination strategies [14-16].  One targeted adaptation of a toxic payload delivery 
with promising results involves the local activation of chemotherapeutic prodrugs to 
limit toxicity to the tumor environment using enzyme prodrug therapies [11, 17].  
Enzyme prodrug strategies localize an enzyme to the tumor microenvironment either 
through gene delivery (gene-directed enzyme prodrug therapy; GDEPT) [18, 19], 
antibody targeting (antibody-directed enzyme prodrug therapy; ADEPT)  [20, 21], local 
administrations, or even with cellular delivery systems  [11, 22, 23].  Once the enzyme 
is localized to the tumor environment, a relatively nontoxic prodrug is administered that 
is then enzymatically converted to a toxic drug in the tumor.  Table 1 lists the features 
exhibited by an ideal enzyme prodrug combination. 
  
Table 1.  Features of an ideal enzyme prodrug combination summarized from 
Greco and Dachs [17] 
Enzyme Prodrug Drug 
Non-toxic (in absence of 
prodrug) 
No activation by processes 
in normal tissue 







Cytotoxicity should be cell-
cycle and proliferation 
independent 
Efficient prodrug activation 
(high Kcat, low Km) in 
physiological conditions 
Suitable stability for 
systemic administration 
Suitable stability to allow 
for diffusion and bystander 
effect (half-life should be 
>1 min to allow diffusion 
100-200 µm in tumor [24]) 
 
Enzyme prodrug therapies attempt to achieve a high therapeutic index and 
therapeutic selectivity through the generation of toxic levels of drug from inert prodrug 
at the tumor cells [18, 19]. Current enzyme prodrug systems face limitations, 
particularly GDEPT and its derivative VDEPT (virus-directed enzyme prodrug 
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therapy).  Most significantly, gene delivery strategies suffer from poor gene expression 
in vivo; however selective delivery, insertional mutagenesis, and immunogenicity are 
persistent concerns as well [25-27].  Delivery of active enzyme (as in ADEPT 
strategies) circumvents expression issues; however antibody-enzyme conjugate 
accessibility to the tumor antigen limits antibody delivery approaches [25, 28].  Another 
drawback of ADEPT systems is the cost involved in producing and purifying sufficient 
quantities of antibody conjugates [25]. 
The projects discussed in this dissertation are enzyme prodrug systems targeted 
to phosphatidylserine, expressed externally on cancer cells and tumor vasculature, 
through the fusion of the enzyme to annexin V or annexin I, both of which bind to 
phosphatidylserine with high affinity.  Figure 1 outlines the scheme of a 
phosphatidylserine targeting enzyme prodrug therapy. Our target, phosphatidylserine, 
allows for delivery of active enzyme to the tumor vasculature, overcoming the 
permeability issues plaguing most ADEPT approaches.  Fusions of enzyme to annexin I 
or annexin V allow for high affinity targeting of phosphatidylserine on the tumor 
vasculature using well established and inexpensive bacterial expression systems.  
Delivery of cytotoxic payloads to the vascular wall results in destruction of tumor 
endothelial cells and vessel occlusion, hence cutting off the nutrient and oxygen supply 
to the tumor.  The membrane diffusibilty of the small molecule cytotoxic agents allows 
for permeation into the tumor and a bystander killing effect of the surrounding tumor 
cells [29-35]. 
Three targeted enzyme prodrug systems, summarized in Table 2, were 
developed and evaluated in vitro (two previously [36, 37]) and in vivo.  Binding 
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strength, stability, and cytotoxicity were the primary criteria evaluated in vitro using 
several breast cancer cell lines and endothelial cells.  Tumor progression and survival 
were the primary criteria evaluated in vivo using immune-deficient SCID mice and 
immune-competent BALB/cJ mice.  The most efficient system, methionine-γ-lyase 
fused to annexin V (Met-AV) was then adapted to an immune competent model using 





Figure 1. Outline of enzyme prodrug system targeted to phosphatidylserine.   
The first phase of the treatment is to administer the targeted enzyme.  The fusion 
protein, containing annexin I (AI) or annexin V (AV) at the carboxy terminus, will be 
localized to tumor and tumor vasculature.  AI and AV bind to externally expressed 
phosphatidylserine (PS) expressed on the endothelial cells of tumor vasculature and 
tumor cells.  The second step, following plasma clearance of the fusion protein, is the 
administration of a non-toxic dose of prodrug.  The prodrug will be converted to toxic 




Table 2.  Enzyme prodrug systems targeted to phosphatidylserine. 
Enzyme Species Substrate 
(Prodrug) 
Products 













































Enzyme Prodrug Therapies 
Cytosine Deaminase and 5-Fluorocytosine 
Mammalian cells exposed to 5-fluorouracil (5-FU) convert the molecule to the 
toxic pyrimidine antimetabolites, 5-FdUMP, 5-FdUTP, and 5-FTUP.  These 
antimetabolites inhibit thymidylate synthase and misincorporate into RNA and DNA 
resulting in 5-FU RNA/DNA complex formations and eventual cell death [17, 38, 39].  
Though a high dose is required for tumor response, 5-FU is currently used as a 
chemotherapeutic and radiosensitizer for the treatment of some solid tumors, including 
breast, gastrointestinal, ovary, head, and neck tumors [40, 41].  The high systemic 
chemotherapeutic dose administered causes a range of side effects, primarily 
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gastrointestinal and hematological, supporting the advantages of 5-FU localization to 
the tumor as in the enzyme prodrug therapies [42, 43].   
Cytosine deaminase (CD) is a component of the pyrimidine salvage pathway in 
bacteria and yeast [44].  The enzyme catalyzes the hydrolytic deamination of cytosine to 
uracil, as well as 5-fluorocytosine (5-FC) to 5-FU which does not occur with the 
mammalian pyrimidine salvage enzyme, cytidine deaminase [17, 44].  The prodrug, 5-
FC, is fairly nontoxic and is approved for use as an antifungal/antimicrobial agent [17, 
45].  Cell and tumor sensitivity to the drug, 5-FU, is up to 2000x greater than the 
sensitivity to 5-FC [46].  5-FU readily diffuses across cell membranes through non-
facilitated diffusion [30, 47, 48], resulting in significant bystander effects without the 
requirement of cell to cell contact [48].   
The lack of human cytosine deaminase and the cytotoxicity of 5-FU has 
generated significant interest in CD for a number of ADEPT [49-51] and GDEPT [52-
54] strategies.  More recent enzyme prodrug applications utilize yeast CD, as it was 
found to have a 22x stronger binding affinity to its substrate and a 4x faster reaction rate 
than bacterial CD when 5-FC is used as the substrate [55].  Though primarily a cell 
cycle dependent mechanism and a relatively low potency compared to other enzyme 
prodrug strategies, 5-FU generation within a tumor using an enzyme prodrug approach 
has shown significant promise for the treatment of multiple types of cancer. 
 
Purine Nucleoside Phosphorylase and Fludarabine Phosphate 
Fludarabine phosphate (9-β-D-arabinofuranosyl-2-fluoroadenine 5’-
monophosphate, 2-Fluoro-ara-AMP, F-ara-AMP), a purine nucleoside analogue, is an 
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approved treatment for chronic lymphocytic leukemia [56-59].  Fludarabine phosphate 
has undergone numerous clinical trials for treatment of both solid tumors and leukemia; 
however success was hindered by dose limiting factors including myelosuppression and 
neurotoxicity when treating solid tumors [59, 60].   
More recently, fludarabine phosphate has become the subject of study as the 
prodrug for enzyme prodrug systems as therapies for cancers such as glioma [61], 
prostate [62, 63], bladder [64], and liver [65] and is currently undergoing a phase 1 
clinical trial for local administrations of adenovirus delivered purine nucleoside 
phosphorylase (PNP) for head and neck cancers.  In vivo PNP gene delivery studies 
used intraperitoneal fludarabine doses ranging from 37.5 mg/kg/day [62, 65] to 450 
mg/kg/day [66] in mouse models.  Minimal effect was attained by fludarabine alone, 
but results were positive with the conversion to 2-fluoroadenine by the enzyme prodrug 
therapies.  No signs of systemic toxicity or negative side effects were reported at these 
doses in either the groups with fludarabine or fludarabine with PNP.  The GDEPT 
clinical trial has reported no serious adverse events or toxicities and a pronounced effect 
on tumor volumes in some patients using only 60% of the standard prescribed 
fludarabine doses [67].  Despite early successes, the current untargeted GDEPT 
approach requires local gene administration, leaving distant sites primarily unaffected 
and severely limiting future clinical utility. 
The Escherichia coli enzyme PNP cleaves the ribose-1-phosphate group from 
fludarabine, resulting in 2-fluoroadenine [68, 69] which inhibits protein, RNA, and 
DNA synthesis [70].  Fludarabine is not a substrate for the human PNP [44, 68, 71, 72]; 
therefore undesired systemic production of 2-fluoroadenine from fludarabine is not a 
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concern.  2-fluoroadenine toxicity to cancer cells occurs at a concentration several 
orders of magnitude below that required for the same effect from fludarabine [73], 
partially stemming from the requirement of membrane transport carriers to allow 
fludarabine to cross the cell membrane in contrast to the free diffusion of 2-
fluoroadenine across membranes.  This allows for the systemic administration of 
fludarabine significantly below problematic levels while improving the cytotoxic effect 
at the site of the tumor.  Figure 2 summarizes the treatment mechanism for a PNP 
molecule targeted to the outside of a cell using annexin V, with fludarabine as the 
prodrug. 
One advantage of this enzyme prodrug therapy is that there is a significant 
bystander effect of the 2-fluoroadenine generated against both proliferating and non-
proliferating cells [70, 74].  The bystander effect results from the ability of 2-
fluoroadenine to freely diffuse across cell membranes, eliminating the need for PNP to 
be present in each individual cell.  This property helps to alleviate transfection 
efficiency problems of studies using suicide gene-directed enzyme prodrug therapies 
(GDEPT) [63] and viral-directed enzyme prodrug therapies (VDEPT) [61, 62, 65].  
Additionally, unlike the products of some other enzyme prodrug systems, 2-
fluoroadenine is toxic to proliferating and non-proliferating cells [70].  A PNP based 
enzyme prodrug system therefore addresses two limitations of many systems: bystander 




Figure 2.  PNP-AV mechanism of action.   
Fludarabine monophosphate is converted in serum to a dephosphorylated form by a 5’ 
nucleotidase [75]. PNP attached to the cell surface via annexin V, and 
phosphatidylserine binding then cleaves the ribose-1-phosphate group, resulting in 2-
fluoroadenine [68, 69]. The freely diffusible molecule enters the cell and inhibits 
protein, RNA, and DNA synthesis [70]. Nucelotide-specific membrane transport 
carriers transport the dephosphorylated form across the cell membrane, where it is then 




Methionine-γ-Lyase and Selenomethionine 
Methionine-γ-lyase (methioninase, Met) catalyzes the production of 
methanethiol, α-ketobutyrate, and ammonia from L-methionine [76] and methylselenol, 
α-ketobutyrate, and ammonia from L-selenomethionine [77].  The most active 
methioninases have been purified from Brevibacterium linens BL2, Psuedomonas 
putida and Aeromonas sp., though P. putida showed maximum catalytic efficiency [78-
81].  The enzyme from P. putida has been utilized in two anti-cancer capacities: using 
methionine as the substrate for methionine depletion therapies, and selenomethionine as 
the substrate for enzyme prodrug therapies.   
Asparaginase and glutaminase successfully treat some forms of L-glutamine and 
L-asparagine dependent leukemias [80, 82, 83], with a similar strategy in development 
for L-methionine dependent tumors.  Methioninase anticancer therapies were first 
developed as an effective tool for L-methionine depletion of tumors with success found 
both in vitro and in vivo [84-88].  Methioninase-aided depletion of L-methionine 
enhances the effects of dietary replacement of methionine with homocysteine which 
results in normal growth of healthy cells [89] but restricted growth of cancer cells [88, 
90, 91].  These therapies function on the basis that healthy cells are capable of 
manufacturing methionine from homocysteine and therefore are methionine 
independent [92-94]; however, many cancer cells are methionine dependent including 
some bladder, brain, colon, kidney, lung, hematological, neurological, and breast 
cancers [90, 92, 95-98].  Reduced levels of methionine synthase, responsible for the 
methylation of homocysteine in the methionine synthesis process, results in methionine 
dependence of some cancer cells and sensitivity to methionine depletion therapies [99, 
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100].  Further studies have reported additional mechanisms for the development of 
methionine dependence of cancer cells, including loss of the methionine salvage 
pathway enzyme methylthioadenosine phosphorylase, which is genetically located in 
close proximity to the p15 and p16 tumor suppressor genes and frequently co-deleted 
[101].  
Methioninase is found in nearly every organism except mammals [80, 102], and 
its products are significantly more toxic than its substrate, making it a strong candidate 
for an enzyme prodrug therapy.  Methylselenol, a product of the reaction with 
selenomethionine, is 200-1000 times more cytotoxic to cancer cells than 
selenomethionine [87, 103] and diffuses through membranes, producing a significant 
bystander effect [80, 103].  The presence of methylselenol in cancer cells causes cell 
cycle arrest and apoptosis primarily through the oxidation of thiols and generation of 
superoxides [103-109].  The reactive oxygen species cause mitochondrial swelling 
resulting in increased permeability, loss of membrane potential, and release of 
cytochrome c which activates the caspase cascade and induces apoptosis [103, 110-
112].  Alone, selenomethionine is relatively non-toxic to mammalian cells because it is 
not converted to selenol [113, 114] and is one form of dietary selenium supplementation 
[115].  The lack of a mammalian methioninase, strong cytotoxic effect of 
methylselenol, and significant bystander effect suggest a methioninase-based system 




Targeting Cancer Therapeutics to Phosphatidylserine 
Phosphatidylserine, a cell membrane constituent, is found primarily on the 
inside of cells except on cancer cells and the tumor vasculature, where it has been 
externalized.  Philip Thorpe’s group at the University of Texas Southwest Medical 
Center in Dallas initiated phosphatidylserine targeting as an anti-cancer strategy and 
with Peregrine Pharmaceuticals developed the anti-phosphatidylserine monoclonal 
antibody bavituximab.  Clinical trials have been performed or are currently undergoing 
with lung, breast, and pancreatic cancers primarily in combination with a cytotoxic 
agent (gemcitabine, docetaxel, or paclitaxel and carboplatin).  Our lab has instead 
utilized the smaller native protein, annexin V (AV), which has a strong affinity for 
phosphatidylserine and coupled it to an enzyme for use in enzyme prodrug therapies.  
Additionally, preliminary studies with annexin I (AI) targeted to phosphatidylserine 
have been conducted.  The annexins bind to phosphatidylserine expressed externally on 
tumor cells [116-118] and endothelial cells of tumor vasculature, but not normal 
vascular endothelial cells [119, 120].  Expression of the target on both the cancer cells 
and tumor vascular endothelium provides a significant advantage because the tumor is 
affected through the targeted cytotoxic mechanism as well as nutrient and oxygen 
deprivation resulting from vessel infarction [121].  Additionally, the endothelium does 
not exhibit the severe genetic instability that frequently results in acquisition of 




Phosphatidylserine is an anionic membrane phospholipid that constitutes 8 to 
15% of cellular phospholipid content [123]; however it is maintained almost exclusively 
on the inner leaflet of the cell membrane in healthy mammalian cells [124, 125].  A 
series of enzymes maintains the asymmetric localization of phosphatidylserine within 
the cell membrane.  A family of ten aminophospholipid translocases (flippases) 
transports lipids (primarily the anionic phospholipids phosphatidylserine, 
phosphatidylethanolamine, phosphatidic acid, and phosphoinositides) to the internal 
leaflet in an ATP-dependent manner, transporting polar phospholipid heads through the 
hydrophobic membrane core against concentration gradients [126, 127].  A different 
family of enzymes (floppases) is responsible for transport of lipids (primarily cationic 
phospholipids) to the external membrane leaflet [116, 128].  Scramblase promotes the 
collapse of asymmetry through bidirectional transport of both cationic and anionic 
phospholipids and is typically activated when a cell undergoes apoptosis or upon 
cellular Ca
2+
 influx [123].  Under normal conditions flippases are highly efficient and 
quickly shift anionic phospholipids to the internal membrane leaflet, particularly 
phosphatidylserine which found exclusively on the inner leaflet [125, 129-132]. 
Phosphatidylserine externalization does occur in several processes including 
platelet activation, cell aging, degranulation, apoptosis, necrosis, and malignancy and 
has also been associated with sickle cell anemia, thalassemia, malaria, uremia, diabetes, 
pre-eclampsia, hepatitis C, HIV, and measles [123, 133-137].  Targeting anti-cancer 
therapeutics to phosphatidylserine has generated research interest since a number of 
tumor cells have been found to significantly increase levels of externalized 
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phosphatidylserine, possibly through dysfunction of the pathways responsible for 
maintenance of membrane asymmetry [116, 117, 119, 138-144].  The altered regulatory 
pathways resulting in phosphatidylserine externalization provide benefit to cancer cells 
and tumors as a whole, as phosphatidylserine externalization is a natural mechanism for 
immune suppression to allow clearance of dying cells without inflammation [145-147].  
Additionally, tumor vascular endothelium externalizes phosphatidylserine [148], likely 
resulting from the tumor microenvironment.  Acidity, hypoxia, reactive oxygen species, 
and inflammatory conditions are associated with the tumor microenvironment and have 
been found to increase phosphatidylserine externalization in vitro in endothelial cells 
[119, 120, 148]. 
 
Annexin Protein Family 
The annexin superfamily consists of 13 proteins that bind calcium and 
phospholipid and exhibit significant structural and biological homologies [149-151].  
To some degree most annexins bind phosphatidylserine, phosphatidic acid, and 
phosphatidylinositol, but minimal binding is seen with phosphatidylethanolamine, 
phosphatidylcholine, and sphingomyelin [150].  The C terminal of the protein core is a 
34 kDa domain conserved among the annexins and is responsible for both membrane 
and calcium binding [150, 152].  The N terminal domain varies among the family of 
proteins and can provide differing functionalities.  The project discussed in this 
dissertation primarily uses annexin V as the targeting component of the fusion protein; 
however annexin I has also been evaluated.   
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Annexin I is one of the longer annexins and has been shown to form aggregates 
on membranes.  Specifically, once the core protein has bound a phosphatidylserine 
molecule, the N terminal domain is capable of binding a second phosphatidylserine, 
another annexin I molecule, and a different calcium binding protein, S100 [149, 150].  
The resulting enhanced avidity may improve overall binding of the complexes [152].  
When excreted, annexin I will bind externally to anionic phospholipids in the cell 
membrane causing anti-migratory and anti-inflammatory responses [149].  The 
capability of annexin I to bind multiple phosphatidylserine molecules has been 
theorized to play a role in tethering apoptotic cells to phagocytes [149, 153]. 
Annexin V is one of the smallest members of the annexin family and has only a 
few amino acids in the N terminal variable region of the protein [150].  Annexin V has 
been implicated as an anti-inflammatory molecule, an anticoagulant, and plays a role in 
ion channel activity and membrane fusion [150, 154].  Fusions and tagging of annexin 
V have been performed and are available commercially, primarily for its utility in 
detecting apoptotic cells [155, 156].  The annexin V binding to phosphatidylserine may 
also be involved in promoting the non-inflammatory clearance of apoptotic cells. 
   
Clinical Relevance of Phosphatidylserine Targeted Therapies 
While the annexin targeted enzyme prodrug therapies possess the capacity to 
bind to phosphatidylserine on the cancer cells, data suggests the localization of the 
enzyme and annexin fusion protein primarily on the tumor vasculature [157].  
Vascularization is crucial for progression of tumors beyond 1-2 mm
3
 due to the limits of 
diffusion for the oxygen and nutrients necessary for cell survival [158-160].  The 
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dependence of nearly all solid tumors (including colon, lung, breast, cervix, bladder, 
prostate, and pancreas) on vascularization [160] indicates that phosphatidylserine 
targeted therapies are not limited to breast cancer (the focus of this work) and could be 
applied to other solid tumor-forming cancers and for the treatment of metastatic lesions 
[118].   
 
Summary of Targeting Strategy 
Significantly enhanced phosphatidylserine exposure on cancer cells and tumor 
vasculature presents a unique therapeutic target present both in the tumor, its supporting 
vasculature, and possibly metastatic sites of multiple types of cancer.  The annexin 
family of proteins, most commonly used in research for detection of apoptotic cells, 
exhibit strong binding properties to phosphatidylserine and similar anionic 
phospholipids.  Annexin I and annexin V were selected as targeted delivery vehicles for 
enzyme prodrug systems, which, through the fusion of the enzyme to the annexin 
protein, allows for localization of the enzyme to the tumor. 
  
Overcoming Protein Immunogenicity 
Immunogenicity is a major concern for therapeutic protein products.  Generation 
of an immune reaction results from a number of subject-specific and product-specific 
factors.  Adverse immunological reactions can be unpredictable and can result in 
neutralizing antibodies that render a therapy ineffective, produce anaphylactic responses 
potentially leading to death, or elicit cross-reactive responses that turn the immune 
system against native proteins [161]. 
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 The subject-specific response can be dependent on the route of administration, 
dose, frequency of administration, allergy, immune competency, and prior sensitization 
or tolerance [161].  Product or protein-specific factors include protein origin, size and 
structure, product purity, and presence of post-translational modification [161].  
Subject-specific responses are addressed primarily through appropriate development of 
dosing regimens and recognition of therapeutic contraindications.  The protein-specific 
factors require significant attention and development primarily during the preclinical 
phases of evaluation. 
FDA approval of biologics includes human, murine, chimeric, and humanized 
antibodies, as well as recombinant, recombinant human, and even bovine products 
[162].  Approved therapeutic proteins fall in a large range of sizes using varied 
production systems and purification techniques; however large non-mammalian proteins 
present major obstacles preventing clinical use (though possible, as evidenced by FDA 
approved PEGylated forms of bacterial asparaginase and adenosine deaminase [163]).  
Table 3 summarizes the expected degree of immune response to foreign proteins based 
on size, emphasizing a strong expected immune response for foreign proteins over 100 
kDa.  The large structures of the enzyme component of the enzyme prodrug systems, 
shown in the models in Figure 3 and summarized in Table 4, combined with the non-
mammalian origin of CD, PNP, and Met suggest a strong degree of immunogenicity.  
To ultimately progress beyond the preclinical phase, enzyme prodrug therapies must 
address the immunogenicity concerns stemming from the need to use enzymes not 
present in normal tissue to avoid off-target prodrug activation.  Two major strategies 
exist to address immunogenicity, both of which have been utilized for current FDA 
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approved products: PEGylation and protein engineering to exhibit stronger similarities 
to human proteins.   Both PEGylation and protein engineering strategies were pursued 
to reduce the immunogenicity of the enzyme prodrug systems. 
 
Table 3.  Size-relationship to immunogenicity of 
foreign proteins adapted from [164] 
Molecular Weight Amino Acids Immunogenicity 
< 1 kDa 1-10 Rare 
1-10 kDa 10-100 Weak 
10-100 kDa 100-1000 Immunogenic 







Figure 3.  Ribbon structures of fusion protein components.  
The PyMOL Molecular Graphics System (version 1.2r3pre; Schrödinger, LLC) 
generated protein ribbon structures using data files obtained through the Protein Data 




Table 4.  Fusion protein molecular weights 
Fusion Protein Monomer Subunits Multimer 
CD-AV 53 kDa dimer 106 kDa 
PNP-AV 65 kDa hexamer 390 kDa 
Met-AV  80 kDa tetramer 320 kDa 
mCGL-AI 83 kDa tetramer 332 kDa 
mCGL-AV 80 kDa tetramer 320 kDa 
 
 
Conjugation of hydrophilic poly(ethylene glycol) (PEG) to therapeutic proteins 
has been utilized to enhance circulation time, prevent protein aggregation, decrease 
proteolysis, and reduce immunogenicity [165-167].  In general, PEG is considered to be 
safe, nontoxic, and non-immunogenic with normal clearance mechanisms through renal 
filtration and liver uptake [163, 167].  Conjugation of PEG occurs through many 
strategies targeting different reactive sites including those present on amino acid side 
chains for protein PEGylation.  PEG molecules conjugated to therapeutics range from 
<10 kDa linear chains to >40 kDa branching PEG units and reduce immunogenicity 
through a steric hindrance effect [163]. 
Elimination of antigenic sites from protein structure through a protein 
engineering approach acts as a viable alternative to the steric blockage of antigenic sites 
on therapeutic agents through chemical conjugation of PEG. The protein engineering 
approach can rely on identification and direct removal of antigenic epitopes, 
replacement of some foreign domains with native human protein as in the case of 
chimeric or humanized antibodies, or modification of native proteins to obtain desired 
bioactivities [168, 169].  In general, increasing the human sequence content of a 
therapeutic protein minimizes the possibility of epitope detection and an immune 
reaction [168]. 
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Use of Combination Therapies for Enhanced Response 
The hallmarks of cancer describe a set of biological capabilities acquired during 
tumor development, specifically: resistance to cell death, sustained proliferation, 
evasion of growth suppressors, induction of angiogenesis, replicative immortality, 
activation of metastasis and invasion, reprogramming of energy metabolism, and 
immune evasion [170, 171].  Genomic instability causes the development of these traits 
which produce an adaptable tumor microenvironment that challenges anti-cancer 
strategies.  Tumor heterogeneity and genetic changes among and within cancers allude 
to the potential for successful treatment using combination therapies rather than a single 
agent approach.  Combination strategies attempt to combine agents with different 
killing mechanisms, sometimes addressing a different tier in the hallmark biological 
capabilities of cancer cells without causing an overlap in toxicity [172]. 
Initial efforts with combination therapies focused on increasing the presence of 
our targeted enzymes through the use of docetaxel; however the most recent studies 
have included the addition of rapamycin to target the hypoxic response and the use of 
cyclophosphamide for immune stimulation.  This three-pronged anti-cancer approach 
includes the targeted delivery of a cytotoxic agent, antitumor immune stimulation, and 
modulation of the hypoxic response within the tumor microenvironment.  Together, this 
strategy addresses many of the hallmark traits of cancer while still minimizing any 
impact on healthy tissue. 
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Docetaxel Enhanced Phosphatidylserine Targeting 
Docetaxel, an FDA approved anti-mitotic chemotherapeutic, targets 
microtubules with a high therapeutic index, in a similar fashion to paclitaxel [173].  
Docetaxel is used primarily as an adjuvant therapy for patients with high risk breast 
cancer as a result of problems with cumulative systemic toxicity after prolonged high 
dose therapies [174].  Several chemotherapeutics, including docetaxel, have been found 
to significantly increase externalization of phosphatidylserine without inducing 
apoptosis in multiple cell types when used at low doses [175].  Additional studies 
examined the possibility of using sub-toxic levels of chemotherapeutic to increase 
phosphatidylserine externalization within a tumor with particular focus on the tumor 
vasculature endothelial cells, of which only about 10-40% externalize 
phosphatidylserine [176].  Low dose docetaxel was found to successfully increase 
external phosphatidylserine positive tumor vessels by 70% with no reported systemic 
impacts or effects on normal vasculature [146, 176].  Increased exposure of the target 
with minimal systemic effect is highly desirable, particularly with a targeted enzyme 
prodrug system as it allows a higher concentration of localized enzyme and an 
exponential increase in generation of cytotoxic agents.   
 
Countering the Hypoxic Response with Rapamycin  
Aggressive cancers can outgrow the blood supply and surpass angiogenic 
requirements resulting in a hypoxic tumor microenvironment.  In fact, necrotic cancer 
sections, commonly found in solid tumors, indicates severe intratumoral hypoxia 
resulting in insufficient oxygenation and decreased cell viability [177].  Hypoxia-
23 
inducible factors (HIF) activate mechanisms to improve oxygenation as well as 
reprogram metabolic processes to enhance cell survival under oxygen deprivation [178].  
HIF-1 and HIF-2 regulate over 1000 genes involved in cancer biology, including the 
pro-angiogenic vascular endothelial growth factors (VEGF)  and enzymes responsible 
for matrix remodeling and cellular migration [4, 179, 180].  The hypoxic tumor 
microenvironment activates this cellular survival mechanism which cascades and 
ultimately plays a role in the development of a number of the hallmark traits of cancer, 
including angiogenesis, metastasis and invasion, altered metabolism, and apoptotic 
resistance. 
The hypoxic response involves a vast number of molecules and pathways 
potentially intertwined with vital non-cancer related processes, making complete 
inhibition difficult.  Rapamycin, an inhibitor of mammalian/mechanistic target of 
rapamycin (mTOR), acts as an upstream downregulator of HIF-1α and subsequently 
angiogenesis.  The subunits HIF-1α and HIF-1β comprise HIF-1 (with similar 
constituents for HIF-2), though the β unit is constitutively expressed and only the α 
subunit undergoes oxygen-dependent regulation [181, 182].  Rapamycin and analogues 
CCI-779, RAD001 (Everolimus), and AP23573 have undergone clinical trials for 
various cancer treatments and are generally well tolerated [178].  Despite its origins as 
an immunosuppressive drug, reduced VEGF levels and the anti-angiogenic properties of 
rapamycin and its analogues generate interest in oncology research because it acts 
significantly upstream from many of the available anti-angiogenic agents and affects 
not only angiogenesis but also cell growth, proliferation, and survival [183].  Most anti-
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angiogenic drugs act downstream of the cell proliferation pathways, focusing primarily 
on VEGF (bevacizumab) and its receptors (sorafenib, sunitinib) [184, 185]. 
mTOR regulates a signaling cascade through control of phosphorylation of 
proteins S6K1 and 4E-BP-1, important for translation of mRNAs involved in cell 
growth and proliferation processes including HIF [186, 187].  Inhibition of mTOR 
results in decreased translation of HIF-1α and possibly HIF-2α [181, 187, 188].  
Generally HIF-2 is not considered to be rapamycin sensitive as rapamycin only inhibits 
one of the two mTOR complexes (rapamycin inhibits mTORC1, and HIF-2 is mTORC2 
dependent); however some studies show reduced levels of HIF-2α mRNA translation 
and inhibition of mTORC2 with rapamycin in some conditions [187-189].   
HIF-1α expression increases vascular permeability, promotes intravasation of 
cancer into circulation, and results in increased metastasis [4, 180].  Additionally, HIF-1 
signaling is theorized to play a role in tumor cell repopulation following cytotoxic 
therapies [190].  Effective reduction of HIF-1α levels with rapamycin could 
significantly reduce the pro-survival signaling of the hypoxic response and inhibit 
tumor progression.  Combination therapy with rapamycin and the vascular-targeted 
enzyme prodrug therapies may be especially complementary, as the enzyme prodrug 
therapy has been shown by this research group to result in necrotic tumor cores and 
reduced blood flow [157] (and likely oxygen diffusion) in the tumor environment which 
is already plagued by abnormal vasculature. 
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Immunostimulation with Cyclophosphamide Depletion of Regulatory T Cells 
Regulatory T cells are a subset of CD4+ T cells that help to establish peripheral 
tolerances to self-antigens and are often classified by the expression of CD25 and the 
transcription factor forkhead box P3 (FoxP3) [191-194].  The peripheral tolerances 
established by regulatory T cells are of particular interest in regards to cancer due to the 
resultant immune evasion capabilities, one of the hallmark biological traits of cancer.  
Regulatory T cells have been shown to exhibit direct suppressive activity against tumor 
antigen-specific immune responses.  The secretion of immunosuppressive cytokines IL-
10, TGF-β, IL-35, and VEGF and results in suppression of helper and effector T cells 
[191, 192, 195]. Depletion of regulatory T cells reduces immune evasion capabilities of 
tumors, enhances antitumor immunity, and facilitates tumor rejection [196, 197].   
Numerous strategies exist for inhibition of regulatory T cells, including 
cyclophosphamide, gemcitabine, mitoxantrone, fludarabine, thalidomide analogues, 
COX-2 inhibitors, and anti-CTLA-4 antibodies [191].  In particular, low dose 
cyclophosphamide has been shown to selectively deplete regulatory T cells.  
Cyclophosphamide acts by alkylating DNA, creating inter-strand and intra-strand 
crosslinks that ultimately result in cell death [198, 199].  Increased apoptosis and 
decreased immunosuppressive activity of regulatory T cells upon low dose 
cyclophosphamide treatment results from a hypersensitivity possibly related to a 
decreased capacity for DNA damage repair [199].  Combined with other antitumor 
therapies, low dose cyclophosphamide can enhance the antitumor immune response, 
leading to tumor rejection and improved survival [198, 200-202].  Previously, we have 
shown that low dose cyclophosphamide combined with tumor thermal ablation using an 
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annexin V targeted system likely allows for direct antigen release into circulation and 
results in improved survival compared to thermal ablation alone [203].  Additionally, 
the apoptosis induced by the enzyme prodrug systems is expected to enhance tumor 
antigen presentation, and when combined with cyclophosphamide, could tip the balance 
away from tolerance and augment an antitumor immune response [204]. 
 
Project Summary and Experimental Overview 
The overarching goal of this project is to develop a targeted enzyme prodrug 
therapy through the fusion of an enzyme to annexin V for the treatment of breast cancer 
in an immune competent mouse model.  The first objective of this work was to develop 
the PNP-AV enzyme prodrug system by first constructing, producing, and purifying the 
PNP-AV fusion protein.  The PNP-AV enzyme prodrug system would then be 
characterized in vitro in a similar fashion to the previously developed systems using 
CD-AV and Met-AV. 
The second objective is the assess the three enzyme prodrug systems in immune 
deficient mice bearing human breast tumors with the primary evaluation criteria being a 
reduction in tumor volume without introducing negative side effects.   The most 
successful candidate among the three enzyme prodrug systems is to be selected for 
further development for immune competent models, either through PEGylation or 
protein engineering strategies. 
Upon performing in vivo trials with all three systems and selecting a candidate 
for immune competent models, the third objective is to reduce the immunogenicity of 
the fusion protein and maximize antitumor efficacy and survival in immune competent 
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mice bearing breast tumors.  A combination therapy approach will be utilized to 
maximize therapeutic efficacy.   
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Chapter II: Materials and Methods 
Fusion Gene Construction and Transformations 
Construction of Recombinant Expression Plasmid for PNP-AV 
The PNP (gift of Dr. Joanne Turnbull, Concordia University Department of 
Chemistry and Biochemistry, Montreal, Canada) and AV (gift of Dr. Stuart Lind, 
University of Colorado, Denver, CO) genes were amplified separately with the Expand 
High Fidelity PCR system from Roche Applied Sciences (Madison, WI).  The 
oligonucleotide PCR primers were synthetically produced (Integrated DNA 
Technologies, Coralville, IA) and are displayed below.  The bold regions on the primers 
indicate the sequences complementary to the genes.  BamHI restriction enzyme sites are 
shown as the boxed regions with the cut sites indicated.  The underlined segment in the 
PNP antisense primer is a linker region. 
 
PNP gene sense primer: 
5’-GAC GAC GAC AAG ATG CCC GCT ACC CCA CAC ATT AAT GCA G- 3’ 
PNP gene antisense primer: 
5’-CGC G|GA TCC AGA ACC GGA GCC CTC TTT ATC GCC CAG CAG AAC-
3’ 
Annexin V sense primer: 
5’-CGC G|GA TCC GCA CAG GTT CTC AGA GGC-3’ 
Annexin V antisense primer: 
5’-GA GGA GAA GCC CGG TTA GTC ATC TTC TCC ACA GAG C-3’ 
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The PCR products were purified using a QIAquick PCR purification kit 
(Qiagen, Valencia, CA; 28104) and separately digested with BamHI restriction enzyme 
(New England Biolabs, Ipswich, MA; R0136S).  The digested genes were purified and 
ligated with T4 DNA ligase (New England Biolabs; M0202S).  The fusion gene was 
amplified via PCR with the following sense and antisense primers:  
 
Fusion gene sense primer: 
5’-CGC T|CT AGA ATG GCT ACC CCA CAC ATT AAT GCA G-3’ 
Fusion gene antisense primer: 
5’-CGC C|TCGAG CGG ACC CTG GAA CAG AAC TTC CAG GTC ATC TTC TCC 
ACA GAG CAG C-3’ 
 
The bold regions indicate the complementary sequences for the start of the PNP 
gene for the sense primer and the end of the AV gene on the antisense 
primer.  Restriction enzyme sites were incorporated, shown as the boxed regions with 
the cut site indicated.  The sense strand site is for Xba1 and the antisense strand site is 
for Xho1.  The antisense strand also includes a cleavage site for the protease HRV-3C, 
shown in italics, to allow for separation of the protein from the C-terminal 6x His-tag 
using immobilized metal affinity column chromatography (IMAC).  PCR was 
performed with the Phusion High Fidelity PCR kit (New England Biolabs; E0553S). 
The PCR products were again purified using a QIAquick PCR purification kit, 
run on an agarose gel, and extracted with a QIAquick gel extraction kit (Qiagen; 
28704).  A restriction enzyme digest was performed on the purified PNP-AV gene and 
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pET303/CT-His vector (Life Technologies, Grand Island, NY; K630203) with Xho1 
(New England Biolabs; R0146S) and Xba1 (New England Biolabs; R0145S).  Ligation 
was performed with T4 DNA ligase (New England Biolabs; M0202S).  Plasmids were 
sent for sequence verification (Oklahoma Medical Research Foundation, Oklahoma 
City, OK) following transformation and culture of NovaBlue Gigasingles competent 
cells (EMD Chemicals, Gibbstown, NJ; 71227-4).  E. coli BL21(DE3) cells (EMD 
Chemicals; 69450-3)  were then transformed and cultured for the protein expression. 
 
Construction of Recombinant Expression Plasmids for mCGL Fusions 
mCGL, AV, and AI gene fragments were synthesized (Life Technologies) with 
each fusion, mCGL-AV and mCGL-AI, consisting of three fragments.  Fragment sizes 
ranged from 371 to 1000 amino acids with 40 bp overlapping regions on each end of the 
fragment.  Gene ends were designed with a 40 bp overlap with the ligation independent 
cloning sites in pET-30 Ek/LIC (EMD Chemicals; 69077) for direct assembly of gene 
fragments into the vector using the Gibson Assembly method [205, 206].  Codons were 
optimized for protein production in E. coli using DNAWorks software (Helix Systems, 
National Institutes of Health).  Gene fragment sequences as well as the final construct 
and translated sequences are available in Appendix C: Fusion Gene Construction.   
Gibson assembly uses exonuclease activity that creates 3’ overhangs on double-
stranded DNA and allows annealing of complimentary fragments.  Polymerase and 
ligase activity then fills in and seals the assembled DNA.  Gibson assembly master mix 
(New England Biolabs; E5510S) was held at 50°C for 60 min in a thermocycler with 
the gene fragments and vector.  The assembled product was transformed into NEB 5-
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alpha competent E. coli, expanded, and cultured on kanamycin plates.  Colonies were 
sequenced (Oklahoma Medical Research Foundation) using sequencing primers 
(Integrated DNA Technologies) designed for mCGL-AI and mCGL-AV.  The plasmid 
miniprep for mCGL-AI in pET-30 Ek/LIC was transformed into BL21(DE3) competent 
cells for expression.  The plasmid miniprep for mCGL-AV in pET-30 Ek/LIC was 
transformed into T7 Express lysY competent cells (New England Biolabs; C010I) for 
protein expression, which yielded more protein than BL21(DE3) expression of mCGL-
AV. 
 
Protein Expression and Purification 
BL21(DE3) Expression of CD-AV, PNP-AV, Met-AV, and mCGL-AI 
 BL21(DE3) cells harboring the vector for CD-AV, PNP-AV, Met-AV, or 
mCGL-AI were grown in LB medium at 37°C and 200 rpm to an OD600 nm of 0.6.  LB 
medium contained 100 µg/ml carbenicillin (VWR, Radnor, PA; 97063-144) for PNP-
AV expression or 35 µg/ml kanamycin (Fisher Scientific, Pittsburgh, PA; BP906-5) for 
CD-AV, Met-AV, and mCGL-AI expression.  Growth occurred in two steps; initially at 
10 ml and then expanded to 1 L.  Isopropyl -D-thiogalactopyranoside (IPTG) (VWR; 
EM-5810) was added to a concentration of 0.4 mM to induce protein expression.  
Induction occurred for 6 h at 30°C with shaking at 180 rpm.  Note that both vectors 
used, pET-30 Ek/LIC (CD-AV, Met-AV, mCGL-AI, mCGL-AV) and pET303/CT-His 
(PNP-AV), utilize the T7 lac promoter and could potentially benefit from increased 
induction concentrations up to 1 mM IPTG. 
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T7 Express lysY (DE3) Expression of mCGL-AV 
T7 Express lysY (DE3) cells harboring the vector with mCGL-AV were grown 
in TB medium with 35 µg/ml kanamycin at 37°C and 220 rpm to an OD600 nm of 1.2.  
Growth occurred in two steps; initially at 10 ml and then expanded to 1 L.  IPTG was 
added to a concentration of 1 mM to induce protein expression.  Induction occurred for 
19 h at 25°C at 200 rpm.  The increase of cells resultant from the use of TB medium and 
growth to OD600 nm of 1.2 was necessary for sufficient yields of mCGL-AV. 
 
IMAC Purification 
Recombinant fusion proteins were purified using immobilized metal affinity 
chromatography (IMAC) with immobilized Ni
2+
 to isolate the fusion protein [207].  E. 
coli cells were harvested with centrifugation, lysed through sonication, and cell debris 
removed through further centrifugation.  The supernatant was loaded into a 5 ml 
HisTrap HP column (GE Healthcare Life Sciences, Piscataway, NJ; 17-5248-02) with 
40 mM imidazole and 500 mM NaCl added to reduce non-specific protein binding.  For 
Met and mCGL fusion proteins all buffers also contain 0.02 mM pyridoxal phosphate to 
maintain enzyme activity.  The column was washed with a 20 mM sodium phosphate 
buffer with 40 mM imidazole and 500 mM NaCl followed by an endotoxin removal 
wash which also includes 1.0% Triton X-114, both at pH 7.4.  Elution of the fusion 
protein from the column was performed at pH 7.0 in 20 mM sodium phosphate buffer 
with 500 mM imidazole and 500 mM NaCl. 
Following elution, the fusion protein was dialyzed into 20 mM sodium 
phosphate buffer at pH 7.4 to allow for cleavage of the His-tag with HRV-3C protease 
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(Thermo Scientific Pierce, Rockford, IL; 88946).  A Bradford assay (Bio-Rad 
Laboratories Inc., Hercules, CA; 500-0205) was utilized to determine protein 
concentration (see Appendix B: Laboratory Protocols for details).  Protease was added 
at 10 U/mg protein with 10X cleavage buffer as recommended by the manufacturer and 
incubated for 18 h at 4°C with shaking at 30 rpm.  The solution was then loaded onto a 
5 ml HisTrap HP column with 40 mM imidazole and 500 mM NaCl, and the flow-
through was collected.  Protease and uncleaved protein remain bound to the column and 
elute under the previously described elution conditions.  Cleaved protein was dialyzed 
into 20 mM sodium phosphate and 100 mM NaCl at pH 7.4.  The protein solution was 
passed through a 0.2 µm cellulose-acetate filter for sterilization, flash frozen, 
lyophilized, and stored at -80°C.   
Prior to in vivo work, endotoxin levels are assessed through a chromogenic 
Limulus Amebocyte Lysate assay (Lonza, Walkersville, MD; 50-647U) according to 
manufacturer instructions with details available in Appendix B: Laboratory Protocols.  
Purity is assessed through a densitometric analysis with ImageJ (FIJJ build, National 
Institutes of Health) of SDS-PAGE gels with Coomassie staining of protein samples 
[208].  
 
Enzyme Activity Assays 
Cytosine Deaminase Activity Assay 
Cytosine deaminase activity was measured as previously described [37, 209] 
using the conversion of 5-fluorocytosine (5-FC) to 5-fluorouracil (5-FU) and 
spectrophotometric properties at 255 nm and 290 nm.  5-FC is incubated with dilutions 
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of cytosine deaminase at 37°C and pH 7.4 for 30 min.  The reaction is quenched with 
HCl, and then absorbances are measured in a BioTek Synergy HT microtiter plate 
reader (BioTek Instruments Inc., Winooski, VT).  Activity, with one unit defined as 1 
µmol 5-FU formed per min at 37°C, is calculated according to the formula determined 
by Senter et al [209]. 
 
Purine Nucleoside Phosphorylase Activity Assay 
The purine nucleoside phosphorylase activity assay was adapted from Sigma 
Aldrich protocol EC 2.4.2.1 for nucleoside phosphorylase activity and is previously 
described [210].  Hypoxanthine is generated from the nucleoside phosphorylase from 
the substrate inosine.  Xanthine oxidase then catalyzes the conversion of hypoxanthine 
to uric acid, which can be measured with absorbance at 293 nm.  A microtiter plate 
reader is used to perform kinetic measurements at 293 nm for 3 min or until values are 
constant of a mixture of inosine (Sigma Aldrich, St. Louis, MO; I4125) and xanthine 
oxidase (Sigma Aldrich; X4500).  The maximum rate of change for the linear region of 
change is considered to be the slope of the blank sample.  PNP is added and additional 
measurements are performed for 5 min to determine the maximum rate of change for 
the linear region with enzyme.  One unit is defined as the phosphorolysis of 1.0 µmol of 
inosine to hypoxanthine and ribose 1-phosphate per min at pH 7.4 and 25°C. 
 
Methionine-γ-Lyase Activity Assay 
The methioninase assay is performed as previously described [36, 76].  
Dilutions of enzyme samples were incubated with L-methionine (Sigma Aldrich; 
35 
M9625) or L-selenomethionine (Fisher Scientific; AC25996-0010) for 10 min at 37°C 
to catalyze the production of α-ketobutyrate.  Trichloro-acetic acid (50%, w/v) was used 
to terminate the enzymatic reaction, followed by 2 min of centrifugation at 15000 x g.  
The supernatant was added to sodium acetate buffer and 0.1% 3-Methyl-2-benzo-
thiazolinone hydrazine hydrochloride hydrate (MBTH) for color development.  
Development proceeded for 30 min at 50°C in a PCH02 Peltier Cooler/Heater (Grant 
Instruments Ltd., Cambridge, UK).  Absorbance was read in a microtiter plate reader at 
320 nm.  One unit of enzyme is defined as the amount that catalyzes the formation of 1 




PEGylation was performed using 10 kDa 4-arm branched PEG with a single 
maleimide functional group (NOF America Corporation, White Plains, NY; 
SUNBRIGHT PTE-100MA) or a 20 kDa 2-arm branched PEG with a single aldehyde 
functional group (NOF America Corporation; SUNBRIGHT GL2-200AL3) or a linear 
10 kDa PEG with single aldehyde functional group (NOF America Corporation; 
SUNBRIGHT ME-100AL) or a linear 10 kDa PEG with a single NHS active ester 
functional group (NOF America Corporation; SUNBRIGHT ME-100TS).  
Conjugations were performed in 20 mM sodium phosphate, 100 mM NaCl buffer or 
100 mM borate buffer for varied times, temperatures, molar ratios, and pH.  PEGylation 
was performed on Met-AV and PNP-AV proteins and assessed for degree of 




Wild type human CGL displays no activity toward L-methionine or L-
selenomethionine; however three mutations impart methionine-γ-lyase activity to 
human CGL [169].  Since pre-clinical testing will occur in immune competent mice, 
NCBI BLAST was used to align human and mouse CGL sequences to determine 
comparable mutations.  NCBI BLAST alignments of the human and mouse CGL amino 
acid sequences can be found in Table 23 of Appendix C: Fusion Gene Construction.  
The mutations were located in conserved regions of sequence, presumably an area 
involved in substrate binding, and therefore theorized to impart similar activity upon the 
mouse CGL.  The works in this document refer to mouse CGL with the mutations 
outlined in Table 5.  Gene construction is described in the section “Fusion Gene 
Construction and Transformations” with detailed protocols in Appendix B: Laboratory 
Protocols. 
 
Table 5.  CGL Mutation Summary for Methioninase Activity 




E  N 59 58 
R  L 119 118 
E  V 339 338 
 
 
Mammalian Cell Culture 
HAAE-1 Endothelial Cells 
Human abdominal aorta endothelium (HAAE-1) cells (Coriell Insitute for 
Medical Research, Camden, NJ; AG09799) originated from healthy, non-fetal human 
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tissue and is an accepted model for normal vascular endothelium [211-213].  When 
grown in vitro, non-confluent HAAE-1 cells are actively dividing, as opposed to a 
monolayer culture, and have been shown to externalize phosphatidylserine as in tumor 
vasculature [36, 37, 212].  The endothelial cells were subcultured to a maximum 
passage of six and maintained in a non-confluent state.  F12K (ATCC; Manassas, VA; 
30-2004) culture medium was supplemented with 10% FBS (Atlanta Biologicals, 
Flowery Branch, GA; S11150), 30 µg/ml endothelial cell growth supplement (Fisher 
Scientific; CB-4006B), 17.5 U/ml heparin (Polysciences, Inc., Warrington, PA; 01491-
100), 100 U/ml penicillin, and 100 µg/ml streptomyocin (Atlanta Biologicals; B21210).  
Tissue culture treated plasticware were also precoated with 0.1% gelatin for 15 min 
prior to plating cells.  Cell cultures were maintained at 37°C and 5% CO2 until 70% 
confluence, at which point standard trypsinization subculture procedures were followed 
using a one to three split ratio. 
 
MCF-7 Human Breast Cancer Cells 
   MCF-7 cells (ATCC; HTB-22) are estrogen receptor (ER) positive and human 
epidermal growth factor receptor 2 (HER-2) overexpression negative and are a part of 
the standard repertoire of models used in testing breast cancer therapeutics. MCF-7 cells 
were cultured and maintained in Eagle’s Minimum Essential Medium (ATCC; 30-2003) 
supplemented with 10% FBS, 0.01 mg/ml insulin (Life Technologies; 12585-014), 100 
U/ml penicillin, and 100 µg/ml streptomyocin at 37°C without CO2.  Subculturing was 
performed with standard trypsinization procedures with a subculture ratio of one to 
three once reaching 70% confluence.   
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MDA-MB-231 Human Triple-Negative Breast Cancer Cells 
The MDA-MB-231 cell line (ATCC; HTB-26) is one of the most common 
models for human triple negative (ER negative, PR negative, HER-2 overexpression 
negative) breast cancers.  This model has poor responsiveness to standard therapies and 
results in aggressive metastasis, representative of a poor prognosis breast cancer in 
patients [4, 178].  MDA-MB-231 cells were cultured and maintained in Leibovitz’s L-
15 medium (ATCC; 30-2008) supplemented with 10% FBS, 100 U/ml penicillin, and 
100 µg/ml streptomyocin at 37°C without CO2.  Subculturing was performed with 
standard trypsinization procedures with a subculture ratio of one to three once reaching 
70% confluence.  Some applications required use of MDA-MB-231/GFP cells (Cell 
Biolabs, Inc., San Diego, CA; AKR-201) as specified. 
 
4T1 Murine Triple-Negative Breast Cancer Cells 
The 4T1 cell line is a triple-negative, highly metastatic, and poorly 
immunogenic murine model that is representative of advanced breast cancer in humans 
and derived from BALB/cJ mice [214, 215].  Pulmonary metastasis is the primary cause 
of death in 4T1 mouse models; however spontaneous metastasis to lymph nodes, blood, 
liver, lung, brain, and bone has also been observed [216-218].  A 4T1 orthotopic graft in 
BALB/cJ mice is recognized as one of the most challenging breast tumor models for 
immunotherapies [214, 219].  4T1 cells (ATCC; CRL-2539) were cultured and 
maintained in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin, 
and 100 µg/ml streptomyocin at 37°C and 5% CO2.  Subculturing was performed with 
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standard trypsinization procedures with a subculture ratio of one to four once reaching 
80% confluence.  Some applications required use of 4T1/TdTomato/Luciferase (gift of 
Dr. Rajagopal Ramesh Laboratory, University of Oklahoma Health Sciences Center, 
Oklahoma City, OK). 
 
In Vitro Binding Studies  
Binding Strength 
Cells were grown in 24 well plates and fixed with 0.25% glutaraldehyde once 
70-80% confluent.  Cells were incubated for 2 h with biotinylated fusion protein then 
washed.  See Appendix B: Laboratory Protocols for biotinylation protocol with 
SureLINK Chromophoric Biotin (KPL, Gaithersburg, MD; 86-00-03).  Bound fusion 
protein was quantified by incubation with streptavidin-horseradish peroxidase (HRP) 
(KPL; 71-00-38), washed, incubated with the chromogenic substrate O-
phenylenediamine (OPD) and hydrogen peroxide, and the absorbance measured at 450 
nm on a BioTek Synergy HT microtiter plate reader (Winooski, VT).  At each 
concentration of fusion protein, the specific binding was obtained by subtracting the 
non-specific binding (no CaCl2 present, 5 mM EDTA added) from the total binding (2 
mM CaCl2 added).  The dissociation constant was determined using a hyperbolic 
regression with GraphPad Prism software (GraphPad Software Inc., La Jolla, CA). 
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Figure 4.  Schematic of fusion protein binding quantification.   
Biotinylated fusion protein is incubated with cells and binds to phosphatidylserine on 
the external leaflet of the cellular membrane.  Horseradish peroxidase, conjugated to 
streptavidin, localizes to the fusion protein through strong biotin-streptavidin binding.  
Horseradish peroxidase then catalyzes the development of chromogenic substrate OPD, 
which can then be measured at 450 nm. 
 
Binding Stability 
Cells were grown in 24 well plates to 70-80% confluence and incubated with 
fusion protein for 2 h then washed.  On days 0, 1, 2, and 3 separate sets of cells were 
assessed for viability using an Alamar Blue assay as described in the cytotoxicity test 
methods and for bound protein.  Quantification of bound fusion protein was performed 
using a chromogenic assay as described for evaluating binding strength.   
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Binding Visualization 
 Multiple microscopy methods were utilized for evaluation of fusion protein 
binding.  Fixed cell microscopy involved growth of cells on a coverslip followed by 
glutaraldehyde fixation to preserve the cell morphology while allowing the exposure of 
membrane binding sites [220].  Cells were incubated with biotinylated fusion protein 
for 1 h at 37°C in growth medium with 2 mM supplemental Ca
2+
.  After washing, 
streptavidin-conjugated green Alexa Fluor 488 (Life Technologies; S-11223) was added 
to the cells at 5 µg/ml for 30 min in order to visual biotinylated fusion protein on the 
membrane surface (streptavidin does not internalize into formerly viable cells after 
fixation [221]).  Cells were counterstained with 5 µg/ml Hoechst 33258 dye (Sigma-
Aldrich; B2883) for nucleic acids for 30 min and with 1 µg/ml CellMask Deep Red 
plasma membrane stain (Life Technologies; C10046) using three 5 min incubations 
followed by washes.  The coverslip was attached to the slide with fluoro-gel with TES 
buffer (Fisher Scientific).  Slides were viewed immediately following preparation with a 
Leica Microsystems SP8 confocal laser scanning microscope (Leica Microsystems Inc., 
Buffalo Grove, IL) in both x-y and x-z planes at the Noble Microscopy Facility 
(University of Oklahoma, Norman, OK). 
Live cell microscopy was performed with Dylight 680 (Thermo Scientific 
Pierce; 46418) labeled fusion protein (see Appendix B: Laboratory Protocols for 
conjugation protocol) to minimize phototoxic effects.  Cells transfected to express 
fluorescent protein (MDA-MB-231/GFP or 4T1/TdTomato) were grown in 35 mm 
Corning petri dishes (Corning, Tokyo, Japan; 430165) in growth medium that does not 
require additional CO2 (L-15 medium).  Prior to imaging, the growth medium was 
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supplemented with 2 mM Ca
2+
 to allow fusion protein binding and 10 µg/ml Hoechst 
33258, which is non-membrane permeable nucleic acid stain that acts as a marker for 
dead cells during live-cell imaging.  The dish was then held at 37°C on the microscope 
with a Peltier Cooling stage and imaged prior to addition of protein.  Cells were imaged 
with Leica’s HyD detection system to allow use of low laser power to minimize 
phototoxic effects.  Fusion protein was added to the samples and allowed to incubate for 
2 h while continuing to obtain live images.  Cells were then washed to remove unbound 
protein and live-imaging continued for 2 h. 
 
In Vitro Cytotoxicity 
Cytotoxicity assays were performed over 3 days (mCGL fusion proteins) or 6 
days (PNP-AV) as one or two 3-day cycles in 24-well plates under standard culture 
conditions with calcium supplemented medium (2 mM Ca
2+
).  On the first day of each 
cycle (day 0, day 3) cells were incubated with 100 nM fusion protein for 2 h at 37°C.  
The plates were washed and medium containing varying concentrations of the prodrug, 
selenomethionine (Fisher Scientific; AC25996-0010) or fludarabine phosphate (VWR; 
101095-016), was added.  Controls of prodrug with no protein were included, as well as 
a control with the enzymatic product, 2-fluoroadenine (Fisher Scientific; 50-012-2249), 
for the PNP-AV study.  The medium containing the prodrug or drug was replaced daily 
for the two subsequent days of each cycle.  An Alamar Blue assay [222-224] was 
performed to determine viability on days 0, 2, 4, and 6 for the PNP-AV studies or on 
days 0, 1, 2, and 3 for the mCGL studies.  Alamar Blue reagent (Life Technologies; 
DAL1100)  was added at 10% to growth medium and incubated with cells for 4 h at 
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37°C.  Fluorescence was measuring using a microtiter plate reader with an excitation 
wavelength of 530 nm and emission wavelength of 590 nm after the solutions had been 
transferred to an opaque 96-well plate. 
 
In Vivo Tumor Models 
All animal studies were performed in accordance with protocols approved by the 
Institutional Animal Care and Use Committee at the University of Oklahoma Health 
Sciences Center.  Animals were housed in the Rodent Barrier Facility, a pathogen-free 
facility, at the University of Oklahoma Health Sciences Center and monitored daily. 
 
MDA-MB-231 Implantation in SCID Mice 
Six to eight week old female SCID mice (The Jackson Laboratory; Bar Harbor, 
ME; 001303) were injected with 6-8 x 10
6
 MDA-MB-231/GFP cells per mouse 
subcutaneously in the flank [157] or 1-2 x 10
6
 MDA-MB-231/GFP cells per mouse in 
mammary fat pad number four.  Tumor locations are illustrated in Figure 5.  Injections 
were performed with 25 G needles with 50% Matrigel (Fisher Scientific; CB-40234A) 
and 50% cell suspension in PBS for total volumes of 200 µL for flank injections and 
100 µL for fat pad injections. 
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Figure 5.  Placement of flank and fat pad tumor grafts. 
 
4T1 Implantation in BALB/cJ Mice 
Six to eight week old BALB/cJ mice (The Jackson Laboratory; 000651) were 
injected with 10
5
 4T1/TdTomato/Luciferase cells in the fourth mammary fat pad as 
described by Lou et al [225].  Injections were performed as with the MDA-MB-231 fat 
pad model using 50% Matrigel and 50% cell suspension in PBS. 
 
Non-terminal In Vivo Procedures and Follow-up Analysis 
Mass and Tumor Volume 
Mass and tumor volume were measured every 3 to 4 days through the duration 
of the studies.  Volume was determined from the modified ellipsoid formula (      
             
 
) [225] using caliper measurements of the longest axis for the length and 
the perpendicular measurement for width. 
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Fluorescence Live Animal Imaging 
To perform live fluorescence imaging of mice bearing fluorescent tumors, mice 
were first anesthetized with isofluorane and maintained under anesthesia for the 
duration of imaging.  An IVIS Spectrum (Perkin Elmer, Waltham, MA) imaging system 
from the Molecular Imaging Core at the Stephenson Cancer Center of the University of 
Oklahoma Health Sciences Center collected images.  Perkin Elmer software performed 
spectral unmixing of the tumor fluorescence from tissue fluorescence and overlaid the 
data on images of the mice.   
 
Antibody Titer 
Protein specific antibody titers were determined based on modified protocols 
from [226-228].  Blood samples were collected from mice at 0, 1, 2, and 3 weeks of 
treatment.  Approximately 150 µL of blood were collected in 3 drops from 
submandibular bleeds, and plasma was isolated using capiject collection tubes (VWR; 
TETMG) with centrifugation at 3500 x g for 90 s and stored at -80°C. 
A sandwich ELISA assay was performed to determine protein specific antibody 
titers.  A 0.1 M carbonate coating buffer and 20 µg/mL fusion protein were incubated 
overnight at 4°C on high binding capacity ELISA 96 well plates (VWR; 82050-740).  
Plates were then washed and blocked with fetal bovine serum and plasma dilutions were 
incubated overnight at 4°C.  Following additional washes, goat anti-mouse IgG and IgM 
conjugated to HRP (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA; 
315-035-044) was used to develop OPD as described in the in vitro binding assays.  
Antibody titers are presented as the greatest dilution that produces a positive result. 
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Terminal In Vivo Procedures and Follow-up Analysis 
Fusion Protein Clearance 
Fusion protein was biotinylated and administered by intraperitoneal (IP) 
injection into mice at 10 mg/kg IP in PBS.  The biotinylation protocol is detailed in 
Appendix B: Laboratory Protocols.  At appropriate time intervals between 0 and 24 h 
post injection, three to four mice per time point were euthanized and blood collected 
through cardiac draw.  A capiject blood collection vial was used to isolate plasma with 
centrifugation at 3500 x g for 90 s and stored in cryovials at -80°C.  Control mice at 
time point 0 h were not injected with protein. 
An ELISA assay was used to determine fusion protein concentration in the 
plasma.  A calibration curve using biotinylated protein was constructed with each assay.  
Plasma samples were incubated in wells of a streptavidin-coated 96 well plate (Thermo 
Scientific Pierce; 15500) to bind biotinylated fusion protein in the samples.  After 
washing the plates, rabbit polyclonal anti-annexin V antibody (Abcam, Cambridge, 
MA; ab14196) was added and incubated for 1 h at 37°C.  After further washes, anti-
rabbit IgG conjugated to HRP (Jackson ImmunoResearch Laboratories, Inc.; 111-035-
003) was incubated for 1 h at 37°C.  Following additional wash steps, OPD 
development and absorbance at 450 nm allowed quantification of bound fusion protein. 
 
Measurement of Metastatic Nodules in Lungs 
Immediately following euthanasia, mice were dissected using standard 
procedure and organs were removed.  Organs were placed on ice and stored at -80°C.  A 
Leica stereomicroscope was used to obtain light and fluorescence images of the organs.  
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An automated image processed macro was developed for ImageJ to remove background 
fluorescence and quantify fluorescent nodules in the lung, recording number and size.  
User input was required for thresholding purposes of each image.  The macro code is 
available in Appendix B: Laboratory Protocols.    
 
Tumor Section Immunohistochemistry 
Immediately following euthanasia, mice were dissected using standard 
procedure and organs and tumor were removed.  The tumor was placed in 10% neutral 
buffered formalin and fixed for 24 h at room temperature.  Tumors were then sliced to 
appropriate size and oriented in cassettes for paraffin embedding and fixation by the 
Tissue Pathology Core of the Stephenson Cancer Center at the University of Oklahoma 
Health Sciences Center.  Hematoxylin and eosin (H + E) stained sections were produced 
by the Tissue Pathology Core for evaluation of histology and tumor necrosis.  Slides 
were viewed on a Nikon Eclipse E800 compound microscope (Nikon Corporation, 
Tokyo, Japan) and whole slide images were collected with a Leica stereomicroscope at 
the Noble Microscopy Facility (University of Oklahoma).  Necrotic sections were 
quantified with ImageJ.   
Immunohistochemistry slides were produced using DAB staining for activated 
caspase-3, ki-67, and HIF-1α with hematoxylin counter staining.  Details of the 
antibodies and staining procedure are included in Table 6.  Tumor sections for activated 
caspase-3 and ki-67 staining were imaged at 20X using a Nikon Eclipse E800 
microscope collecting 15 images per section from the non-necrotic portion of the tumor.  
An automated ImageJ macro was developed for quantification of DAB staining.  A 
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color deconvolution was used to separate the hematoxylin and DAB stains, and cells 
were counted as DAB positive or DAB negative.  User input was required for each 
image for thresholding purposes.  ImageJ macro code is available in Appendix B: 
Laboratory Protocols with the process outlined in Figure 6.  HIF-1α images were 
collected with a Leica stereomicroscope to capture the entire tumor section in a single 
image, as the HIF-1α staining was more disperse than the other stains.  Instead, HIF-1α 
was quantified as a percentage of tumor area expressing HIF-1α using the same color 
deconvolution method previously described.  A median filter was applied to the whole 
section images to reduce noise without affecting the boundaries of the regional staining.  
The HIF-1α image processing scheme is outlined in Figure 7.  The antibody details and 





Figure 6.  Outline of process for automated quantification of DAB staining of 
tumor sections with activated caspase-3 and ki-67.   
A hematoxylin and DAB stained image is input (a) into the ImageJ macro, background 
is subtracted, and color deconvolution is performed resulting in a DAB (b) and 
hematoxylin (c) image.  User thresholding is used to generate a mask for each image, 
and then cell counting is performed with each DAB (d) and hematoxylin (e) stained cell 
outlined.  An overlay of stained regions outlined and counted is shown (f) for 




Figure 7.  Outline of process for quantification of DAB staining of tumor sections 
with HIF-1α.   
Whole tumor section images were obtained on a Leica stereomicroscope. The DAB 
image with hematoxylin counterstain (a) undergoes background subtraction (b), and 
then color deconvolution to isolate DAB signal (c).  A median filter is applied to 
remove noise without blurring the boundary of the stained region (d). 
 
Table 6.  Immunohistochemistry antibody staining details 




























Quantification of Regulatory T Cells in Spleen 
Immediately following euthanasia, mice were dissected using standard 
procedures and organs were removed.  Cells of the spleen were mechanically 
dissociated from the organ in FACS buffer and passed through a 70 µm cell strainer 
(VWR; 10054-456) to obtain single cell suspensions. 
A mouse regulatory T cell staining kit (eBioscience, Inc., San Diego, CA; 88-
8111) was used to stain splenocytes for flow cytometry according to manufacturer 
instructions.  A BD Accuri C6 flow cytometer (BD Biosciences, San Jose, CA) was 
used for data acquisition and analysis.  The detailed staining protocol is available in 
Appendix B: Laboratory Protocols.  Cells were first blocked, then stained for CD4 and 
CD25, and then fixed and permeabilized for intracellular staining of FoxP3.  CD4+ 
CD25+ Foxp3+ cells were considered to be regulatory T cells and quantified as a 
percentage of total spleen lymphocytes [229-231]. 
 
Statistical Analysis 
Results are expressed as mean ± standard error (SE).  Statistical significance of 
cytotoxicities, tumor volumes, and section staining was assessed using a one-way 
ANOVA and Tukey-Kramer multiple comparisons test with GraphPad Prism software.   
Assessment for synergism of combination therapies was performed using the 
Bliss independence model on primary tumor growth inhibition [232, 233].  The 
probability of additivity of the measured percent inhibition of the individual 
constituents was subtracted from the measured percent inhibition of the combination 
therapy undergoing analysis for synergism.  For example, to evaluate the synergism of 
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mCGL combined with selenomethionine, the predicted inhibition was calculated using 
probability theory as the product of the inhibition of the mCGL group alone and the 
selenomethionine group alone, subtracted from the sum of the two inhibitions.  The 
predicted inhibition is subtracted from the inhibition exhibited  by the group treated 
with mCGL and selenomethionine together.  Positive values are indicative of 
synergism. 
Statistical significance for survival was assessed based on Kaplan Meier survival 
curves using the log-rank (Mantel-Haenszel) test with a 0.05 significance level 
corrected for family-wise significance based on the number of comparisons according 
to the Bonferroni corrected threshold (significance level/number of comparisons). 
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Chapter III: Results and Discussion 
Cytosine Deaminase and 5-Fluorocytosine 
In Vivo CD-AV Plasma Clearance 
Prior to conducting a study to evaluate the efficacy of the CD-AV system in 
vivo, plasma levels of the CD-AV fusion protein were evaluated to ensure that the 
protein would be cleared from circulation before administration of the prodrug (5-FC).  
It is necessary for complete clearance of the enzyme from circulation prior to prodrug 
administration to eliminate off-target activation of the prodrug, as generation of 5-FU in 
the general circulation could produce negative effects and renders the idea of a targeted 
enzyme prodrug system ineffective.  Blood drawn at various time points and measured 
for CD-AV indicate complete clearance from circulation within 8 hours of 
administration, shown in Figure 8.  The clearance data suggests that prodrug 






Figure 8.  CD-AV clears from the circulation of SCID mice in <8 h.   
An ELISA assay for CD-AV was performed on serum samples at intervals following 
administration of CD-AV at 10 mg/kg IP.  Data is presented as mean ± standard error 
(n = 3). 
 
Evaluation of CD-AV System In Vivo 
The volume of subcutaneous MDA-MB-231 tumors grown on the flank of SCID 
mice was the primary means for the evaluation of efficacy of the CD-AV and 5-FC 
enzyme prodrug system in vivo.  Four consecutive cycled treatments, one day of fusion 
protein administration followed by three days of prodrug administration, were 
conducted in an effort to replicate successful in vitro cytotoxicity experiments using the 
same scheme [37].  Unfortunately in contrast to the in vitro work with MDA-MB-231 
cells, the CD-AV enzyme prodrug system had negligible effects on tumor volume in 
SCID mice, shown in Figure 9.  As expected, the CD-AV system did not produce any 
negative side effects in the mice or result in any weight loss over the duration of the 
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Figure 9.  Poor efficacy of CD-AV and 5-FC against MDA-MB-231 tumors on the 
flank of SCID mice.   
CD-AV was administered every 4 days (10 mg/kg IP) with 5-FC administered (500 
mg/kg IP) each of the subsequent 3 days of the cycle for 4 cycles.  Treatment period is 
indicated by the arrow.  Data is presented as mean ± standard error (n = 6-7).  No 
statistical significance was observed. 
 
 




















































The experimental design of the CD-AV in vivo studies aimed to follow up in 
vitro studies and allow for comparison among the three enzyme prodrug systems, CD-
AV, PNP-AV, and Met-AV.  Certain aspects of the in vitro work are not directly 
translatable to in vivo studies in mice, specifically the dosing of the fusion protein and 
prodrug.  Fusion protein dosing of 10 mg/kg was selected based on plasma clearance 
tests that suggest saturating levels of fusion protein enter the blood stream and are 
cleared in a reasonable time frame and with no apparent side effects.  A study 
previously performed by our research group also evaluated plasma levels of fusion 
protein (Met-AV) at 1 mg/kg, which yielded plasma levels an order of magnitude below 
those observed at a dose of 10 mg/kg.  The 5-FC dose of 500 mg/kg was selected based 
on other enzyme prodrug evaluations [55] and a known LD50 of  >1000 mg/kg [234].    
A comparable study with the Met-AV system using the same MDA-MB-231 
tumor model on the flank of SCID mice and using the same dosing scheme with a single 
fusion protein administration followed by three days of prodrug injections yielded much 
more promising results [157].  After only three treatment cycles with the Met-AV 
system, tumor growth was inhibited by 84%; whereas the CD-AV system achieved 0% 
tumor growth inhibition after three and four treatment cycles (see Figure 9). 
Further optimization of the enzyme prodrug system may enhance therapeutic 
efficacy; however in vitro cytotoxicity results suggest that while the CD-AV system can 
be successful, other systems are likely to have a stronger antitumor effect.  The in vitro 
cytotoxicity of the CD-AV system achieved acceptable cancer cell viability reductions 
following 9 days of treatment, as opposed to 6 days and 3 days for the PNP-AV and 
Met-AV systems, respectively [37, 210].  Similar in vitro efficacy against MDA-MB-
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231 cells and MCF-7 cells suggests that poor in vivo results is unlikely a cell dependent 
issue and possibly a function of the required duration of treatment time and 5-FU 
concentrations necessary to achieve cell death.  Death through achievable levels of the 
generated drug, 5-FU, may simply be too slow to produce a beneficial effect in vivo.  
Additionally, the primary in vivo mechanism of action is suspected to act more directly 
on the tumor endothelium (supported by the in vivo data of Van Rite et al. using the 
Met-AV system [157]) and in vitro results show that effect on endothelial cell viability 
is less significant than the treatment on MCF-7 or MDA-MB-231 cells.  This therapy 
could possibly be more effective if the fusion protein and prodrug were injected daily, 
more than 8 hours apart.  Other delivery mechanisms of cytosine deaminase for enzyme 
prodrug treatment utilizing either gene directed or cell directed strategies may allow for 
greater accumulation of protein and hence greater accumulation of 5-FU, rendering 
those strategies more effective in the case of this particular system in vivo [235, 236]. 
The primary objective for the in vivo evaluation of the CD-AV system was to 
obtain comparative results to allow for selection of one of the three systems for 
optimization and transition to immune competent models.  An alternative dosing 
schedule may have been more successful; however given the success of Met-AV and 
selenomethionine with a similar dosing schedule [157], we opted out of further in vivo 
testing of CD-AV.  
 
Summary of CD-AV System 
The CD-AV and 5-fluorocytosine enzyme prodrug system failed to produce a 
therapeutic effect in SCID mice bearing MDA-MB-231 tumors, despite promising in 
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vitro work.  Further optimization of the system could certainly enhance results; however 
pre-existing data for the Met-AV enzyme prodrug system suggest that the CD-AV 
system would be unlikely to surpass the efficacy of the other systems in vivo.  Lack of 
any comparable in vivo effect eliminated the CD-AV system as a candidate for further 
work to transition to a non-immunogenic system. 
 
Purine Nucleoside Phosphorylase and Fludarabine 
Fusion Protein Construction, Expression, and Purification 
The PNP-AV fusion gene was successfully constructed into an expression 
plasmid (pET303/CT-His) bearing ampicillin/carbenicillin resistance, as confirmed 
through sequencing.  Protein modeling was utilized in the design of the fusion gene, as 
previous efforts yielded poor results suspected to be related to the orientation of the 
protein chains and purification tag.  Examination of PNP subunit termini, shown in 
Figure 11, suggests that fusion to the exposed C-termini of the subunit may have less 
structural impact than N-terminal fusions.  Additionally, previous success with fusion to 
the N-terminal of AV [36, 37] supported gene construction utilizing the following 
orientation (written N to C): PNP – linker – AV – HRV-3C protease site – 6X His-tag.  
Additional modeling of the PNP-AV fusion is shown in Figure 12.  Incorporation of a 
flexible glycine-serine ([GS]3) linker between the PNP and AV genes is standard in 
protein fusions to maximize appropriate folding of proteins and for maintenance of 




Figure 11.  PNP hexamer model with highlighted terminals.   
The PyMOL Molecular Graphics System (version 1.2r3pre; Schrödinger, LLC) 
generated an image of a PNP hexamer using crystal structure data files obtained through 
the Protein Data Bank Europe.  C-termini of each subunit were highlighted and circled 
in blue and N-termini were highlighted and circled in red. 
 
Figure 12.  PNP-AV protein model.   
The PyMOL Molecular Graphics System (version 1.2r3pre; Schrödinger, LLC) 
generated a mesh image of a model PNP-AV hexamer using data files obtained through 
the Protein Data Bank Europe. 
 
The purification process regularly yields in excess of 60 mg purified PNP-AV 
per liter of culture.  The PNP-AV monomers were confirmed with SDS-PAGE, shown 
in Figure 13, to be approximately 65 kDa as expected based on the known monomeric 
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PNP size of 26 kDa [237, 238], AV size of 36 kDa, and amino acid linker size of 3 kDa.  
Densitometric analysis of SDS-PAGE results determined a purity of >93%.   
 
Figure 13.  SDS-PAGE of purified PNP-AV indicates >90% purity. 
M, marker proteins; lane 1, purified PNP-AV. 
 
Enzymatic activity of PNP-AV was determined to be 35 U/mg PNP-AV.  The 
kinetic absorbance measurements of the enzymatic reaction are shown in Figure 14.  A 
specific activity of PNP-AV of 35 U/mg corresponds to a PNP specific activity of 87.5 
U/mg when accounting only for the PNP portion of the fusion.  Recombinant PNP 
production in other studies has yielded enzyme activities between 27 and 180 U/mg 




Figure 14.  PNP-AV enzyme assay kinetic absorbance measurements over 5 min. 
 
Acceptable yields, purity, and enzyme activity were obtained with PNP-AV, 
allowing for further characterization and potential therapeutic efficacy using in vitro 
models. 
 
In Vitro Binding 
Using the calcium dependent nature of specific AV binding to 
phosphatidylserine, total, nonspecific, and specific binding curves were obtained on 
non-confluent HAAE-1, MCF-7, and MDA-MB-231 cells.  Removal of calcium from 
the medium, using the chelator EDTA, allows for the quantification of only nonspecific 
protein binding.  Subtracting the nonspecific binding from the total binding in medium 
containing calcium allows for the quantification of the specific binding of AV to 


























regression of the binding curves (data can be found in Figure 58, Figure 59, and Figure 
60 of Appendix A:  Supplemental Data) and is summarized in Table 7.   
Table 7.  Dissociation constant of PNP-AV binding to cells. 
Cell Line Dissociation Constant  
(Kd) ± standard error (n = 
3) 
HAAE-1 18.3 pM ± 16.4 pM 
MCF-7 51.6 pM ± 18.0 pM 
MDA-MB-231 75.3 pM ± 52.3 pM 
 
PNP-AV binding to non-confluent endothelial cells and MCF-7 and MDA-MB-
231 breast cancer cells was determined to be relatively strong, with all dissociation 
constants in the picomolar range.  In fact, the dissociation constants were determined to 
be stronger for PNP-AV than the other annexin targeted enzymes Met and CD, which 
both had dissociation constants for the same cell lines in the nanomolar range [36, 37].  
Enhanced binding of the PNP-AV system over Met-AV and CD-AV is likely a function 
of avidity (binding of a complex, enhanced with multiple binding sites) rather than 
improved affinity (binding interactions at a single site) as the AV protein is identical 
with each system and the hexameric PNP-AV has six AV per molecule as opposed to 
four AV for Met-AV and two AV for CD-AV.  The additional AV present on the PNP-
AV molecule increase the number of binding sites per molecule, increasing the capacity 
to bind to phosphatidylserine compared to Met-AV and CD-AV and lowering the 
dissociation constant values. 
An analysis of binding stability of PNP-AV on endothelial cells and breast 
cancer cells, shown in Figure 15, confirms presence of protein on cells after 3 days as 
seen with the CD-AV and Met-AV fusion proteins [36, 37].  Presented as a percentage 
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of the amount of protein bound to the cells on day 0, there is an expected drop over 
time. 
 
Figure 15.  Binding stability data for PNP-AV.   
Biotinylated PNP-AV was incubated with cells for 2 h at 37°C and excess was washed 
away.  For three days binding on different cell types was quantified with streptavidin 
conjugated peroxidase.  (□), non-confluent HAAE-1; (▲), MDA-MB-231; and (x) 
MCF-7 cells.  Data is presented as a percentage of fusion protein present immediately 
after the initial wash and is shown as mean ± standard error (n = 3). 
 
Confocal microscopy confirms that the fusion protein is bound to the cell 
membrane but does not continuously cover the membrane, shown in Figure 16.  
Discontinuous exposure of phosphatidylserine has been observed by other studies 
specifically with MDA-MB-231 breast cancer cells and is expected, as externalized 
phosphatidylserine exists primarily in patches of lipid rafts [138, 239].  Epifluorescence 
microscopic approaches have also confirmed cellular association of AV fusion proteins; 
however our confocal approach utilizes secondary staining with a streptavidin 
conjugated fluorophore to allow detection of only fusion protein exposed on the cell 





















of the enzyme prodrug therapy as the prodrug fludarabine requires transporters to move 
it across the cell membrane whereas the drug, 5-fluoroadenine, is freely diffusible 




Figure 16.  Fixed cell confocal imaging of PNP-AV binding.  
Confocal microscopy of MCF-7 cells confirms the presence of externally bound 
biotinylated PNP-AV, with streptavidin-conjugated Alexa Fluor 488 in green (a, b), red 
CellMask plasma membrane stain (c, d), and blue Hoechst 33258 nucleic acid stain (e, 
f). Images a, c, and e show the color channels of an x-y confocal image with the 
composite shown in g. Images b, d, and f show the color channels of an x-z cross-
section of cells with the composite shown in h and the coverslip indicated by the white 
in each image.  Images were obtained on a Leica SP8 scanning confocal microscope. 
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In Vitro Cytotoxicity 
Cytotoxicity studies indicate a significant cytotoxic effect of the PNP-AV 
enzyme prodrug system on breast cancer cell lines MCF-7 and MDA-MB-231 and 
endothelial cells representative of the tumor vasculature, non-confluent HAAE-1.  Cell 
viability over two treatment cycles, each with a duration of 3 days, is shown for the 
three cell lines in Figure 17, Figure 18, and Figure 19.  A 6-day incubation period is 
clearly relevant for the enzyme prodrug treatment for all three cell lines tested, since the 
cell viability declined after each 2-day interval in every case.  The enzyme prodrug 
treatment was particularly effective for the MCF-7 cancer cells and the non-confluent 
endothelial cells, where greater than 95% cytotoxicity was obtained after 6 days of 
treatment.  The lack of significant effect on confluent endothelial cells, Figure 20, is a 
further indication that no binding of the fusion protein had occurred and that confluent 
endothelial cells are representative of the normal vasculature. 
The in vitro cytotoxic effect of fludarabine alone on breast cancer cells confirms 
work in another study that found significant cell killing between 2.5 and 10 µM 
fludarabine, particularly with the MCF-7 cell line [58].  This effect could potentially 
result from active transport across the cell membrane and an increased capacity to retain 
nucleoside analogue triphosphates in tumor cells and is not of significant concern for 
further testing as the same effect is not observed in confluent HAAE-1 cells, which are 
representative of normal vasculature [240].  These findings are not surprising given that 
fludarabine has undergone clinical evaluation as a chemotherapeutic agent for solid 
tumors. 
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The presence of PNP-AV does provide enhanced cell killing over fludarabine 
alone as expected since the conversion of fludarabine to 2-fluoroadenine increases the 
compound’s toxicity, affecting dividing and non-dividing cells and allowing for a 
bystander killing effect due to free diffusion across cell membranes [65].  Fludarabine 
alone is clinically limited as a result of dose dependent myelosuppression, so 
enhancement of the cytotoxic effect only at the site of the tumor using PNP-AV could 
potentially enhance fludarabine efficacy and reduce the necessary therapeutic dose if 





Figure 17.  Cytotoxic effect of PNP-AV enzyme prodrug therapy on non-confluent 
HAAE-1 cells.   
The effects of fludarabine, 2-fluoroadenine, and fludarabine converted to 2-
fluoroadenine by PNP are shown.  Groups that received PNP-AV were treated on days 
0 and 3 of the study.  Fludarabine and 2-fluoroadenine were administered daily.  
Viability was determined by the Alamar Blue assay on days 2, 4, and 6 (black, gray, and 
white bars, respectively), and each sample was represented as a percentage of untreated 
control on each day.  Statistical analysis was performed with a one-way ANOVA test 
with data presented as mean ± standard error (n = 3).  Statistical significance vs. 
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Figure 18.  Cytotoxic effect of PNP-AV enzyme prodrug therapy on MCF-7 cells.   
The effects of fludarabine, 2-fluoroadenine, and fludarabine converted to 2-
fluoroadenine by PNP are shown.  Groups that received PNP-AV were treated on days 
0 and 3 of the study.  Fludarabine and 2-fluoroadenine were administered daily.  
Viability was determined by the Alamar Blue assay on days 2, 4, and 6 (black, gray, and 
white bars, respectively), and each sample was represented as a percentage of untreated 
control on each day.  Statistical analysis was performed with a one-way ANOVA test 
with data presented as mean ± standard error (n = 3).  Statistical significance vs. 
untreated control on the same day is denoted by *(p < 0.001). 
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Figure 19.  Cytotoxic effect of PNP-AV enzyme prodrug therapy on MDA-MB-231 
cells.   
The effects of fludarabine, 2-fluoroadenine, and fludarabine converted to 2-
fluoroadenine by PNP are shown.  Groups that received PNP-AV were treated on days 
0 and 3 of the study.  Fludarabine and 2-fluoroadenine were administered daily.  
Viability was determined by the Alamar Blue assay on days 2, 4, and 6 (black, gray, and 
white bars, respectively), and each sample was represented as a percentage of untreated 
control on each day.  Statistical analysis was performed with a one-way ANOVA test 
with data presented as mean ± standard error (n = 3).  Statistical significance vs. 





































































































































































[Fludarabine] or [2-Fluoroadenine] (µM) 
Day 2 Day 4 Day 6
71 
 
Figure 20.  Lack of cytotoxic effect of PNP-AV enzyme prodrug therapy on 
confluent HAAE-1 cells.   
The effects of fludarabine, 2-fluoroadenine, and fludarabine converted to 2-
fluoroadenine by PNP are shown.  Groups that received PNP-AV were treated on days 
0 and 3 of the study.  Fludarabine and 2-fluoroadenine were administered daily.  
Viability was determined by the Alamar Blue assay on days 2, 4, and 6 (black, gray, and 
white bars, respectively), and each sample was represented as a percentage of untreated 
control on each day.  Statistical analysis was performed with a one-way ANOVA test 
with data presented as mean ± standard error (n = 3).  Statistical significance vs. 
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In Vivo PNP-AV Plasma Clearance 
The pharmacokinetic profile of PNP-AV was similar to the other fusion 
proteins, with plasma clearance occurring within 8 h of intraperitoneal administration, 
as shown in Figure 21.  Clearance within 8 h suggests the prodrug fludarabine could be 
safely administered as early as 8 h post fusion protein administration.  The peak plasma 
concentration of PNP-AV was higher than for CD-AV (Figure 8), so the increased size 
of PNP-AV does not appear to inhibit movement from the peritoneal cavity into the 
circulation. 
 
Figure 21.  PNP-AV clears from the circulation of SCID mice in <8 h.   
An ELISA assay for PNP-AV was performed on serum samples at intervals 
following intraperitoneal administration of PNP-AV at 10 mg/kg.  Data is 
presented as mean ± standard error (n = 3). 
 
In Vivo Evaluation of PNP-AV System and Combination with Docetaxel 
The PNP-AV enzyme prodrug system was evaluated in SCID mice bearing 
subcutaneous MDA-MB-231 tumors placed on the flank.  Tumor volumes were 
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administered on a daily basis, with PNP-AV administration in the morning and 
fludarabine administration following 12 h later in the evening.  Fludarabine was 
administered at 100 mg/kg, as the concentration was found to be safe and effective in 
mice given as an intraperitoneal bolus injection [62, 65, 66, 241]. 
 
Figure 22.  Mild antitumor effect of PNP-AV and fludarabine against MDA-MB-
231 tumors on the flank of SCID mice.   
PNP-AV was administered daily at 10 mg/kg IP followed 12 h later by the 
administration of fludarabine at 100 mg/kg IP.  Treatment occurred for 10 days and is 
indicated by the arrow.  Data is presented as mean ± standard error (n = 6-7).  Statistical 
significance compared to the untreated group is indicated by *(p < 0.01). 
 
The enzyme prodrug therapy produced a mild antitumor effect, with suppression 
of tumor growth achieved during the treatment period and for a brief time following the 
conclusion of the treatment.  As expected, the fusion protein alone and the prodrug 
alone had minimal effect on tumor volume.  None of the groups exhibited signs of 
































negative reaction to the treatment nor displayed significant weight loss, as shown in 
Figure 23. 
 
Figure 23.  Minimal effect of PNP-AV system on weight of SCID mice. 
 
A stronger antitumor effect may have been observed with increased 
concentrations of fludarabine.  PNP enzyme prodrug therapies dose fludarabine ranging 
from 12.5 mg/kg three times daily [65, 242] up to 160 mg/kg three times daily [243].  
Reports of differing tolerances of up to 8-fold between strains of mice suggest that 
optimization for each model may be necessary [241].  Additionally, multiple 
fludarabine injections throughout the day may increase bioavailability, though 
mathematical modeling of plasma levels of fludarabine, shown in Figure 24,  suggest 
our dosing regimen may be nearly optimized based on the requirement that circulating 
fludarabine drop below that of the lethal level of 2-fluoroadenine prior to the 
administration of PNP.  The plasma concentrations were estimated based on a 
fludarabine plasma half-life of 185 minutes [244] and experimentally determined levels 
of PNP-AV, shown in Figure 21.  Stability of the fusion protein bound within the tumor 






















fludarabine could potentially be administered at higher doses or with higher frequency, 
potentially enhancing therapeutic efficacy. 
 
Figure 24.  PNP-AV and fludarabine mathematical modeling of plasma levels 
based on dosing regimen.   
 
Combination with docetaxel was evaluated alongside the PNP-AV enzyme 
prodrug system to cause greater externalization of phosphatidylserine and increase the 
presence of PNP-AV within the tumor.  Docetaxel was used at 5 mg/kg, below the 
typical therapeutic level (30-60 mg/kg [245-247]), to minimize systemic effects yet 
enhance tumor phosphatidylserine exposure.  As expected, docetaxel alone caused no 
significant effects compared to the untreated tumors, shown in Figure 25.  Docetaxel 
combined with the enzyme prodrug treatment resulted in significant tumor regression 
during the treatment period, however regrowth did occur following the conclusion of 
the treatment.  The enhanced therapeutic efficacy with docetaxel was theorized to be a 
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of some synergy between docetaxel treatment and the PNP and fludarabine enzyme 
prodrug system [248]. 
 
Figure 25.  Enhanced antitumor effect of PNP-AV and fludarabine in combination 
with docetaxel against MDA-MB-231 tumors on the flank of SCID mice.   
PNP-AV was administered daily at 10 mg/kg IP followed 12 h later by the 
administration of Flud at 100 mg/kg IP.  Docetaxel (Doc) was administered at 5 mg/kg 
IP every third day, beginning one day prior to the start of the enzyme prodrug treatment.  
Treatment occurred for 10 days and is indicated by the arrow.  Data is presented as 
mean ± standard error (n = 6-7).  Statistical significance compared to the untreated 








































Tumor regrowth was theorized to initiate from a viable rim of cells near the edge 
of the tumor, shown with the darker hematoxylin staining of the intact nuclei of viable 
cells in Figure 26.  Figure 27 confirms the presence of some PNP-AV bound within the 
tumor after administration of the protein to an untreated mouse bearing an MDA-MB-
231 tumor.  A central necrotic core and viable periphery are characteristic of vascular 
targeted agents as observed, whereas direct antitumor chemotherapeutics are most 
effective against the periphery of the tumor, which is typically well oxygenated and 
consists of rapidly dividing cells [249] [138].  Presence of cellular death both at the core 
and at the periphery suggest the therapy may exhibit some properties of both vascular 
directed and proliferation directed therapies, which may result from phosphatidylserine 
expression both on the vasculature and tumor cells.  Immunohistochemical detection of 
PNP-AV may only be possible on the tumor vasculature due to higher exposure to 
protein, but cell death within the tumor may result from free diffusion of 2-





Figure 26.  Hematoxylin stained MDA-MB-231 tumor section from PNP-AV and 




Figure 27.  PNP-AV staining of MDA-MB-231 tumor section. 
Untreated mice were injected with PNP-AV and then sacrificed after 8 h.  Tumors were 
harvested and cryopreserved.  PNP-AV staining was developed with DAB (brown) and 
is indicated with the arrows.  A hematoxylin counterstain (purple) was included for 




Summary of PNP-AV System 
The PNP-AV system produced in vitro results comparable to the CD-AV and 
Met-AV enzyme prodrug systems, with even stronger binding capabilities.  Confocal 
microscopy of PNP-AV confirmed that binding to phosphatidylserine does indeed occur 
and that some enzyme is maintained on the exterior surface of the cells. 
A subcutaneous MDA-MB-231 breast tumor model on the flank of SCID mice 
was utilized for in vivo evaluations.  The enzyme prodrug system alone resulted in a 
suppression of tumor growth during the treatment period, which is a stronger response 
than that observed with the CD-AV system however not as strong as the tumor 
regression seen with the Met-AV system discussed below.  As a result, Met-AV rather 
than PNP-AV was selected as the best candidate for reduction of immunogenicity. 
The combination of docetaxel with PNP-AV did result in tumor regression 
during the treatment period, which provided advantage over the PNP-AV enzyme 
prodrug system alone.  Improved efficacy is suspected to be primarily a result of 
enhanced phosphatidylserine externalization rather than synergy with 2-fluoroadenine, 
but failure to replicate results with the Met-AV system (discussed in upcoming section) 
may provide some evidence to the contrary.  
While the PNP-AV system was ultimately not selected for transition to immune 
competent models, the system did perform with adequate proficiency in immune 
deficient mice and does hold continued promise, particularly with docetaxel 
combination strategies.  Should future work be conducted with the PNP-AV system, it 
would be quite feasible to perform an approach similar to that of the humanized system 
of methioninase using CGL through the use of a humanized version of PNP, developed 
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for gene directed enzyme prodrug therapies at the University of California, Los Angeles 
[250-252]. 
 
Methionine-γ-Lyase and Selenomethionine 
In Vivo Met-AV Plasma Clearance 
The Met-AV fusion protein entered the blood stream and was cleared from 
circulation within 8 h after intraperitoneal administration, as shown in Figure 28.  The 
pharmacokinetic profile was similar for all three fusion proteins in SCID mice. 
 
Figure 28.  Met-AV clears from the circulation of SCID mice in <8 h.   
An ELISA assay for Met-AV was performed on serum samples at 
intervals following intraperitoneal administration of Met-AV at 10 mg/kg.  
Data is presented as mean ± standard error (n = 3). 
 
In Vivo Evaluation of Met-AV System 
The Met-AV enzyme prodrug system was first evaluated in vivo on the cyclic 
dosing regimen that consists of an intraperitoneal injection of Met-AV followed by 
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subcutaneous MDA-MB-231 tumors on the flank of SCID mice and evaluated tumor 
volume, as shown in Figure 29.  Additionally, this study confirmed the vascular directed 
nature of the targeted enzyme prodrug therapies by showing a reduction in blood flow 
in the tumor as well as strong immunohistochemical evidence of Met-AV binding to 
tumor blood vessels [157].  The Met-AV and selenomethionine enzyme prodrug therapy 
significantly inhibited tumor growth and caused moderate tumor regression for the 
duration of the treatment period.  No negative side effects or weight loss was observed 
as a result of treatment.  The regression achieved by the Met-AV system was a 
significant improvement over the CD-AV system, which exhibited no detectable 
antitumor activity, and over the PNP-AV system, which was able to suppress growth 





Figure 29.  Met-AV and selenomethionine reduce MDA-MB-231 tumor growth on 
the flank of SCID mice.   
Met-AV was administered every 4 days (10 mg/kg IP) with selenomethionine 
administered (5 mg/kg IP) each of the subsequent 3 days of the cycle for 3 cycles.  
Treatment period is indicated by the arrow.  Data is presented as mean ± standard error 
(n = 7).  Statistical significance compared to the untreated group is indicated by *(p < 
0.001).   
 
Transition to Orthotopic Tumor Models 
The MDA-MB-231 xenograft model is a standard system for evaluation of 
therapies against human breast cancer; however orthotopic implantation into the 
mammary fat pad is generally considered a more challenging model than the growth of 
the subcutaneous grafts on the flank.  In comparative studies, orthotopic breast cancer 
xenografts showed stronger tumor growth, enhanced vascularization, and differing 
methylation patterns of breast cancer-related gene promoters compared to the same cells 



































metastatic nature of the MDA-MB-231 cell line, no metastatic formation was observed 
using the subcutaneous injection of the cells on the flank of SCID mice in treated or 
untreated mice.  The targeted nature of the enzyme prodrug therapy could theoretically 
also inhibit metastatic growth and formation if phosphatidylserine is externalized as 
anticipated.  The lack of metastatic formation in any experimental groups limits further 
analysis of the treatment; however use of an orthotopic MDA-MB-231 cell injection has 
been shown to result in aggressive metastatic formation at multiple locations [254]. 
Evaluation of the Met-AV system in SCID mice bearing orthotopically injected 
MDA-MB-231 tumors in the mammary fat pad number four did indeed present a more 
challenging model.  Tumor volumes, shown in Figure 30, indicate faster and more 
aggressive growth than previous studies using xenograft growth on the flank of the 
SCID mice.  Despite the significantly more aggressive model, the Met-AV system did 
show therapeutic effect and resulted in significantly reduced tumor volumes compared 
to the untreated group.  As previously observed, tumor regrowth did ultimately occur 
following the conclusion of the treatment.   
Additionally, metastases were observed on the lungs, livers, and spleens of mice, as 
shown in  
Table 8.  The treatment exhibited some beneficial effects on the metastatic 
formations including prevention of splenic metastasis in 75% of treated mice compared 
to presence of splenic metastasis in all untreated mice.  The presence of liver and lung 
metastasis did not appear to be significantly altered by the treatment, though organs 
were only evaluated as positive or negative for nodules.  Spread of the tumor to other 
mammary fat pads occurred in 100% of untreated mice and 0% of treated mice, though 
it was unclear if this observation was due to the significantly larger tumor volumes of 
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untreated mice or metastatic processes.  As previously observed, no negative effects or 
weight loss was displayed as a result of treatment, as shown in Figure 31.   
 
 
Figure 30.  Met-AV and selenomethionine reduce orthotopic MDA-MB-231 tumor 
growth in mammary fat pad of SCID mice.   
Met-AV was administered daily at 10 mg/kg IP followed 12 h later by the 
administration of selenomethionine at 5 mg/kg IP.  Treatment period is indicated by the 
arrow.  Data is presented as mean ± standard error (n = 6-7).  Statistical significance 
compared to the untreated group is indicated by *(p < 0.001).   
 
Table 8.  Metastases in SCID mice with orthotopic MDA-MB-231 tumors. 
The percentage of mice with metastases to various sites is indicated. 
 Spleen Liver Lung Mammary 
Fat Pads* 
Untreated 100% 50% 100% 100% 
mCGL-AV & Sel 25% 58% 100% 0% 


































Figure 31.  Minimal effect of Met-AV system on SCID mouse weight. 
 
In Vivo Evaluation of Docetaxel Combination with Met-AV System 
Significant enhancement of antitumor effects on the PNP-AV system combined 
with docetaxel and the theorized mechanism of increased binding of fusion protein gave 
rise to a reasonable optimism for an enhanced effect when combining docetaxel with 
the Met-AV system.  Unfortunately, tumor volume data, shown in Figure 32, indicated 
no beneficial effect from the combination of docetaxel with Met-AV and 
selenomethionine.  Continued observation further supported that docetaxel had no 
beneficial effect when combined with Met-AV and selenomethionine based on tumor 
volume or mouse survival. 
Several variables exist between the PNP-AV system combined with docetaxel 
and the Met-AV system combined with docetaxel that potentially impact the conflicting 
results regarding the benefit of docetaxel.  The most likely mechanism for differing 
docetaxel contributions is the transition from a subcutaneous tumor on the flank to an 
orthotopic tumor grown in the mammary fat pad.  The differing tumor models have 






















phosphatidylserine directly accessible from the circulation and could even effect 
docetaxel induced externalization.   
Alternatively, the reduced impact of docetaxel may be system specific.  There is 
reported synergy of docetaxel with the PNP and fludarabine enzyme prodrug system 
[248], and if that action is the primary antitumor mechanism as opposed to the 
hypothesized enhancement of phosphatidylserine externalization, that effect could 
supersede any effect resultant from increased phosphatidylserine exposure.  If the 
beneficial docetaxel results are actually due to a mechanistic synergy with 2-
fluoroadenine, the same effect would be unlikely with the Met-AV system.  
Furthermore, differing cytotoxic mechanisms resultant from the systems’ production of 
2-fluoroadenine and methylselenol may cause a therapeutic plateau at different levels of 
generated drug.  For example, the Met-AV system alone may already produce sufficient 
levels of methylselenol to achieve the maximum therapeutic effect, whereas the PNP-
AV system could potentially benefit by increasing levels of 2-fluoroadenine through 
additional binding of PNP-AV.   A number of possible explanations or combinations of 
explanations are feasible, and additional experimentation would be necessary to further 




Figure 32.  Docetaxel combination has no apparent enhancement of antitumor 
effect of Met-AV and selenomethionine for orthotopic MDA-MB-231 tumors in 
SCID mice.   
Met-AV was administered daily at 10 mg/kg IP followed 12 h later by the 
administration of selenomethionine at 5 mg/kg IP.  Doc was administered at 5 mg/kg IP 
every third day, beginning one day prior to the start of the enzyme prodrug treatment.  
Treatment period is indicated by the arrow.  Data is presented as mean ± standard error 
(n = 6-7).  Statistical significance compared to the untreated group is indicated by *(p < 
0.001).  No statistical significance between the Met-AV and Sel and Met-AV and Sel + 




































Preliminary In Vivo Investigation of Rapamycin Combination Therapy 
Failed enhancement of the Met-AV system with docetaxel suggests that the 
enzyme prodrug therapy alone, even with enhanced levels of protein, may not be 
sufficient to result in sustainable reduction of tumor volumes.  Previous histological 
analysis, exemplified in Figure 26, suggests that incomplete tumor killing and 
subsequent regrowth results from the viable rim of cells surrounding the necrotic tumor 
core.  Regrowth is hypothesized to occur as a result of the hypoxic response associated 
with tumor necrosis.  Therefore, upon failure of the Met-AV and selenomethionine 
treatment, rapamycin was introduced concurrently to counter the hypoxic response 
while continuing to administer the enzyme prodrug therapy.   
Despite beginning rapamycin treatment at large tumor volumes of 
approximately 5% of total body mass, a strong therapeutic effect was achieved when 
combining the Met-AV system with rapamycin, shown in Figure 33.  This preliminary 
data suggests that the hypoxic response does indeed play a role in tumor progression 




Figure 33.  Preliminary enzyme prodrug combination therapy with rapamycin 
produces antitumor effect on large orthotopic MDA-MB-231 tumors in SCID 
mice.   
Met-AV was administered daily at 10 mg/kg IP followed 12 h later by the 
administration of selenomethionine at 5 mg/kg IP.  Upon strong tumor growth despite 
enzyme prodrug treatment, daily rapamycin co-treatment was initiated at 5 mg/kg IP.  
Data is presented as mean ± standard error (n = 6-9).  Statistical significance is 
indicated by *(p < 0.05).   
 
Summary of Met-AV System 
The Met-AV enzyme prodrug system caused tumor regression in SCID mice 
bearing MDA-MB-231 tumors on the flank.  Regression resultant from the enzyme 
prodrug treatment alone provided advantage over the PNP-AV system, which could 
only achieve growth suppression, and the CD-AV system which produced no 
measureable effect.  Consequently, the Met-AV system was selected as the primary 




























Prior to attempting immunogenicity reduction strategies, the Met-AV system 
was evaluated in a different model of tumor growth utilizing orthotopic injections of 
cancer cells into the mammary fat pad.  The orthotopic model did indeed exhibit 
characteristics more challenging to the treatment such as faster tumor growth and 
aggressive metastatic formation at multiple sites.  The therapeutic effect of the Met-AV 
system was not as pronounced but still apparent.  Combination with docetaxel did not 
replicate the beneficial results seen with the PNP-AV system; however it is uncertain if 
that is a system-specific or model-specific difference.  Promising preliminary results 
with a rapamycin combination therapy were obtained, supporting the theory that the 




Optimization of conditions for PEGylation of Met-AV proved challenging, 
though successful conjugation was achieved with all PEG evaluated through a 
combination of reaction time, pH, molar ratio, and temperature variations.  Figure 34 
and Figure 35 represent typical results for a series of experiments evaluating reaction 
time and reaction temperatures of 25°C and 4°C for a maleimide PEG conjugation to 
Met-AV.  Maleimide reactions were targeted to an available cysteine on AV used 
successfully in our laboratory in AV conjugation to single-walled carbon nanotubes 
[203].  Mono-PEGylation was desirable, as we have previously shown that maleimide 
conjugation to AV can leave binding to phosphatidylserine uninhibited.  Poly-
PEGylation likely results in conjugation to the enzyme component of the fusion protein 
91 
and interruption of enzyme activity.  Additionally, larger PEGylation extents also pose 
greater potential for binding inhibition.  Small percentages of mono-PEGylated protein 
make size-exclusion separations difficult as each protein contains multiple subunits with 
a somewhat stochastic degree of PEGylation (four subunits for Met-AV and six 
subunits for PNP-AV) resulting in a high polydispersity and low yields of any separable 
homogeneous product.  
Activity analysis of PEGylated product suggests a reduction in activity with 
increased degree of PEGylation, though this analysis was not preceded by a size-based 
separation due to the previously mentioned difficulties.  Samples containing mostly 
poly-PEGylated product generally did not retain activity, suggesting that activity 
present in some PEGylated samples is possibly from residual unPEGylated protein.  
However, some groups have shown some retention of methioninase activity for non-
fused methioninase with up to eight PEGs per subunit [226, 227] and non-fused purine 
nucleoside phosphorylase with up to four PEGs per subunit [255].  The inability to 
directly reproduce or adapt existing protocols for comparable PEGylation is likely a 
result of the multimeric size increases of 164 kDa to 320 kDa (195% increase) for 
tetrameric Met [36]  of 156 kDa to 390 kDa (250% increase) for hexameric PNP [210, 
237, 238] upon fusion of the monomers to a 36 kDa AV and 3 kDa linker region.  
Accompanying the molecular mass increases are increased numbers of the targets of the 
PEG functional groups due to the presence of multiple AV per molecule, resulting in 
poor scaling of reaction conditions. 
Activity retention and acceptable yield were pre-requisites to two additional 
gauges of an ultimately successful PEGylation: preservation of AV binding to 
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phosphatidylserine and reduction of immunogenicity.  PEGylation of most therapeutic 
enzymes attempts to enhance circulation half-life and requires preservation of substrate 
active sites rather than continued macromolecular access to large binding domains.  
There is likely a very small realm of protein PEGylation strategies that effectively 
shield the antigenic sites of the foreign fusion proteins from immune effectors and 
antigen presenting cells, yet do not inhibit binding of the protein to the cell surface. 
 
Figure 34.  Met-AV Maleimide PEGylation at 25°C.   
A 200:1 molar ratio of PEG to Met-AV subunits was evaluated for PEGylation per 
subunit for reaction times of 2 to 28 h.  SDS-PAGE densitometric analysis with ImageJ 
was used to determine percentages of protein within bands representative of 
unPEGylated Met-AV, Met-AV with one PEG (desired product), and all bands showing 
PEGylation at more than one site per Met-AV subunit.  A 10 kDa 4-arm branched PEG 




























Figure 35.  Met-AV Maleimide PEGylation at 4°C.   
A 200:1 molar ratio of PEG to Met-AV subunits was evaluated for PEGylation per 
subunit for reaction times of 2 to 28 h.  SDS-PAGE densitometric analysis with ImageJ 
was used to determine percentages of protein within bands representative of 
unPEGylated Met-AV, Met-AV with one PEG (desired product), and all bands showing 
PEGylation at more than one site per Met-AV subunit.  A 10 kDa 4-arm branched PEG 
with a single maleimide functional group was used for conjugation. 
 
 
Mouse Mutant Cystathionine-γ-Lyase and Selenomethionine 
Fusion Gene Constructions with Annexin I and Annexin V 
Though previous staining for extracellular protein confirmed the external 
binding of AV targeted proteins (see Figure 16 for external PNP-AV binding to MCF-7 
cells), other studies also showed the presence of internalized AV targeted protein (see 
Figure 57 in Appendix A:  Supplemental Data).  This information motivated the 
comparative study of AI and AV fusion proteins, which may exhibit differing 


























were developed using synthetic gene fragments and the Gibson method for gene 
assembly.  Sequencing confirmed correct assembly of genes into expression vectors 
bearing the T7 promoter system. 
 
Protein Expression and Purification 
Both vectors containing mCGL-AI and mCGL-AV genes were successfully 
transformed into BL21(DE3) E. coli, and protein was expressed as described for PNP-
AV and the other enzyme prodrug systems.  Despite codon optimization, purified 
protein yields ranged from 3 mg/L of culture to 20 mg/L of culture, which was 
sufficient for the preliminary in vitro and in vivo analysis but not for the larger-scale in 
vivo studies to follow.  Upon completion of preliminary work that ultimately led to the 
selection of mCGL-AV for further study, that expression system was selected for 
optimization.  Transformation into T7 Express LysY (DE3) cells was performed to 
enhance expression by allowing higher growth densities prior to induction, resulting 
from lower susceptibility to cell lysis and stronger control of the T7 RNA polymerase.  
Purified protein yields in excess of 120 mg/L culture were achieved after optimization 
with this system. 
Immobilized affinity chromatography purification, including proteolytic 
cleavage of the 6X His-tag, was successfully performed as previously described for 
PNP-AV.  An endotoxin removal step during chromatography was included to obtain 
endotoxin levels of <10 EU/mg as assessed by Limulus Amebocyte Lysate assay.  The 
endotoxin removal step of 1% Triton X-114 with 70 column volumes was sufficient to 
reduce levels to below 10 EU/mg.  Initial attempts with 0.1% Triton X-114 resulted in 
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>10 EU/mg and may have resulted in negative side effects in BALB/cJ mice after 




Enzyme activities with the substrate L-methionine for mCGL-AI and mCGL-
AV were 1.0 ± 0.1 U/mg and 1.3 ± 0.2 U/mg, respectively, compared to 1.0 U/mg for 
Met-AV [36].  As native CGL exhibits no detectable activity towards L-methionine 
[169], these results suggest that the mutations of the mouse CGL are comparable to the 
mutations of the human CGL engineered by the Georgiou group at the University of 
Texas [169].  As our enzyme prodrug therapy utilizes the conversion of L-
selenomethionine to methylselenol and not L-methionine depletion alone, we evaluated 
the activity of the engineered mouse CGL towards L-selenomethionine which has not 
been previously evaluated for the engineered human or mouse CGL.  mCGL-AI and 
mCGL-AV exhibited an activity of 0.75 ± 0.2 U/mg and 0.95 ± 0.1 U/mg, respectively. 
 
In Vitro Binding 
Dissociation constants, summarized in Table 9, were calculated from the 
hyperbolic regression of the binding curves (data can be found in Figure 61, Figure 62, 
and Figure 63 of Appendix A:  Supplemental Data).  Binding differences between the 
annexin V molecules on the different fusions can be attributed to experimental 
variation; however mCGL-AV does utilize mouse AV and Met-AV utilizes human AV 
so species differences could contribute to the minor variability observed.  Interestingly, 
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the AI fusion exhibited stronger binding to MDA-MB-231 cancer cells than the AV 
fusions; however the inverse was observed with non-confluent HAAE-1 cells 
representative of tumor vasculature.  The three fusion proteins were evaluated 
concurrently to avoid any experimental differences in phosphatidylserine exposure.  As 
will be further discussed regarding in vivo antitumor efficacy, a phosphorylation site 
resulting in proteolysis of AI but not AV may play a role.  It is possible that cell line 
specific differences in protease expression or phosphorylation capabilities result in 
differing binding strengths between AI and AV.  The dissociation constants for 
describing binding strength were comparable to the other annexin targeted enzyme 
prodrug systems, and all three fusion proteins fell within the expected range. 
Table 9.  Dissociation constants of mCGL-AI, mCGL-AV, and Met-AV on 
MDA-MB-231 and HAAE-1 cells 
Dissociation Constant  (Kd) ± standard error (n = 3) 
 MDA-MB-231 HAAE-1 
mCGL-AI 0.68 nM ± 0.3 nM 2.3 nM ± 1.1 nM 
mCGL-AV 2.5 nM ± 1.7 nM 0.11 nM ± 0.02 nM 
Met-AV 4.9 nM ± 0.9 nM 0.5 nM ± 0.2 nM 
 
Binding stability was also evaluated for the three fusion proteins on MDA-MB-
231 breast cancer cells, as shown in Figure 36.  mCGL-AI, mCGL-AV, and Met-AV all 
exhibited >40% of the protein that initially bound to the cells after three days.  Data is 
consistent with expectations based on the other enzyme prodrug systems.  The 
decreased binding stability observed with AI, though not significant, could also be 
related to its potential proteolysis site. 
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Figure 36.  Binding stability of mCGL-AI, mCGL-AV, and Met-AV 
on MDA-MB-231 cells for 3 days.   
Biotinylated mCGL-AI (x), mCGL-AV (□), and Met-AV (▲) were 
incubated on MDA-MB-231 cells for 2 h at 37°C and unbound protein 
was washed away.  Streptavidin conjugated peroxidase was used to 
determine fusion protein present on the three following days and is 
presented as a percentage of fusion protein present immediately after the 
initial wash.  Data is mean ± standard error (n = 3). 
 
 
Live cell confocal microscopy was performed with fluorochrome conjugated 
mCGL-AI and mCGL-AV and GFP expressing MDA-MB-231 breast cancer cells.  
Cells were maintained at 37°C in a buffered medium without supplemental CO2 
required and monitored for viability using membrane impermeable Hoechst 33258.  The 
cells were imaged for several hours prior to fusion protein administration, during 
incubation with the fusion proteins, and following a wash step to remove unbound 
fusion protein.  Live cell imaging allowed for comparative observation of the binding 
and possible internalization and subsequent dissociation from the membrane of the 





















analysis.  Association of both fusion proteins with the membrane was confirmed, shown 
in the post-wash phase in Figure 37.   
 
Figure 37.  Live cell confocal microscopy confirms membrane binding of mCGL-
AI and mCGL-AV.   
(a) mCGL-AI and (b) mCGL-AV were conjugated to Dylight 680 (red) and incubated 
with MDA-MB-231/GFP cells (green).  After 2 h at 37°C, cells were washed with 
culture medium to remove excess protein and imaged using a Leica SP8 confocal 
microscope with HyD detectors.  Cells were kept at 37°C using a Peltier stage and 
viability was confirmed through the lack of nucleic acid staining despite inclusion of 
membrane impermeable Hoechst 33258 in the imaging medium. 
 
From these images it is impossible to distinguish external membrane binding 
from internal membrane binding (this requires inclusion of a physical method of 
detecting only external or internal protein such as that described for the fixed confocal 
image shown in Figure 16), but internalization would likely have to occur through an 
endocytic pathway which is not observed (fusion protein does not appear to be present 
in endocytic vesicles).  The membrane association remained consistent and comparable 
among the mCGL-AI and mCGL-AV proteins for the duration of the observation period 
(up to 6 h post-wash). 
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In Vitro Cytotoxicity 
Concurrent cytotoxicity studies examined the therapeutic effect of the three 
fusion proteins, mCGL-AI, mCGL-AV, and Met-AV on MDA-MB-231 breast cancer 
cells, as shown in Figure 38.  The three systems exhibited comparable cytotoxic effect 
over 3 days of selenomethionine administration following a single fusion protein 
administration at the beginning of the study.  When fusion protein administration was 
also performed daily, the therapeutic effect was enhanced, as shown in Figure 39.  Daily 
fusion protein administration had a particularly beneficial effect for the mCGL-AI 
system which elicited significantly stronger decreases in viability at lowered prodrug 
concentrations.  Enhancement of therapeutic efficacy using higher frequency 
administrations of fusion protein in vitro also supports the transition to the daily fusion 
protein administration in vivo. 
Prior to in vivo studies in immune competent BALB/cJ mice bearing 4T1 murine 
breast tumors, the cytotoxic effect was confirmed in vitro on 4T1 murine breast cancer 
cells.  The data, shown in Figure 40, is consistent with the cytotoxicity results on the 
human MDA-MB-231 breast cancer cells.  Interestingly, the mCGL-AI targeted system 
appeared to have a moderately stronger effect than the mCGL-AV and Met-AV systems 




Figure 38.  Comparison of the cytotoxic effect of mCGL-AI, mCGL-AV, and Met-
AV enzyme prodrug therapy on MDA-MB-231 cells.   
Groups that received fusion protein were treated on day 0.  Selenomethionine was 
administered daily.  Viability was determined by the Alamar Blue assay on days 1, 2, 
and 3 (black, gray, and white bars, respectively), and each sample was represented as a 
percentage of untreated control on each day.  Statistical analysis was performed with a 
one-way ANOVA test with data presented as mean ± standard error (n = 3).  Statistical 






* * * 
* 






































































































































































































Day 1 Day 2 Day 3
101 
 
Figure 39.  Comparison of the cytotoxic effect of daily administration of mCGL-AI 
and mCGL-AV enzyme prodrug therapy on MDA-MB-231 cells.   
Fusion protein and selenomethionine was administered daily.  Viability was determined 
by the Alamar Blue assay on days 1, 2, and 3 (black, gray, and white bars, respectively), 
and each sample was represented as a percentage of untreated control on each day.  
Statistical analysis was performed with a one-way ANOVA test with data presented as 
mean ± standard error (n = 3).  Statistical significance vs. untreated control on the same 
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Figure 40.  Comparison of the cytotoxic effect of mCGL-AI, mCGL-AV, and Met-
AV enzyme prodrug therapy on 4T1 cells.   
Groups that received fusion protein were treated on day 0.  Selenomethionine was 
administered daily.  Viability was determined by the Alamar Blue assay on days 1, 2, 
and 3 (black, gray, and white bars, respectively), and each sample was represented as a 
percentage of untreated control on each day.  Statistical analysis was performed with a 
one-way ANOVA test with data presented as mean ± standard error (n = 3).  Statistical 
significance vs. untreated control on the same day is denoted by *(p < 0.001). 
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In Vivo Comparison of Annexin I and Annexin V Therapy Efficacy 
Strong in vitro results for binding and cytotoxic effect of both mCGL-AI and 
mCGL-AV enzyme prodrug systems warranted a comparative in vivo study.  Minor 
differences in in vitro binding and cytotoxicity failed to generate a clear picture of the 
superiority of one system over the other, especially considering how unknown effects of 
the tumor microenvironment may alter the therapeutic efficacies. 
A small scale study was performed to examine the mCGL-AI and mCGL-AV 
enzyme prodrug systems for therapeutic efficacy in BALB/cJ mice bearing orthotopic 
4T1 tumors.  The data, shown in Figure 41, suggest that the minor advantage observed 
with the mCGL-AI system in vitro cytotoxicity studies does not translate to the in vivo 
environment.  While both systems performed adequately with some growth suppression, 
the effect was more pronounced with the mCGL-AV system. 
Despite improved binding strengths, the decreased binding stability observed 
with annexin I may be exacerbated in vivo.  Annexin I, but not annexin V, contains a 
tyrosine phosphorylation site on the variable N terminal domain which can result in 
proteolytic truncation of the annexin I protein [150, 152].  The orientation of the fusion 
proteins (N to C) is mCGL-linker-annexin and proteolytic separation of the annexin I N 
terminal would release the enzymatic component of the fusion from the 
phosphatidylserine binding C terminal domain of the annexin.  It is possible that while 
annexin I can exhibit improved initial binding, proteolysis ultimately occurs that 
releases a majority of the fusion protein.  As evidenced from the strong in vitro 
cytotoxicity data, if proteolysis is limiting the therapeutic efficacy then it is likely 
occurring to a greater extent in the in vivo tumor environment. 
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The mildly stronger antitumor effect of the mCGL-AV system with the 4T1 in 
vivo model led to the selection of mCGL-AV as the primary candidate for further in 
vivo studies.  While AI targeted systems may exhibit utility in future studies, selection 
of a single system for the immediate studies to follow was necessary for logistical 
purposes and feasibility. 
 
 
Figure 41.  Comparison of efficacy of AV and AI targeted mCGL enzyme prodrug 
therapy with selenomethionine on orthotopic 4T1 tumors in BALB/cJ mice.   
mCGL-AV and mCGL-AI were administered daily (10 mg/kg IP).  Selenomethionine 
(5 mg/kg IP) was administered 10 h post fusion protein administration.  Treatment 
began on day 11 and continued until day 18 as indicated by the arrow.  Statistical 
significance vs. untreated is indicated by *(p < 0.001).  No significant difference was 
observed between treatment groups.  No negative effects were observed with either 






































In Vivo Comparison of Protein Administration Method 
Comparison of IV and IP administration of mCGL-AV suggested stronger 
efficacy using IP injections, as shown in Figure 42.  It was originally anticipated that IV 
administration would result in more fusion protein entering circulation, hence 
enhancing therapeutic efficacy; however the opposite results were observed.  After 
repeated administrations (daily), the tail vein became decreasingly accessible making 
this method unsuitable for daily injections.  No problems were observed with daily IP 
administration of mCGL-AV. 
 
 
Figure 42.  Intraperitoneal route of administration of fusion protein produces 
stronger antitumor effect than tail vein administration for orthotopic 4T1 tumors 
in BALB/cJ mice.   
mCGL-AV was administered daily (10 mg/kg) either IP or IV.  Selenomethionine (5 
mg/kg IP) was administered 10 h post fusion protein administration.  Treatment began 
on day 11 and continued until day 18 as indicated by the arrow.  Statistical significance 
between IP and IV administration is indicated by *(p < 0.05).  Data is presented as 
mean volume ± standard error (n = 6). 
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In Vivo mCGL-AV Plasma Clearance 
Clearance of the mCGL-AV protein from the circulation of BALB/cJ mice 
occurred with pharmacokinetics similar to the other enzyme prodrug systems in SCID 
mice.  Complete clearance occurred within 10 h of a 10 mg/kg intraperitoneal 
administration of mCGL-AV (Figure 43).  Interestingly, a higher peak concentration of 
mCGL-AV was observed when compared to other enzyme prodrug systems.  This 
difference is most likely mouse strain dependent since the protein properties are similar.  
Alternatively, insufficient peak resolution could be a factor causing observed but not 
actual differences that could be resolved with higher frequency sampling; however the 
pharmacokinetic study was simply designed for confirmation of protein entrance into 
circulation and clearance by a specific time point (10 h). 
 
 
Figure 43.  mCGL-AV clears from the circulation of BALBC/cJ mice 
in <10 h.   
An ELISA assay for mCGL-AV was performed on serum samples at 
intervals following intraperitoneal administration of mCGL-AV at 10 
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Efficacy and Immunogenicity of Met-AV vs. mCGL-AV 
The reasoning behind the development of the mCGL-AV system, consisting 
entirely of native protein with the exception of the three amino acid mutations, was the 
theorized immunogenicity in mice and anticipated immune reaction in humans of the 
comparable bacterial Met-AV system.  A reduction of immunogenicity was a 
prerequisite for any consideration of clinical trials regardless of Met-AV enzyme 
prodrug system performance and immunogenicity in mice.  The three amino acid 
mutations in the human CGL, equivalent to those performed in this study for the mouse 
CGL, are not anticipated to produce any immune response through computational 
analysis [169]. 
A basic analysis was conducted in mice to examine fusion protein specific 
antibody titers as well as antitumor efficacy.   The Met-AV system was included as 
positive control, expected to elicit an immune response based on the enzyme origination 
from P. putida.  The treatments were administered daily over three weeks to immune 
competent BALB/cJ mice bearing 4T1 orthotopic tumors.   No anaphylactic response or 
other negative side effects were observed with either treatment group.  For the mice 
injected daily with Met-AV, an analysis of blood samples collected weekly during the 
treatment revealed the presence of Met-AV specific antibodies within 7 days of the start 
of the treatment.  By the third week, Met-AV specific antibody levels were an order of 
magnitude higher than after one week of treatment.  Contrary to the Met-AV results, no 
mCGL-AV specific antibodies were detected through three weeks of treatment.  
Antibody titer results are summarized in Table 10.   
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Observation of tumor volumes showed tumor progression to occur significantly 
faster with the Met-AV system compared to the mCGL-AV system, as shown in Figure 
44.  Significant tumor progression during Met-AV and selenomethionine treatment 
within one week of treatment initiation suggests that the elicited antibody response has 
neutralizing capabilities, rendering the therapy ineffective and indistinguishable from 
untreated mice.  The mCGL-AV system does ultimately revert from tumor growth 
suppression to tumor progression, as observed with the other enzyme prodrug systems 
in SCID mice.  Eventual tumor progression is hypothesized to be a result of the hypoxic 
response to the vascular targeted therapy rather than the generation of neutralizing 
antibodies, which is supported by the antibody titer data. 
BALB/c mice are considered a conventional model for immunogenicity analysis 
of mammalian proteins though differences between the mouse and human immune 
system limit utility [256].  In fact, the BALB/c model may overestimate protein 
immunogenicity compared to the human response [256, 257].  A more comprehensive 
immunogenicity analysis could include computational analysis and use of HLA-
transgenic mice that have a stronger correlation with human T-cell responses [258].  
Any animal or computational immunogenicity analysis though has limited utility, as the 
human response remains unpredictable and even non-human primate models provide 
inadequate comparisons [162, 258].  The ultimate evaluation for immunogenicity would 
require FDA regulated trials [168], which would first look for the development of a 
specific antibody response [161].  The lack of a specific antibody response in mice is 
certainly an important achievement and the first criterion should any adaptation of the 
therapy advance beyond preclinical studies in the future. 
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Table 10.  Fusion protein specific IgG + IgM titers in BALB/cJ mice improved 
with daily administration of mCGL-AV over Met-AV (10 mg/kg IP) 
 Day 0 Day 7 Day 14 Day 21 
mCGL-AV Not detected Not detected Not detected Not detected 








Figure 44.  Comparison of efficacy of mCGL-AV and Met-AV enzyme prodrug 
therapy with selenomethionine on 4T1 tumors in BALB/c mice.   
mCGL-AV and Met-AV were administered daily (10 mg/kg IP).  Selenomethionine (5 
mg/kg IP) was administered 10 h post fusion protein administration.  Treatment began 
on day 10 and continued until day 30 as indicated by the arrow.  Statistical significance 
vs. untreated is indicated by *(p < 0.001).  Statistical significance of mCGL-AV and 
Sel vs. Met-AV and Sel is indicated by #(p < 0.001).  No negative effects were 














































Rapamycin and Cyclophosphamide Combination Therapies 
Despite a lack of neutralizing antibodies and a model with a functional immune 
system, the mCGL-AV and selenomethionine enzyme prodrug system failed to 
eliminate 4T1 tumors from the mammary fat pad of BALB/cJ mice.  Genomic 
instability significantly contributes to a tumor’s adeptness at immune evasion and 
development of treatment resistance.  As genetic variation accumulates over time, so 
does the tumor’s ability to avoid immune detection or therapeutic destruction [259].  
Delayed and incomplete antitumor responses beyond the early stages of tumor 
development fail to eliminate small populations of cells that have adapted to the 
immune response and other therapeutic conditions.  Tumor repopulation occurs 
according to Darwinian logic in which the cancer cells that have successfully adapted to 
treatment conditions and any immune response proliferate to a greater extent than other 
cells.  Tumor regrowth results despite the continuance of initially successful treatment 
conditions.  These properties of cancer cells result in the development of the biological 
hallmarks of cancer and necessitate early and effective elimination of the cancer, likely 
through multiple mechanisms. 
The hypoxic response, theorized to be augmented due to the vascular targeted 
approach of the therapy and resultant reduction in blood flow [157], was addressed 
through the incorporation of rapamycin with the enzyme prodrug therapy.  Additionally, 
the cytotoxic effect against the tumor vasculature could allow for direct release of tumor 
antigens into circulation, so combination with cyclophosphamide was included to 
enhance antitumor immunity.   
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When examining the rapamycin and cyclophosphamide combinations with the 
enzyme prodrug therapy in BALB/cJ mice bearing aggressive 4T1 mammary tumors, 
shown in Figure 45, it is apparent that the rapamycin combined with the enzyme 
prodrug therapy produces beneficial antitumor effects.  The mCGL-AV and 
selenomethionine system alone do produce a significant improvement in tumor volume 
over untreated mice; however the effect is not sustainable as previously observed.  
Rapamycin without the mCGL-AV system does exhibit some effect alone; however the 
advantage of the combined therapies produces the strongest antitumor results.  
Cyclophosphamide alone or in combination with the mCGL-AV system or rapamycin 
does not appear to have a significantly beneficial effect on tumor volumes, though its 
inclusion does not seem to negatively impact the therapies’ capacities to restrict tumor 
progression.  Neither rapamycin, cyclophosphamide, nor the mCGL-AV system were 
administered at doses high enough to elicit side effects or weight loss in the mice, as 
shown in Figure 46. 
The injection of 4T1 cells into the mammary fat pad results in the formation of 
highly aggressive tumors that rapidly form pulmonary metastases.  For the majority of 
mice, metastases are the limiting factor for survival rather than the growth of the 
primary tumor.  Upon examining the survival curves, shown in Figure 47, and median 
survivals of each group, shown in Table 11, it is apparent that cyclophosphamide 
exhibits a beneficial effect on survival even to some degree without any combination 
treatment, though significance is established only when combined with the enzyme 
prodrug therapy and rapamycin.  The enhanced median survival suggests that 
cyclophosphamide may indeed be stimulating an antitumor immune response that limits 
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the progression of the metastases, since improved median survival is not only a function 
of primary tumor volume, particularly in the case of cyclophosphamide alone.   
The mCGL-AV enzyme prodrug system also exhibits an enhancement of 
median survival to a degree similar to that with the presence of cyclophosphamide.  
With this particular 4T1 tumor model where death is predominantly a function of 
metastatic progression, an increased survival with the mCGL-AV system suggests some 
anti-metastatic action, either through phosphatidylserine exposure on metastatic lesions 
or action on the primary tumor limiting metastatic formation.  Minimal enhancement of 
survival is observed with the mCGL-AV system combined with cyclophosphamide 
when compared to either cyclophosphamide or the enzyme prodrug system alone.  As 
expected, the individual constituents of the enzyme prodrug system itself do not have a 
significant impact on survival. 
The main intended mechanism of action for rapamycin is against the primary 
tumor and the hypoxic response and was not theorized to have reducing effect on 
metastatic progression (in fact some studies report the contrary, likely from the 
immunosuppressive properties of rapamycin [178]).  Interestingly, rapamycin combined 
with the enzyme prodrug therapy did enhance survival compared to the untreated group.   
The complete combination of rapamycin, cyclophosphamide, and the mCGL-
AV enzyme prodrug system does have a significant beneficial effect on survival, 
exceeding the benefit seen with any of the individual components or combinations of 
the individual components.  Primary tumor volume for the complete combination is 
similar to the combination lacking cyclophosphamide; however the inclusion of 
cyclophosphamide clearly enhances survival benefits.  When examining both primary 
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tumor volume and survival, the two primary designators of preclinical therapeutic 
success, the combination of cyclophosphamide, rapamycin, and mCGL-AV and 





Figure 45.  Combination therapy effects on orthotopic 4T1 tumor volume in 
BALB/cJ mice.   
mCGL-AV was administered daily (10 mg/kg IP).  Selenomethionine (5 mg/kg IP) was 
administered 10 h post fusion protein administration.  Rapamycin (5 mg/kg IP) and 
cyclophosphamide (10 mg/kg IP) are administered daily.  Treatment began on day 10 
and continued until day 30 as indicated by the arrow.  Statistical significance vs. 
untreated is indicated by *(p < 0.001).  Data is presented as mean volume ± standard 
error (n = 5 to10 initially, though does drop to as low as 2 as survival decreases towards 











































Days after inoculation 
Untreated mCGL-AV
Cyc mCGL-AV & Sel
Rap mCGL-AV & Sel + Rap
Cyc + Rap mCGL-AV & Sel + Cyc
Sel mCGL-AV & Sel + Cyc + Rap
115 
 
Figure 46.  Minimal effect of mCGL-AV system and combination therapies on 
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Table 11.  Median mouse survival and log-rank p-values of Kaplan-Meier survival 






(vs. mCGL-AV & Sel) 
Untreated 14 days   
Cyc 23 days 0.2739  
Rap 14 days 0.7830  
Cyc + Rap 24 days 0.1315  
Sel 18 days 0.8813  
mCGL-AV 18 days 0.5215  
mCGL-AV & Sel 26 days 0.1005  
mCGL-AV & Sel + Rap 27 days * 0.0015 0.0303 
mCGL-AV & Sel + Cyc 28 days 0.0079 0.0560 
mCGL-AV & Sel + Cyc + Rap 36 days * 0.0002 * 0.0014 
 
Therapeutic Contributions of Combination Constituents 
Further analysis, primarily comprised of immunohistochemistry studies, was 
performed to confirm the general hypothesized mechanisms of the antitumor responses.  
The degree to which the targeted mechanisms are successful or unsuccessful could help 
guide the design of future combination studies.  The cytotoxic effect on the cancer cells, 
theorized to result primarily from the action of the enzyme prodrug therapy, was further 
evaluated with immunohistochemical staining for apoptosis (activated caspase-3) and 
proliferation (ki-67).  The reduction of the hypoxic response, the reason for inclusion of 
rapamycin, was evaluated through immunohistochemical staining of HIF-1α and 
quantification of tumor necrosis.  Representative images from each of these 
experimental approaches are presented in Figure 48.  Evaluation of cyclophosphamide’s 
immunostimulatory and anti-metastatic effects was performed through the 




Figure 48.  Representative immunohistochemistry images. 
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The extrinsic and intrinsic apoptotic pathways, extrinsic involving the death 
receptors and the intrinsic involving cell stress causing mitochondrial release of 
cytochrome c, converge with the proteolytic cascade and activation of caspase-3 [260].  
The presence of activated caspase-3 indicates forthcoming apoptosis (though necrosis is 
possible), and the data in Figure 49 suggest the enzyme prodrug therapy results in 
increased activation of apoptotic pathways.  Evidence also exists that while cell death 
does occur, caspase-3 activation also results in a mechanism that stimulates the 
repopulation of the tumor from the small proportion of surviving cells [261], suggesting 
that this response could be further explored in the prevention of tumor regrowth. 
Staining for ki-67, a common marker for proliferative activity [262, 263], 
displayed the inverse trend of that observed with activated caspase-3, as anticipated.  
The quantification of ki-67 staining is presented in Figure 50.  Based on the data 
showing increased levels of apoptosis in mCGL-AV and selenomethionine treated 
groups, decreased levels of proliferation in the enzyme prodrug treated groups is 





Figure 49.  Enzyme prodrug treatment for 3 weeks results in increased staining of 
apoptosis marker activated caspase-3 in mice with orthotopic 4T1 tumors.   
A Nikon Eclipse E800 compound microscope was used to capture 15 fields of view of 
tumor sections from 3 mice per group (necrotic tumor cores were excluded).  
Immunostaining for activated caspase-3 was quantified as percent of cells (hematoxylin 
counterstain) with DAB and is presented as mean ± standard error.  Statistical 




Figure 50.  Enzyme prodrug treatment for 3 weeks results in decreased staining of 
proliferation marker ki-67 in mice with orthotopic 4T1 tumors.   
A Nikon Eclipse E800 compound microscope was used to capture 15 fields of view of 
tumor sections from 3 mice per group (necrotic tumor cores were excluded).  
Immunostaining for ki-67 was quantified as percent of cells (hematoxylin counterstain) 
with DAB and is presented as mean ± standard error.  Statistical significance between 




Intratumoral hypoxia frequently results in necrotic tumor cores, particularly with 
in vivo models bearing tumor grafts.  Some degree of coagulative necrosis was apparent 
in tumor sections from all treated and untreated groups, with the quantification shown in 
Figure 51.  The fast-growing and aggressiveness of the 4T1 mammary tumors results in 
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high necrotic percentages in untreated tumors as the tumor mass outgrows its blood 
supply.  The targeted mCGL-AV enzyme prodrug therapy may be expected to actually 
increase necrosis since it is known to reduce tumor blood flow [157], however minimal 
increase of necrotic percentage compared to untreated mice was observed.  Reduced 
necrosis in tumor sections treated with rapamycin is unsurprising given the role of 
mTOR-dependent tumor necrosis factor-α (TNF-α) related necrosis [189, 264], 
potentially through the inhibition of TNF-α production [265].  The rapamycin induced 
reduction of necrosis remains independent from the enzyme prodrug therapy effects on 
apoptosis and proliferation.  Reduced necrosis appears to be entirely dependent on the 
rapamycin treatment, and apoptosis and proliferation effects appear to be solely a 
function of the administration of the enzyme prodrug therapy. 
The primary intended downstream target of mTOR inhibition with rapamycin 
and the main controller of the hypoxic response is HIF-1α.  Necrosis is a strong 
indicator of hypoxia and the subsequent enhanced expression of HIF-1α, which is 
expected to be highest in the surrounding viable cancer tissue [4].  Quantification of 
HIF-1α staining of tumor sections is shown in Figure 52.  The decreased levels of HIF-
1α in rapamycin treated mice correlate with the observed decreased necrotic region, as 
anticipated.  Unexpectedly, low dose cyclophosphamide also resulted in a drastic 
reduction of HIF-1α expression in the tumor sections.  The effect was not as 
pronounced when combined with the enzyme prodrug therapy, though results were 
variable.  Implications of these observations are unknown as the necrotic tumor 
percentages were not reflective of a cyclophosphamide induced reduction in HIF-1α 
expression.  Additionally, the quantitative data presented in Figure 52 represents HIF-
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1α staining as a regional percentage of tumor area and does not adequately quantify the 
small but strong HIF-1α “hot spots” apparent in the cyclophosphamide group shown in 
Figure 48. 
 
Figure 51.  Rapamycin reduces percent necrosis in 4T1 tumor sections.   
Necrotic regions were determined from hematoxylin and eosin stained tumor sections 
and quantified from whole section images of mice sacrificed after 3 weeks of treatment.  
Data is presented as mean ± standard error (n = 3 mice).  Statistical significance 




Figure 52.  Rapamycin reduces percent of tumor expressing HIF-1α.   
Immunohistochemistry staining of HIF-1α with DAB development was quantified from 
whole section images of mice sacrificed after 3 weeks of treatment.  Data is presented 
as mean ± standard error (n = 3 mice).  Statistical significance between groups is 
indicated by +(p < 0.01) or *(p < 0.001). 
 
Metastatic progression is hypothesized as the predominant cause of death in the 
mice bearing 4T1 mammary tumors; hence determination of the presence of metastatic 
nodules holds predictive therapeutic value [266].  Individual metastatic nodules on the 
lungs of tumor bearing mice are graphically presented as a function of nodule size, with 
nodule quantities summarized in Figure 53.  A logarithmic scale is utilized for the 
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graphical display of metastatic nodules, as the sizes are fairly normally distributed on 
the logarithmic scale, explained by the expected exponential growth of the cells at the 
metastatic sites [267, 268].  The quantities of metastatic nodules observed for each 
experimental group correlate well with the observed survival data for all groups except 
the mCGL-AV and Sel + Rap group. 
Cyclophosphamide provides clear benefit through reduced numbers of 
metastases.  The enzyme prodrug therapy also shows reduced numbers and size of 
metastatic nodules.  Rapamycin, however, exhibits no benefit regarding metastatic size 
or quantity.  When rapamycin is combined with the enzyme prodrug therapy, metastatic 
progression is actually enhanced compared to the enzyme prodrug therapy alone, 
contrary to the observed survival data.  Enhanced metastatic formation with rapamycin, 
likely a result of its immunosuppressive properties, can be attenuated with a reduced 
dose (reduction from 5 mg/kg to 1.5 mg/kg eliminated metastatic progression, though 
the antitumor effect at the reduced dose is unreported) [178]. Fortunately, rapamycin 
does not act in an antagonistic manner with cyclophosphamide and the complete 
combination of rapamycin, cyclophosphamide, and mCGL-AV and selenomethionine 

























































































Figure 53.  Cyclophosphamide reduces number of pulmonary metastasis in 
orthotopic 4T1-TdTomato BALB/cJ model.   
A Leica stereomicroscope with an automated ImageJ macro was used to quantify 
fluorescent nodules in the lung.  Data is shown as individual nodules from the lungs of 
three mice per group after 3 weeks of treatment on a log-normal scale, as the nodule 
sizes were logarithmically distributed.  Median nodule size on the log scale is marked.  
Total nodules per group (n = 3 mice) is summed and shown. 
 
To confirm cyclophosphamide’s anti-metastatic activity as a result of reduced 
regulatory T cell numbers, flow cytometry of the spleens of the mice was performed.  
Representative raw flow cytometry data, as well as gating methodology for the 
quantification of the regulatory T cells, is presented in Figure 54.  The quantification of 
the regulatory T cell levels for each experimental condition is shown in Figure 55.  A 
drastic reduction in regulatory T cell levels upon cyclophosphamide treatment was not 
observed as expected to corroborate the anti-metastatic activity of cyclophosphamide.  
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Perhaps, the most viable comparisons presented in Figure 55 are actually between the 
mCGL-AV& Sel, mCGL-AV & Sel + Cyc, and mCGL-AV & Sel + Cyc + Rap, as 
those experimental groups presented with similar levels of metastases and in a similar 
state of health at the time of data collection.  Among those groups, cyclophosphamide 
did cause a mild reduction in regulatory T cell levels.   
 
 
Figure 54.  Flow cytometry gating of regulatory T cells from the spleens of 
BALB/cJ mice.   
Lymphocytes were first gated with forward and side scatter (a, P1).  Regulatory T cells 
were considered to be CD4+ and FoxP3+ and quantified (b).  CD+ FoxP3+ (c, light 















































































































Figure 55.  Effects of combination treatments of regulatory T cell levels in the 
spleen.   
CD4+ CD25+ FoxP3+ regulatory T cell levels were quantified with flow cytometry and 
are presented as a percentage of spleen lymphocytes in BALB/cJ mice with 4T1 grafts 
after 3 weeks of treatment or healthy BALB/cJ mice with no tumor.  Data is mean ± 
standard error (n = 3 mice).  Statistical significance was observed compared with 
healthy mice, but no statistical significance was observed between groups bearing 
tumors. 
 
Despite similar levels of regulatory T cells, rapamycin clearly does not impart 
the anti-metastatic properties exhibited by cyclophosphamide treated groups.  Taken 
together, Figure 53 and Figure 55 support the expectation that regulatory T cell 
quantities alone are not entirely responsible for the success or failure of pulmonary 
metastatic formations.  High quantities and sizes of metastatic nodules of rapamycin 
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treated groups in Figure 53 raise concerns regarding the documented 
immunosuppressive properties of rapamycin; however near complete attenuation of 
these observations with the addition of cyclophosphamide allow for continued positive 
speculation of combinatory treatments.  Rapamycin, generally considered a cytostatic 
agent, can be viewed as immunosuppressive considering the requirement for constant 
expansion of immune cells, though the anti-proliferative effects on cancer cells may 
prove to be a more dominant action [269].    
Unexpectedly, rapamycin combination had a similar, though mild, effect on 
splenic regulatory T cell levels to cyclophosphamide combinations.  When used 
together, rapamycin and cyclophosphamide appear to exhibit a complementary 
downregulation of regulatory T cells compared to the enzyme prodrug treatment alone.  
The hypoxic promotion of regulatory T cell activity has been established [270-272], 
therefore the reduction of hypoxia with rapamycin may indirectly result in decreased 
levels of regulatory T cells.  To my knowledge the phenomenon of rapamycin reduction 
of regulatory T cell levels has not been observed, though mTOR inhibition with 
rapamycin does result in the blockade of IL-2 signaling [269], which is necessary for 
the development and maturation of regulatory T cells [273-275].  Note that regulatory T 
cell levels in Figure 55 are reported as a percentage of spleen lymphocytes, so 
rapamycin related reductions are not attributed simply to the general 
immunosuppressive properties of rapamycin. 
Interestingly, mice bearing 4T1 tumors had decreased levels of CD4+ CD25+ 
FoxP3+ regulatory T cells compared to healthy mice.  This is in opposition to other 
tumor models that show increasing regulatory T cell levels with tumor progression 
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[276], though some other work corroborates the lack of increased regulatory T cells in 
the tumor and spleen of BALB/c mice bearing 4T1 tumors [277].  It is possible that 4T1 
tumor development results in immune tolerance through the expansion of myeloid-
derived suppressor cells rather than expansion of regulatory T cells, indicating there 
may be more effective means for immunostimulation of this model.  Important to note 
however is that the criteria of interest is actually the prevalence of metastatic nodules 
and the theorized reduction of regulatory T cells was a means to that end.  While 
cyclophosphamide and rapamycin both caused mild reductions in regulatory T cell 
levels, only cyclophosphamide produced beneficial results regarding prevalence of 
metastatic nodules in the lung.  This observation, combined with the higher regulatory T 
cell levels in healthy mice suggest that low dose cyclophosphamide plays an additional 
role in metastatic progression in addition to the documented effect on regulatory T cells. 
An alternative mechanism to the beneficial impact of cyclophosphamide on 
pulmonary metastatic prevalence is the increased presence of regulatory T cells local to 
the metastasis.  This phenomenon has been previously observed with bone metastasis of 
4T1 cells and provides a plausible explanation to the therapeutic advantage of 
cyclophosphamide despite negligible effects on spleen regulatory T cells [278].  
Additionally, some evidence exists for the 4T1 model that low levels of regulatory T 
cells persist, though they maintained strong immunosuppressive activity and even minor 
depletions caused significant improvements in antitumor immunity [279].  A further 
extension of that possibility is the cyclophosphamide related reduction in activity, not 
necessarily quantity, of regulatory T cells.  Essentially, a flow cytometry analysis of 
spleen regulatory T cells was insufficient to confirm that cyclophosphamide did in fact 
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improve antitumor immunity and the conflicting literature suggests that a full 
immunological workup including quantification of tumor infiltrating immune cells, 
metastases-localized immune cells, and levels of immune-regulatory cytokines would 
be necessary to further elucidate the mechanism of cyclophosphamide efficacy against 
metastases.   
 
Commentary on 4T1 Mouse Model 
The 4T1 tumor model was intentionally selected for its highly aggressive nature, 
poor immunogenicity, and low treatment response rates.  The moderate success of the 
presented treatment strategies could potentially show significantly stronger effects and 
possibly result in tumor cure in other less aggressive and more immunogenic models.  
The triple negative status of the 4T1 model also contributes to its challenging nature, as 
a result of altered signaling pathways.  Specifically, lack of the estrogen receptor 
reduces PI3K/Akt/mTOR pathway activation and hence rapamycin sensitivity [186].   
Even a reduced growth rate, possible with injection of fewer cancer cells 
initially could enhance therapeutic efficacy as this particular model produces extremely 
immature vasculature, as shown in Figure 56.  No vasculature was visible in treated 
tumors.  Slower growth may be a stronger representation of human tumor development 
[280] and may allow stronger angiogenesis, effectively allowing enhanced drug 
delivery and increasing the presence of a primary therapeutic target, phosphatidylserine.  
Additional studies would be interesting that evaluate a slower growth model, for 
example, injection of only 10
3
 4T1 cells rather than 10
6
 cells.  Possibly even more 
applicable for furthering this research would be evaluation in genetically engineered 
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mouse models with spontaneous tumorigenesis to better represent the pathologies in 
humans, including not only primary tumor development but also metastatic formation 
and antitumor immunity [280].   
 
Figure 56.  Low vasculature density in untreated 4T1 tumors in BALB/cJ mice.   
Immunohistochemistry staining of CD31 with DAB development (brown) and 
hematoxylin counterstain (purple) revealed minimal vasculature presence in untreated 
tumor sections (shown above) and no vasculature presence in any treated group.  Tumor 
sections from three mice from each experimental group were examined.  Arrows 
indicate CD31 staining. 
 
Analysis of Combination Therapies for Synergism 
The definition of drug synergy can be vague and application dependent, though 
in general an enhanced effect achieved through the combination of two compounds 
beyond the sum of the two effects is considered superadditive or synergistic [281].  
Assessment of drug synergy is typically approached using different variations of the 
Bliss independence and Loewe additivity models [232, 233].  The Bliss independence 
model is more relevant for examination of treatment effect enhancement and applies to 
mechanistically independent combination approaches [232, 233].  Alternatively, the 
Loewe additivity model applies more directly to competing compounds and efforts 
towards dose reduction [232, 233]. 
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The implication of synergism of the combination therapy as opposed to purely 
additive effects stems from the design of the combination therapy in which each 
therapeutic component acts upon separate mechanisms and pathways.  The full 
combination therapy (mCGL-AV and selenomethionine, cyclophosphamide, 
rapamycin) is a three-pronged anticancer approach that introduces targeted cytotoxicity 
to promote tumor death, immune stimulation for reduction of metastases, and 
attenuation of the hypoxic response to prevent tumor regrowth.  The primary means for 
evaluating treatment efficacy, survival and tumor volume, and the independent 
mechanisms of drug action implicate the Bliss independence approach as the most 
relevant methodology to analyze potential synergism. 
Using this approach, the predicted response of a combination therapy can be 
achieved using the additivity of probability theory for independent mechanisms (A and 
B) which can be applied to inhibition of tumor growth using the equation below [232].  
The predicted percent inhibition of a combination therapy is determined using the 
experimentally observed percent inhibitions of the combination therapy constituents.   
                                                                                    
Subtracting the predicted effect value from the actual observed value generates a 
“synergism assessment factor” introduced by [233], adapted to simply define synergism 
as values greater than 0, additive effects equal to 0, and antagonistic effects less than 0.  
For example, to evaluate the synergism of selenomethionine with mCGL-AV, the 
measured values for tumor growth percent inhibition at a determined time point for 
mCGL-AV alone and for selenomethionine alone would replace A and B in the above 
equation.  That calculated value would then be subtracted from the measured value for 
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the selenomethionine and mCGL-AV group to obtain the synergism assessment factor.  
Table 12 displays the synergism assessment factors for the different combinations for 
the first two weeks of treatment, after which the values become skewed by plateaued 
tumor volumes of untreated mice rapidly reaching the end points of the study.  The 
ampersand indicates grouped components and the plus sign indicates the separation of 
the constituents undergoing evaluation for synergism.  For example, “mCGL-AV + Sel” 
represents the evaluation of mCGL-AV and selenomethionine for synergism whereas 
the other representation “mCGL-AV & Sel” classifies the enzyme prodrug therapy as its 
own constituent to provide a stronger comparison for the evaluation of rapamycin and 
cyclophosphamide synergism. 
Table 12.  Synergism assessment factors for tumor growth inhibition 
 Day of Treatment 
 0 2 6 9 13 
Rap + Cyc 0.00 -0.03 0.06 -0.10 -0.02 
mCGL-AV + Sel 0.00 0.12 0.07 0.06 0.04 
mCGL-AV & Sel + Rap 0.00 -0.23 0.10 0.06 0.20 
mCGL-AV & Sel + Cyc 0.00 0.09 -0.01 0.00 0.12 
mCGL-AV & Sel + Rap & Cyc 0.00 -0.03 0.07 0.15 0.19 
 
Evaluation of tumor growth inhibition at the conclusion of the treatment period 
using the Bliss independence model for synergy indicates that combination of the 
mCGL-AV enzyme prodrug system with rapamycin produced a synergistic effect.  The 
mCGL-AV system combined with rapamycin and cyclophosphamide also exhibits 
synergism compared to the effects of the enzyme prodrug system alone and rapamycin 
and cyclophosphamide effects together.  Cyclophosphamide combined with the enzyme 
prodrug treatment does not have a consistent synergistic effect on inhibition of tumor 
growth.  Notably, the combination of rapamycin and cyclophosphamide without the 
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enzyme prodrug therapy is also not synergistic.  Strong synergism of mCGL-AV and 
selenomethionine was apparent through the duration of the treatment.   
The synergistic effect on tumor growth inhibition exhibited by the combination 
of rapamycin with the enzyme prodrug therapy likely results from the cytotoxic effect 
of the enzyme prodrug therapy combined with the inhibition of the hypoxic response by 
rapamycin.  Alone, rapamycin reduces HIF-1α expression as expected; however it is 
only through combination with the enzyme prodrug therapy that a significant inhibition 
of tumor growth occurs.  The enzyme prodrug therapy alone does achieve tumor growth 
inhibition; however continuous regrowth of cancer cells, presumably increased through 
the hypoxic response, contributes to the eventual progression of the tumor.  Enzyme 
prodrug therapy related killing of the tumor cells combined with the modulation of 
tumor regrowth resulting from rapamycin inhibition of the hypoxic response produce 
the synergistic effect on tumor growth inhibition. 
The theorized utility of the enzyme prodrug combination with 
cyclophosphamide is an enhancement of mouse survival through reduction of 
pulmonary metastases by stimulating the immune system.  Hence, a lack of synergistic 
inhibition of tumor growth with cyclophosphamide and the enzyme prodrug therapy is 
unsurprising.  Evaluation of primary tumor growth is a standard strategy for the 
evaluation of an antitumor therapy; however survival is a function of metastatic 
formation in addition to tumor growth.  Metastatic formation is perhaps a more vital 
indicator of treatment efficacy, as evidenced by the enhanced survival with 
cyclophosphamide and cyclophosphamide combination therapies and the related 
reduction in metastases.  The synergistic antitumor effect of rapamycin with the enzyme 
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prodrug therapy produces an enhanced survival as anticipated, however does not 
significantly reduce metastatic formation.  Further enhancement of survival with the 
enzyme prodrug therapy combined with rapamycin and cyclophosphamide occurs as a 
result of the antitumor growth effects as well as metastatic reductions.  The total 
combined advantage is not obvious and, in fact, opposes the reasonable theory that 
rapamycin, an immunosuppressive drug, would have an antagonistic effect when 
combined with cyclophosphamide used at immunostimulatory doses.   
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Summary of mCGL System and Combination Therapies 
The mCGL enzyme was successfully designed and fused to annexin I and 
annexin V and confirmed to have methioninase activity that allows for the conversion 
of selenomethionine to methylselenol.  In vitro results with mCGL-AI and mCGL-AV 
were obtained as expected based on the Met-AV system.  Strong binding and cytotoxic 
efficacy was apparent and comparable among the three systems: mCGL-AI, mCGL-
AV, and Met-AV. 
In BALB/cJ mice bearing orthotopic 4T1 mammary tumors, the mCGL-AV 
system showed improved efficacy over the mCGL-AI system and was selected for 
further study.  mCGL-AV and selenomethionine effectively suppressed tumor growth 
but only on a temporary basis.  Immunohistochemical analysis confirmed that the 
enzyme prodrug therapy did enhance apoptosis and reduced proliferation within the 
tumor.  Additionally, mCGL-AV showed strong improvement over Met-AV when 
compared in the BALB/cJ model.  Daily administration led to the generation of 
neutralizing antibodies for Met-AV, but not for mCGL-AV.  Despite a lack of any 
negative immune reaction, mCGL-AV and selenomethionine were not sufficient for 
tumor cure, stimulating the evaluation of combination therapies.   
Rapamycin was included to reduce the hypoxic response theorized to augmented 
by the enzyme prodrug therapy.  The addition of rapamycin to mCGL-AV and 
selenomethionine significantly reduced primary tumor volumes in a synergistic fashion.  
Cyclophosphamide was included with the intention of reducing regulatory T cell levels 
to stimulate an antitumor and anti-metastatic immune response.  While regulatory T cell 
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levels were not significantly reduced, the number of metastatic nodules dropped 
drastically with the addition of cyclophosphamide.   
Together, cyclophosphamide, rapamycin, and mCGL-AV and selenomethionine 
reduce primary tumor volumes, reduce metastatic progression, enhance survival, 
increase apoptosis, decrease proliferation, and decrease necrosis and the hypoxic 
response.  The three pronged approach involving a cytotoxic mechanism, an 
immunostimulatory mechanism, and an anti-hypoxic response mechanism addresses 
many of the challenges presented with the highly aggressive and metastatic, poorly 
immunogenic, treatment resistant, triple-negative 4T1 tumor model. 
  
138 
Chapter IV: Conclusions and Future Directions 
The first objective of this work was to develop the PNP-AV enzyme prodrug 
system.  The PNP-AV fusion protein was successfully produced and purified, resulting 
in strong in vitro binding and promising cytotoxicity results. 
The second objective was to assess the CD-AV, PNP-AV, and Met-AV enzyme 
prodrug systems in vivo and select the best candidate for transition into immune 
competent models.  The CD-AV system yielded underwhelming results.  The PNP-AV 
system was able to achieve some tumor growth suppression; however the Met-AV 
system outperformed the other enzyme prodrug systems and achieved temporary tumor 
regression.  Resultantly, Met-AV was selected for work aimed at reducing 
immunogenicity. 
The third objective, reduced immunogenicity for the highest performing system, 
was first attempted through various protein PEGylation methods.  Ultimately, however, 
a protein engineering method was determined to be more effective.  Native mouse CGL 
was mutated in three amino acid positions to impart methioninase activity, eliminating 
the foreign component of the fusion protein. 
The central goal of the project was to effectively treat breast cancer in mice with 
a targeted enzyme prodrug therapy.  The single cytotoxic mechanism presented by each 
of the therapies individually was not sufficient for sustained tumor regression or 
suppression, spurring work with combination therapies.  Cyclophosphamide was 
evaluated to enhance antitumor immunity, and rapamycin was included to prevent the 
hypoxic response of the tumor with allowed for continued progression and regrowth.  
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The combination of cyclophosphamide, rapamycin, mCGL-AV, and selenomethionine 
effectively reduced tumor volumes and enhanced mouse survival. 
Moving forward, there is much room for dosing improvements as a result of the 
complications of combining multiple drugs.  None of the combination constituents 
could be considered to be optimally dosed.  It is possible that a higher dose of fusion 
protein is required to saturate tumoral phosphatidylserine.  Additionally, a higher dose 
of rapamycin may prove to exhibit a stronger effect on primary tumor volume, yet a 
lower dose may further improve the metastasis data.  
The dosing schedule may also require optimization.  It was originally 
hypothesized that maximizing the frequency of fusion protein administration would 
provide the greatest cytotoxic effect, which was supported by in vitro data.  However, 
the daily saturation of phosphatidylserine may not prove to be entirely advantageous, 
given phosphatidylserine’s role in non-inflammatory clearance of apoptotic cells.  
Fusion protein binding to phosphatidylserine could inhibit clearance of dying cells and 
cellular debris.  Less frequent administrations may actually allow for natural clearance 
mechanisms to play a role in cell removal and could allow for increased tumor antigen 
presentation.  The perceived in vitro benefit of daily fusion protein administration may 
not translate to the in vivo environment since dying cells are not able to be simply 
washed off of a plate.  In vivo data with Met-AV fusion protein administration 
occurring once every 4 days displayed a strong effect, originally attributed to slower 
tumor growth overall among the groups.  Regardless, enough evidence and literature 
support exist to warrant some evaluation with altered dosing schedules. 
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In addition to dosing considerations, alternative compounds may exhibit higher 
bioactivities utilizing the same or similar mechanisms.  A number of rapamycin 
analogues and derivatives exist and are under current clinical and preclinical 
evaluations for slightly different activities, including Everolimus for breast cancer.  
Cyclophosphamide activity was hypothesized to lower regulatory T cell levels, which 
can also be altered through a variety of mechanisms, including Ipilimumab (anti-CTLA-
4). 
Immunostimulation with anti-CTLA-4 (cytotoxic T lymphocyte antigen 4) 
therapies in combination with the enzyme prodrug system may enhance the antitumor 
response in the 4T1 model.  It has been shown to successfully elicit an antitumor 
immune response in the 4T1 model when combined with radiation therapies[266].  
CTLA-4 plays a role in the maintenance of peripheral tolerance through the inhibition 
of T cell activation and contributes to tumor evasion of the immune system [282]. The 
blockade of CTLA-4 –related inhibition of T cells is an immunostimulatory mechanism 
independent from the cyclophosphamide-induced preferential depletion of regulatory T 
cells.  Use of an anti-CTLA-4 antibody with the enzyme prodrug therapy may prove to 
significantly enhance survival, even with the 4T1 model, either in conjunction with 
cyclophosphamide or as an alternative approach. 
Improvements to the enzyme prodrug system itself are also possible.  CGL is a 
mammalian protein that is granted full methioninase activity towards selenomethionine 
from essentially zero activity with only three amino acid substitutions.  It is possible 
that additional protein engineering could further enhance CGL activity towards 
selenomethionine. 
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Performing follow-up studies in additional immune competent breast cancer 
models would likely validate the therapeutic value of the enzyme prodrug therapy and 
the combination approaches.  The 4T1 model is highly aggressive, metastatic, and 
poorly immunogenic with a histology characteristic of high-grade human breast cancer; 
all of which make it a valuable model for evaluation of immunotherapies [266].  A more 
immunogenic tumor model, while less representative of human breast cancers, would 
yield valuable information in the evaluation of the immunostimulatory approaches used 
in combination with the enzyme prodrug therapy.  For example, the EMT6 murine 
breast cancer cell line implanted into BALB/c mice can elicit an immune response 
leading to a T cell mediated regression of the tumor [283] and enhanced survival even 
with multiple tumor rechallenges [284].  Additionally, the EMT6 model produces 
lymphatic, pulmonary, and hepatic metastasis allowing for evaluation of the anti-
metastatic nature of the immunotherapies at multiple sites [285].  Alternatively, models 
exhibiting slower growth could provide additional insight into the efficacy of the 
vasculature directed enzyme prodrug therapy, since our current models grow at a rate 
too fast for significant development of tumor vasculature.  A simple approach would be 
to reduce the quantity of implanted cells, either 4T1 or EMT6.  Another strategy would 
be to utilize a transgenic mouse strain that develops highly vascularized spontaneous 
tumors (for example, Jackson Laboratory’s FVB/N-Tg(MMTV-PyVT)634Mul/J strain 
which develops spontaneous mammary tumors in 100% of mice within 5 weeks with 
spontaneous pulmonary metastasis in 80-94% of mice). 
Overall, the mCGL-AV system has demonstrated efficacy in very challenging 
mouse models, particularly when combined with rapamycin and cyclophosphamide.  
142 
The therapeutic system appears to be quite promising but requires significant 
optimization to progress beyond preclinical studies and may benefit specifically with 
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Appendix A:  Supplemental Data 
PNP-AV In Vitro Binding Data 
 
Figure 57.  Fixed cell confocal imaging with differential interference contrast 
(DIC).   
Confocal fluorescence microscopy overlaid on a DIC image confirms association of 
PNP-AV with MDA-MB-231 cells.  Representative cells are shown in (a and b).  FITC-
conjugated PNP-AV is shown in green, CellMask stain of the plasma membrane in red, 



















Figure 58.  PNP-AV dissociation constant binding data on non-confluent HAAE-1 
cells.   
Specific binding (▲) was determined by subtracting total binding (●) in calcium 
supplemented medium from nonspecific binding (■) in calcium deficient medium. 
Binding was quantified with biotinylated protein and HRP-conjugated streptavidin, 
developed with OPD. Data are presented as mean ± standard error (n = 3). 
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Figure 59.  PNP-AV dissociation constant binding data on MCF-7 cells.   
Specific binding (▲) was determined by subtracting total binding (●) in calcium 
supplemented medium from nonspecific binding (■) in calcium deficient medium. 
Binding was quantified with biotinylated protein and HRP-conjugated streptavidin, 





















Figure 60.  PNP-AV dissociation constant binding data on MDA-MB-231 cells.   
Specific binding (▲) was determined by subtracting total binding (●) in calcium 
supplemented medium from nonspecific binding (■) in calcium deficient medium. 
Binding was quantified with biotinylated protein and HRP-conjugated streptavidin, 

























Figure 61.  mCGL-AI dissociation constant binding data on MDA-MB-231 cells.  
Specific binding (▲) was determined by subtracting total binding (○) in calcium 
supplemented medium from nonspecific binding (□) in calcium deficient medium. 
Binding was quantified with biotinylated protein and HRP-conjugated streptavidin, 






















Figure 62.  mCGL-AV dissociation constant binding data on MDA-MB-231 cells.  
Specific binding (▲) was determined by subtracting total binding (●) in calcium 
supplemented medium from nonspecific binding (■) in calcium deficient medium. 
Binding was quantified with biotinylated protein and HRP-conjugated streptavidin, 

























Figure 63.  Met-AV dissociation constant binding data on MDA-MB-231 cells.  
Specific binding (▲) was determined by subtracting total binding (●) in calcium 
supplemented medium from nonspecific binding (■) in calcium deficient medium. 
Binding was quantified with biotinylated protein and HRP-conjugated streptavidin, 























Figure 64.  mCGL-AI dissociation constant binding data on non-confluent HAAE-
1 cells.  
Specific binding (▲) was determined by subtracting total binding (●) in calcium 
supplemented medium from nonspecific binding (■) in calcium deficient medium. 
Binding was quantified with biotinylated protein and HRP-conjugated streptavidin, 






















Figure 65.  mCGL-AV dissociation constant binding data on non-confluent HAAE-
1 cells.  
Specific binding (▲) was determined by subtracting total binding (●) in calcium 
supplemented medium from nonspecific binding (■) in calcium deficient medium. 
Binding was quantified with biotinylated protein and HRP-conjugated streptavidin, 
developed with OPD. Data are presented as mean ± standard error (n = 3). 
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Appendix B: Laboratory Protocols 
Protein Design and Vector Construction 
PNP-AV Fusion Gene Construction and Transformation 
1. Culture cells containing PNP-AV gene in 5 mL LB Medium for 16 h at 37°C 
and 250 rpm. 
o LB Medium (500 mL) 
 10 g/L Tryptone (5.0 g) 
 5 g/L Yeast Extract (2.5 g) 
 5 g/L NaCl (2.5 g) 
2. Perform miniprep of plasmid using QIAprep spin columns (protocol included in 
Appendix B: Laboratory Protocols) 
3. Perform PCR to amplify PNP-AV gene using the PNP-AV fusion primers in 
Appendix C: Fusion Gene Construction and the conditions below. 
 Combine components on ice (add Phusion DNA Polymerase last). 
 Mix and centrifuge. 
 Cycle. 
Table 13.  PNP-AV Fusion Gene Amplification PCR Components 





dNTPs 1 10 mM 200 µM 
Sense primer 1 100 µM 2.0 µM 
Antisense primer 1 100 µM 2.0 µM 
Template DNA 1  <250 ng 
HF Buffer 10 5x 1x 
DMSO 1.5  3% 
PCR Grade Water 34   
Phusion Polymerase 0.5  1 U/50mL rxn 
TOTAL 50   
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Table 14.  PNP-AV Fusion Gene Amplification PCR Conditions 
Step # of Cycles Temperature Time 
Initial Denaturation 1 98
o
C 60 sec 
Amplification 31   
        - Denaturation  98
o
C 10 sec 
        - Annealing  60
o
C 30 sec 
        - Elongation  72
o
C 60 sec 
Final Elongation 1 72
o





4. Cleanup PCR products with QIAquick (protocol included in Appendix B: 
Laboratory Protocols, PCR Product Purification). 
5. Isolate PNP-AV gene fragment using DNA gel electrophoresis and gel 
extraction with QIAquick (protocol included in Appendix B: Laboratory 
Protocols). 
6. Perform restriction digest of purified PNP-AV gene with Xho1 and Xba1 
according to conditions below. 
 Pipet mixture up and down or flick to mix. 
 Allow digestion to occur for 1 hour at 37°C. (1 unit of enzyme will 
digest 1 µg of DNA in 1 hour at 37°C [in a total reaction volume of 
50 µl]) 
Note:  DNA estimated based on QIAquick max binding as 10 µg, 











FP gene  15.8 0.208 µg/µL * 3 µg 
NEB Buffer 
#4 
5 10x 1x 
BSA 0.5 100x 1x 
Xho1 1 20 U/µL 20 U/rxn 
Xba1 1 20 U/uL 20 U/rxn 
PCR grade 
H2O 
26.7   
Total 50   
 
7. Digest pET303/CT-His plasmid with Xho1 and Xba1 according to conditions 
below. 
 Pipet mixture up and down or flick to mix. 
 Allow digestion to occur for 1 hour at 37°C. (1 unit of enzyme will 
digest 1 µg of DNA in 1 hour at 37°C [in a total reaction volume of 
50 µl]) 









6.6 0.15 µg/µL  1 µg  
NEB Buffer #4 5 10x 1x 
BSA 0.5 100x 1x 
Xho1 1 20 U/µL 20 U/rxn 
Xba1 1 20 U/µL 20 U/rxn 
PCR grade H2O 35.9   
Total 50   
   
8. Dephosphorylate pET303/CT-His (to prevent intramolecular reclosure) after 
restriction digest. 
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 Heat pET303/CT-His digest mixture for 20 minutes at 65°C to heat 
deactivate restriction enzymes 
 Add 0.5 units of Calf Intestinal Alkaline Phosphatase (CIP) (New 
England Biolabs; M0290S) per μg vector DNA (1.0 µL) 
 Incubate 60 minutes at 37°C 
9. Purify DNA using PCR product purification protocol for the PNP-AV gene and 
pET303/CT-His backbone.  Use 20 µL elutions.  
10. Ligate PNP-AV gene into pET303/CT-His backbone using the conditions 
below. 
 Combine all components (ligase last) in microcentrifuge tube on ice. 
 Incubate overnight at 16°C. 
Table 17.  Components for PNP-AV Ligation into pET303/CT-His 






1.3 39 ng/µL * 0.025 pmol (50 ng) 
FP gene 2.9 ** 0.076 pmol (50 ng) 
Ligase Buffer 2 10x 1x 
T4 DNA Ligase 1 400,000U/mL 400 U/rxn 
PCR grade H2O 12.8   
Total 20   
 
Note: DNA concentrations were estimated as shown below. 
* (Mass DNA in digest)(Xho1 Efficiency)(Xba1 Efficiency)(Purification Recovery) = 
(3.3 µg)(0.95)(0.95)(0.9*0.7) = 1.88 µg in 48 µL = 39 ng/µL 
** (Mass DNA in digest)(Xho1 Efficiency)(Xba1 Efficiency)(Purification Recovery) = 
(1.0 µg)(0.95)(0.95)(0.9*0.7) = 0.81 µg in 48 µL = 17 ng/µL 
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11. Transform plasmid into NovaBlue Gigasingles competent cells (protocol 
included in Appendix B: Laboratory Protocols) and culture for amplification of 
plasmid. 
12. Using a flame sterilized, blunt glass pipet, select several colonies and culture 
each colony in 15 mL of LB medium with antibiotic at 37°C and 250 rpm for 16 
h. 
13. Collect cells through centrifugation at 1000 x g and discard supernatant. 
14. Perform a miniprep using the QIAprep spin columns and submit for sequencing. 
 T7 promoter, T7 terminator, and PNP sequencing primers were used.  
Primer sequences are included in Appendix C: Fusion Gene 
Construction. 
Note: PNP Sequencing primer needed to be diluted from 100 µM to 
5 µM 
 Plasmid DNA should be submitted at approximately 100 ng/µL and 
primers at 3-5 µM. 
15. After confirming correct sequence, transform plasmid miniprep into BL21(DE3) 
competent cells (protocol included in Appendix B: Laboratory Protocols) and 
culture for expression. 
 
 mCGL-AI, mCGL-AV Fusion Gene Constructions and Transformations 
1. Resuspend Life Technologies gene fragments to 40 ng/ul (come as ~2000 ng 
powder) 
 Centrifuge for 2-5 sec at >3000 x g. 
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 Add x µl nuclease free water (final concentration of 40 ng/µl) 
o F1 (1000 bp) – add 49 µl water 
o A1-F2 (1000 bp) – add 38 µl water 
o A1-F3 (452 bp) – add 61 µl water 
o A5-F2 (1000 bp) – add 21 µ water 
o A5-F3 (371 bp) – add 31 µl water 
 Incubate 1 h at room temperature, then resuspend gently with pipet. 
 Aliquot and store at -20°C (2 yr stability) 
2. Combine reagents for Gibson assembly. 
 Use 50 ng of plasmid and 0.2 pmol of each fragment (equimolar) 
o Reaction 1 (total = 9.3 µl) 
 1 ul pET-30 Ek/LIC (at 50 ng/µl) 
 3.3 µl F1 
 3.3 µl F2 
 1.7 µl F3 
 10 µl Gibson Master Mix (2X) 
 Nuclease free DI (adjust to final volume of 20 µl) 
3. Incubate at 50°C for 1 h, then keep on ice (or -20°C) until transformation 
 Exonuclease removes nucleotides at 5’ end leaving single stranded 3’ 
overhang.  Complementary fragments anneal and DNA polymerase fills 
in gaps followed by ligation with DNA ligase. 
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4. Transform NEB 5-alpha competent cells (included in Gibson Assembly kit) with 
Gibson Assembly reaction product (protocol included in Appendix B: 
Laboratory Protocols). 
5. Using a flame sterilized, blunt glass pipet, select several colonies and culture 
each colony in 15 mL of LB medium with antibiotic at 37°C and 250 rpm for 16 
h. 
6. Collect cells through centrifugation at 1000 x g and discard supernatant. 
7. Perform a miniprep using the QIAprep spin columns and submit for sequencing. 
 T7 promoter, T7 terminator, and mCGL-AI and mCGL-AV sequencing 
primers were used.  Primer sequences are included in Appendix C: 
Fusion Gene Construction. 
 Plasmid DNA should be submitted at approximately 100 ng/µL and 
primers at 3-5 µM. 
8. After confirming correct sequence, transform plasmid miniprep for mCGL-AI 
into BL21(DE3) competent cells and plasmid miniprep for mCGL-AV into T7 
Express lysY competent cells (protocols included in Appendix B: Laboratory 
Protocols) and culture for expression. 
 
Plasmid Miniprep 
Note: Miniprep performed with QIAprep Spin Columns (Qiagen; 27104) 
1. Resuspend pelleted bacterial cells in 250 uL Buffer P1 and transfer to 
microcentrifuge tube (make sure RNase A has been added to Buffer P1). 
2. Add 250 uL Buffer P2 and mix thoroughly by inverting the tube 4-6 times. 
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3. Add 350 uL Buffer N3 and mix immediately and thoroughly by inverting the 
tube 4-6 times. 
4. Centrifuge for 10 min at 13,000 rpm in microcentrifuge. 
5. Apply the supernatants from step 4 to the QIAprep spin column by decanting or 
pipetting. 
6. Centrifuge for 30-60 seconds.  Discard flow through. 
7. Wash QIAprep spin column by adding 0.5 mL Buffer PB and centrifuge for 30-
60 seconds.  Discard flow through. 
8. Wash QIAprep spin column by adding 0.75 mL Buffer PE and centrifuging for 
30-60 seconds. 
9. Discard the flow through and centrifuge for an additional 1 minute to remove 
residual wash buffer. 
10. Place QIAprep column in a clean 1.5 mL microcentrifuge tube.  To elute DNA, 
add 50uL Buffer EB to the center of each QIAprep spin column, let stand for 1 
min, then centrifuge for 1 min. 
 
PCR Product Purification 
Note:  PCR product cleanup performed with QIAquick PCR Purification Kit (Qiagen; 
28104) 
1. Add 120 µl of pH indicator I to 30 ml Buffer PB (if not previously completed). 
2. Add 5 volumes of Buffer PB to 1 volume of PCR sample & mix.  (ie. Add 500 
µl Buffer PB to 100 µl PCR sample). 
3. Check to make sure mixture is yellow.  If not, read manual. 
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4. Place QIAquick spin column in a provided 2 ml collection tube. 
5. Apply sample to QIAquick column and centrifuge for 30-60 seconds at 13,000 
rpm. 
6. Discard flow-through.  Replace column back into same tube. 
7. Wash by adding 0.75 ml Buffer PE to column & centrifuge for 30-60 seconds. 
8. Discard flow-through.  Replace column in same tube & centrifuge for an 
additional minute.  (This additional centrifugation will ensure all residual 
ethanol will be removed). 
9. Place QIAquick column in a clean 1.5 ml microcentrifuge tube. 
10. Elute DNA by adding 50 µl Buffer EB to center of QIAquick membrane & 
centrifuge column for 1 minute. 
 
DNA Gel Electrophoresis and Extraction 
Note:  Gel extraction performed with QIAquick Gel Extraction Kit (Qiagen; 28704). 
1. Weigh out 1.0g agarose and dissolve in 50 ml of 1X TE buffer (40 mM Tris, 1 
mM EDTA). Microwave 5 times in 20 second intervals on power level 5 with 
cap loosely on (cap will pop off and contents will spill out or glass will break 
otherwise).  
o 10X TE Buffer (1 L) 
 10 mM EDTA (3.722 g) 
 400 mM Tris (48.456 g) 
 DI water (1 L) 
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2. Let the solution cool to 55oC and add 2.5 µl of 10 mg/ml of ethidium bromide 
stock to the 50 ml volume (mix the solution well to evenly distribute the 
ethidium bromide). Pour the gel into the electrophoretic cell (up to the blue line 
on the comb) and wait 60 min for solidification. 
3. Once the gel has solidified pour the TE buffer over the gel until it covers the gel 
by about 1 mm. The gel is now ready to be loaded. 
4. To each DNA sample to be loaded, add 2 µl of sample DNA to 1 µl loading dye 
(Qiagen; 239901).  The maximum volume of DNA sample is 20 µl for each well 
of the 8 comb gel which has a total volume of 25 µl. 
o Mix 2 µl DNA from PCR and 1 µl loading dye with pipet, and 
then load into each well (for samples). 
5. For the marker lane, add 2 µl of 500 bp ladder (Bio-Rad Laboratories Inc.; 170-
8203) to 1 µl loading dye.  
6. Run the gel at 100 V (low) until the first band gets ¾ of the way to the bottom of 
the gel. 
7. View the gel using the UV box and cut appropriate fragment from the gel with a 
clean scalpel for extraction.  
8. Weigh the gel slice in a colorless tube.  
9. Add 3 volumes of Buffer QG to 1 volume of gel.  (ie. 300 µl Buffer QG to 100 
mg gel) 
10. Incubate at 50°C for 10 minutes (or until gel slice is completely dissolved).  To 
help dissolve, vortex the tube every 2-3 minutes during incubation. 
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11. After gel is dissolved, check to see that the color of the mixture is yellow, 
similar to Buffer QG.  It not, refer to manufacturer instructions.   
12. Add 1 gel volume of isopropanol to the sample & mix.  (ie. Add 100 µl 
isopropanol to 100 mg of gel). 
13. Place a QIAquick spin column in a provided 2 ml collection tube.  Bind DNA by 
applying sample to column.   
14. Centrifuge at 13,000 rpm for 1 minute.  Discard flow-through & replace column 
in same tube. 
15. Add 0.5 ml of Buffer QG to column & centrifuge for 1 minute. 
16. Wash by adding 0.75 ml of Buffer PE to column & centrifuge for 1 minute. 
17. Discard flow-through & centrifuge for an additional minute.  Residual ethanol 
from Buffer PE will not be completely removed unless the flow-through is 
discarded before additional centrifugation. 
18. Place column in a clean 1.5 ml microcentrifuge tube. 
19. Elute DNA by adding 50 µl Buffer EB to center of QIAquick membrane & 
centrifuge for 1 minute. 
 
NovaBlue Gigasingles Competent Cell Transformation 
1. Thaw NovaBlue GigaSingles cells on ice for 5 minutes (with all but the cap 
surrounded by ice) 
2. Resuspend cells by pipetting up and down and transfer 50 µL to transform tube. 
3. Add 1 µL of ligation reaction directly to cells and stir gently (Also add 1 µL of 
test plasmid to second vial of cells). 
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4. Incubate on ice for 5 min 
5. Heat tubes for exactly 30 sec in 42°C water bath. 
6. Place tubes on ice for 2 min. 
7. Add 250 µL SOC medium (at room temperature) to each tube and keep tubes on 
ice. 
8. Incubate at 37°C while shaking at 250 rpm for 60 min prior to plating. 
9. Concurrently, heat LB agar plates (made in advance) to 37°C for ~20 min prior 
to plating. 
 Make LB Agar solution (at least one day prior to transformation) and 
autoclave. 
o LB Agar (250 mL; 25 mL per dish, 10 dishes) 
 10 g/L Tryptone (2.5 g) 
 5 g/L Yeast Extract (1.25 g) 
 5 g/L NaCl (1.25 g) 
 15 g/L Agar (3.75 g) 
 Allow solution to cool slightly after autoclave and add antibiotic. 
 Pipet 25 mL into each petri dish by flame.  Allow dishes to sit with small 
amount of ventilation facing burner.  Once solidified, refrigerate 
overnight until ready for transformation. 
10. Spread 50 µL cell solutions on plates using flame/EtOH sterilized glass pipette 
at several dilutions (1:1 to 1:100) in SOC medium.  
11. Allow plates to sit on benchtop for several minutes (for liquid to be absorbed), 
invert, and incubate overnight at 37°C. 
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BL21(DE3) Competent Cell Transformation 
1. Resuspend cells and then add 1 uL of selected colony miniprep to 20 µL 
BL21(DE3) cells in transformation tube on ice. 
2. Incubate the tube on ice for 5 minutes. 
3. Heat the tube for exactly 30 seconds in 42°C water bath. 
4. Incubate tube for 2 min on ice. 
5. Add 80 µL room temperature SOC medium to tube on ice. 
6. Incubate for 60 minutes at 37°C while shaking at 250 rpm. 
7. Concurrently, heat LB agar + antibiotic plates to 37°C for ~20 min prior to 
plating. 
8. Spread 50 µL cell solution on plates using flame/EtOH sterilized glass pipette at 
several dilutions (1:1 to 1:100) in SOC medium.  
9. Allow plates to sit on benchtop for several minutes (for liquid to be absorbed), 
invert, and incubate overnight at 37°C. 
 
NEB 5-alpa Competent Cell Transformation 
1. Thaw NEB 5-alpha competent cells on ice for 2-5 min. 
2. Resuspend cells and then add 2 uL of Gibson Assembly reaction to 50 µL cells 
in transformation tube on ice. 
3. Incubate the tube on ice for 30 minutes. 
4. Heat the tube for exactly 30 seconds in 42°C water bath. 
5. Incubate tube for 2 min on ice. 
6. Add 950 µL room temperature SOC medium to tube on ice. 
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7. Incubate for 60 minutes at 37°C while shaking at 250 rpm. 
8. Concurrently, heat LB agar + antibiotic plates to 37°C for ~20 min prior to 
plating. 
9. Spread 100 µL cell solution on plates using flame/EtOH sterilized glass pipette 
at several dilutions (1:1 to 1:100) in SOC medium. Use kanamycin plates to 
select for plasmid and ampicillin plates as a control. 
10. Allow plates to sit on benchtop for several minutes (for liquid to be absorbed), 
invert, and incubate overnight at 37°C. 
 
T7 Express lysY Competent Cell Transformation 
1. Thaw T7 Express lysY competent cells on ice for 20 min. 
2. Resuspend cells and then add 1 uL of plasmid miniprep to 50 µL cells in 
transformation tube on ice.  Flick the tube gently 4-5 times to mix the cells and 
DNA. 
3. Incubate the tube on ice for 30 minutes. 
4. Heat the tube for exactly 10 seconds in 42°C water bath. 
5. Incubate tube for 5min on ice. 
6. Add 950 µL room temperature SOC medium to tube on ice. 
7. Incubate for 60 minutes at 37°C while shaking at 250 rpm. 
8. Concurrently, heat LB agar + antibiotic plates to 37°C for ~20 min prior to 
plating. 
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9. Spread 100 µL cell solution on plates using flame/EtOH sterilized glass pipette 
at several dilutions (1:1 to 1:100) in SOC medium. Use kanamycin plates to 
select for plasmid and ampicillin plates as a control. 
10. Allow plates to sit on benchtop for several minutes (for liquid to be absorbed), 
invert, and incubate overnight at 37°C.  
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Protein Expression and Purification 
BL21(DE3) Expression of CD-AV, PNP-AV, Met-AV, and mCGL-AI 
1. Culture 5 µl of E. coli BL21(DE3) harboring vector with fusion gene in 10 mL 
of LB medium containing antibiotic in a 125 mL Erlenmeyer flask overnight at 
37
o
C with shaking at 200 rpm.  
 LB Medium 
o 10 g Tryptone 
o 5 g Yeast Extract 
o 5 g NaCl 
o 1 L DI water 
 Autoclave LB Medium. 
 Add antibiotic to the 1 L of LB medium before taking out the 10 mL 
for the initial culture.  Note:  CD-AV, Met-AV, and mCGL-AI 
require 35 µg/ml kanamycin and PNP-AV requires 100 µg/ml 
carbenicillin. 
 Incubate. 
2. Add 10 mL of the cell culture to 1 L of fresh LB medium with antibiotic and 
incubate at 37
o
C with shaking (200 rpm). Take 1.5 mL of medium before adding 
the bacteria, as a blank. This cell culture was grown to mid-log phase (OD600 = 
0.6).  
 Transfer 10 mL of bacteria to 1 L LB medium. 
 Transfer entire volume of medium to four 1 L flasks.  
 Put in shaker at 37o C at 200 rpm. 
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 Measure optical density at 600 nm (absorbance) at regular intervals 
(1.5 h) using a clear 96 well plate and microtiter plate reader of 
sample (using 250 µL samples).  When OD600nm = 0.6, proceed to 
next step. 
3. Add IPTG to a final concentration of 0.4 mM (96 mg IPTG) to solutions in four 
1 L flasks and incubate at 30
o
C with shaking (180 rpm) for 6 h to induce protein 
expression.  
 Put back in shaker at 30oC for 5 hours.   
- IPTG stimulates the production of fusion protein (IPTG activates the 
promoter in the plasmid that will start the transcription of the gene 
that follows the promoter). 
 
T7 Express lysY (DE3) Expression of mCGL-AV 
1. Culture 10 µL of E. coli T7 Express lysY (DE3) harboring the fusion gene 
mCGL-AV in 10 mL of TB medium containing 35 g/mL kanamycin in a 
125 mL Erlenmeyer flask for 6 h at 37
o
C with shaking at 220 rpm.  
 TB Medium Nutrients 
o 12 g Tryptone 
o 24 g Yeast Extract 
o 4 mL glycerol 
o 900 mL DI 
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 TB Medium Buffering 
o 2.31 g KH2PO4 
o 12.54 g K2HPO4 
o 100 mL DI 
 Autoclave TB components separately then combine once at room 
temperature 
 Add 35 mg kanamycin to the 1 L of TB medium before taking out 
the 10 mL for the initial culture 
 Incubate 
2. Add 10 ml of the cell culture to 1 L of fresh culture medium with kanamycin 
and incubate at 37
o
C with shaking (220 rpm). Take 1.5 mL of medium before 
adding the bacteria, as a blank. This cell culture was grown to mid-log phase 
(OD600 = 0.5).  
 Transfer 10 mL of bacteria to 1 L TB medium. 
 Transfer entire volume of medium to four 1 L flasks.  
 Put in shaker at 37o C at 220 rpm for 9 h. 
 Measure optical density at 600 nm (absorbance) at regular intervals 
using a clear 96 well plate and microtiter plate reader of sample 
(using 250 µL samples).  Adjustment of 9 h incubation time may be 
necessary.  When OD600nm = 1.2, proceed to next step. 
3. Add IPTG to a final concentration of 1 mM (238 mg IPTG total) to solutions in 
four 1 L flasks and incubate at 25
o
C with shaking (200 rpm) to induce protein 
expression.  
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 Put back in shaker at 25oC for 19 h. 
- IPTG stimulates the production of fusion protein (IPTG activates the 
promoter in the plasmid that will start the transcription of the gene 
that follows the promoter). 
 
Fusion Protein Purification 
Note:  Include 0.02 mM pyridoxal phosphate in all buffers for Met and mCGL fusion 
proteins. 
1. Harvest the cells by centrifugation for 10 min at 1000 x g, at 4ºC.  
2. Resuspend the cell pellet in 40 mL of sonication buffer.  
 Vortex to resuspend cell pellets. 
o Sonication Buffer (40 mL) 
 0.05 mM N- p-tosyl-L-phenylalanine chloromethyl ketone 
(TPCK) (0.704 mg) 
 1 mM phenylmethylsulfonyl fluoride (PMSF) (6.968 mg) 
 1% HPLC ethanol (400 µL) 
 0.01% -mercaptoethanol (4 µL) 
 0.02 M sodium phosphate dibasic (113.6 mg) 
 40 mL DI 
 Dissolve TPCK and PMSF in ethanol in microcentrifuge tube, 
and then add to beaker. 
 Make this buffer in the 100 mL beaker. 
 Adjust to pH 7.4 
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3. Lyse the cells by sonication at 4oC for 30 sec at 4.5 watts then allow it to cool 
for 30 sec on ice. This cycle was repeated 4 times (5 times total) for a total 
sonication time of 2.5 min on power level 4.  
 Clean sonicator tip with ethanol before use. 
 Put beaker in tub with ice while sonicating.  
4. Centrifuge the lysate obtained at 12,000 x g for 30 min to remove the cell debris 
and take the supernatant.  The protein will be in the supernatant and the cell 
debris in the pellet. 
5. After taking supernatant sample, add Imidazole (40 mM) and NaCl (500 mM) to 
the lysate to reduce non-specific protein binding.  
 40 mM imidazole (0.0817 g for 40 mL) 
 500 mM NaCl (1.168 g for 40 mL) 
6. Equilibrate a 5 mL HisTrap chromatography column using Wash Buffer 1.  
 Feed wash buffer through column until the output reaches baseline 
o WASH BUFFER 1 (500 mL) 
 20 mM sodium phosphate dibasic (1.42 g) 
 40 mM imidazole (1.362 g) 
 500 mM NaCl (14.61 g) 
 Adjust to pH 7.4 
7. Feed the soluble protein fraction into the column (load entire sample – avoid air 
in column). 
o Discard flow through – contains unwanted proteins 
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8. Wash the column with 60 column volumes (350 mL) of Wash Buffer 2 to 
remove unwanted proteins and endotoxin.  (Run Wash 2 for a minimum of 1.5 
h) 
 Discard flow through – contains unwanted proteins  
o WASH BUFFER 2 (300 mL) 
 20 mM sodium phosphate dibasic (0.8517 g) 
 40 mM imidazole (0.817 g) 
 500 mM NaCl (8.766 g) 
 1.0% Triton X-114 (3 mL) 
 Adjust to pH 7.4 
9. Wash the column with 20 column volumes (100 mL) of Wash Buffer 1 to wash 
the protein until the pen reaches the baseline. (Run Wash 1 for a minimum of 1 
h) 
 Discard flow through – contains unwanted proteins  
10. Elute the protein using elution buffer.    
 Collect the elution – contains fusion protein– Begin collection once 
peak starts to rise and end once peak begins to level off, note there is 
a delay from detector to output 
o ELUTION BUFFER (300 mL) 
 20 mM sodium phosphate dibasic (0.8517 g) 
 500 mM imidazole (10.212 g) 
 500 mM NaCl (8.766 g) 
 Adjust to pH 7 
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11. Clean column for future use. 
o Normally just run enough elution buffer through (without collecting) 
to get a good baseline.  All proteins should be cleared from the 
column. 
o If column is dirty/clogged, regenerate the column using this 
procedure: 
 25 mL of 1 M KCl (make 200 mL, use 14.91 g) 
 25 mL of 1 M NaOH (make 200 mL, use 8.0 g) 
 25 mL of DI Water 
 25 mL of 1 M Ethanol (1.5 mL ethanol + 23.5 mL DI 
Water) 
12. Dialyze eluted protein for 3 hours against 2 liters of dialysis buffer containing 
20 mM sodium phosphate at pH 7.4 to remove NaCl and imidazole from the 
protein solution and make it suitable for His-tag cleavage. 
o Note: volumes greater than 20 mL will typically need 2 dialysis bags 
o DIALYSIS 1 BUFFER (2 L)  
 20 mM sodium phosphate dibasic (5.678 g) 
 Adjust to pH 7.4 
13. Measure the concentration of protein (Bradford Protein assay).   
14. Cleave the His-tag by adding HRV-3C protease at 10 U/mg of protein with the 
recommended 10X buffer provided.  Incubate for 18h at 4
o
C at 30 rpm in dark. 
15. Equilibrate the HisTrap column with Wash Buffer 1.    
 Feed through the column until stable baseline is reached. 
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16. Add imidazole (40 mM) and NaCl (500 mM) to the cleaved protein solution 
(mass depends on volume after overnight cleavage incubation). 
17. Feed the cleaved solution to the HisTrap column and collect protein. 
 Collect first peak solution from the column (flow-through).  This 
contains our protein.   
18. Push remainder of cleaved solution through column and tubing with Wash 1 and 
collect until signal approaches baseline. 
19. Elute uncleaved protein with imidazole.    
 Allow elution to reach baseline so that all protein is cleared from 
column 
 Discard elution – any protein is the protease or uncleaved FP 
20. Dialyze purified protein for 3 hours against 2 liters of dialysis buffer. 
o Note: volumes greater than 20 ml will typically need 2 dialysis bags 
o DIALYSIS 2 BUFFER (2 L) 
 20 mM sodium phosphate dibasic (5.5678 g) 
 100 mM NaCl (11.688 g ) 
 Adjust to pH 7.4 
21. Prepare column for storage.  After reaching a baseline with elution buffer, 
equilibrate column with 1 M EtOH to prevent bacterial growth.  If column is 
very dirty, clean using the procedure above. 
22. Pass the sample through a 0.2 µm cellulose-acetate filter in biohood (now sterile 
practice) 
23. Perform Bradford assay and record final protein yield 
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24. Aliquot purified protein into cryovials (2 mL per vial), flash freeze in liquid 





Bradford Protein Concentration Assay 
1. Add 5 µL sample to each well. 
o Include blank using DI water 
o Include at least a 2x protein dilution (2.5 µL protein, 2.5 µL DI water).  Note:  
Further dilution may be required to obtain values within calibration curve. 
2. Add 250 ul Bradford reagent to each well and incubate at room temperature for 
5 min. 
3. Take absorbance at 595 nm and subtract out blank  
4. Calculate protein concentration (µg/mL) using calibration curve below.  
 
Figure 66.  Bradford protein concentration assay calibration curve using 
bovine serum albumin. 
 
  
y = 0.0005x + 0.0715 



















Bradford Standard Curve 
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SDS-PAGE 
Electrophoresis and Coomassie staining 
1. Make solutions if necessary. 
 10x Running Buffer (1 L) 
o 30.3 g Tris 
o 144.1 g glycine 
o 10 g SDS 
 pH 8.5 
 Loading Buffer 
o 95 µL Laemmli buffer 
o 5 µL β-mercaptoethanol 
 Destain (4 L) 
o 1.8 L DI 
o 1.8 L methanol (45% w/v) 
o 0.4 L acetic acid (10% w/v) 
2. Mix 15 µL sample, 25 µL loading buffer in microcentrifuge tube 
3. Heat for 2 min at 100°C. 
4. Cool at room temperature for 1 min. 
5. Load gel with 10 µL sample and 5 µL ladder (dependent on manufacturer 
recommendation).  Precast gels can be purchased or produced according to the 
protocol below. 
6. Run gel at 150V for 45 min. 
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7. Add stain to gel (0.25% w/v Coomassie Brilliant Blue R250 in destain solution), 
microwave in 15 s intervals until it just starts to boil 
8. Shake at room temperature for 5 min 
9. Rinse gel gently with DI to remove as much stain as possible and discard liquid. 
10. Add destain, shake for 4 h at room temperature. 
11. Discard old destain, add new destain, and shake for 4 h at room temperature. 
12. For analysis, obtain an image and process using ImageJ densitometric analysis. 
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Gel Casting Procedure 
1. Assemble the glass plates on the gel casting stand and fill with water to ensure 
that they are sealed. 
2. Mix the components of separating gel, adding the TEMED last. Mix well and 
immediately fill the glass plates, leaving a 1.5 cm gap at the top (for the stacking 
gel). 
Table 18.  SDS-PAGE gel casting components 








DI 1.82 mL 1.67 mL 1.70 mL 1.74 mL 
1.5 M Tris-HCL pH 8.8 - 1.25  mL 1.25 mL 1.25 mL 
1 M Tris-HCL pH 6.8 312.5 µL - - - 
10 % (w/v) SDS 25 µL 50 µL 50 µL 50 µL 
Acrylamide (29%) Bis (1%) 333 µL 2 mL 1.97 mL 1.93 mL 
Ammonium persulfate 10% 12.5 µL 25 µL 25 µL 25 µL 
TEMED 2.5 µL 5 µL 5 µL 5 µL 
Total 2.5 mL 5 mL 5 mL 5 mL 
 
Table 19.  Gel selection based on monomer molecular weight 
Gel Molecular Weight 
7% 50 kDa - 500 kDa 
10% 20 kDa - 300 kDa 
12% 10 kDa - 200 kDa 
15% 3 kDa - 100 kDa 
 
3. Immediately add 1 mL of isopropanol on top of the gel to prevent oxygen from 
inhibiting the polymerization. Wait 20 min for solidification. 
4. Pour off the isopropanol and rinse with dH2O to remove any residual 
isopropanol. Mix the components for the 4% staking gel and pour on top of the 
separating gel. Insert the well-comb and wait 20 min for solidification. 
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Cytosine Deaminase Activity Assay 
1. Prepare stock of 0.5 mg/mL of 5-FC diluted in PBS buffer (8 g/L NaCl, 1.15 g/L 
Sodium Phosphate Dibasic, 0.2 g/L KCl, 0.2 g/L Potassium Phosphate 
Monobasic, pH 7.4). 
2. Add 775 µL of PBS to the appropriate number of microcentrifuge tubes where 
reaction will take place. 
3. Add 225 µL of enzyme sample to the tubes.  (The following dilution example 
can be done for a 4.5x dilution: add 50 µL enzyme sample + 175 µL PBS.  
When doing a dilution, add the PBS prior to enzyme sample). 
4. Incubate the reaction at 37oC for 30 minutes. 
5. Remove 50 µL of sample and quench it in 1 ml of 0.1 N HCl. 
6. Transfer 250 µL to a clear 96-well plate.  
7. Read absorbance at 255 & 290 nm using a microtiter plate reader. 
Definition of unit:  One unit of enzyme is defined as the amount of enzyme that forms 1 
µmol 5-FU per min at 37°C.  In a 30 minute enzymatic reaction, 1 U of undiluted 
enzyme would produce 30 µmol in 225 µL of undiluted enzyme sample, hence the 
concentration of 5-FU, determined from the absorbances and the equation below, can be 
multiplied by 0.148 (determined by 
 
       
 
 
      
 
       
   
) to obtain activity (U/mL). 
[5-FU]                            
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Purine Nucleoside Phosphorylase Activity Assay 
1. Make solutions for assay. 
 100 mM Potassium Phosphate pH 7.4 
o 0.13609 g Photassium phosphate monobasic 
o 10 mL DI 
 Adjust pH to 7.4 
 7.5 mM Inosine 
o 0.00201 g Inosine 
o 1 mL DI 
 10 U/mL xanthine oxidase 
 Aliquot to 100 uL vials upon arrival 
 Keep solution on ice 
 PNP solution (roughly .125 U/mL) 
o Note: need roughly 0.005 mg/mL protein 
o Keep solutions on ice 
2. Combine reagents (except PNP), mix well by inversion, and allow to reach room 
temperature. 
Table 20.  PNP activity assay components 
Buffer 270 µL 
Inosine 10 µL 
Xanthine Oxidase 10 µL 
PNP 10 µL 
 
3. Add to appropriate wells in a 96 well plate. 
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4. Perform kinetic run (A = 293 nm) on plate reader for 3 min or until values are 
constant. 
5. Add PNP solution (DI for blanks). 
6. Perform kinetic run for 5 min (A = 293 nm). 
7. Use maximum linear rates to determine slope. 
Definition of unit:  One unit of enzyme is defined as the phosphorolysis of 1.0 µmol of 
inosine to hypoxanthine and ribose 1-phosphate per min at pH 7.4 and 25°C.  The 
difference between rate of change of absorbance (uric acid), the uric acid millimolar 
extinction coefficient at 293 nm (12.0), and PNP concentration is used to calculate 
specific activity. 




        
    
          
   




Methionine-γ-Lyase Activity Assay 
1. Make solutions for assay. 
 Buffer: 0.05 M Potassium Phosphate, 0.02 mM PLP 
o 50 mL DI 
o 0.435 g potassium phosphate dibasic 
o 500 uL 100X PLP (24.2 mg in 50 ml) 
 pH to 8 
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 0.1 M L-methionine 
o 3 mL buffer 
o 0.04476 g L-methionine 
 50% (w/v) trichloro-acetic acid 
o 10 mL DI 
o 5.0 g trichloro-acetic acid 
 1 M Sodium Acetate 
o 30 mL DI 
o 2.46 g sodium acetate 
 pH to 5 
 0.1% 3-Methyl-2-benzo-thiazolinone hydrazone hydrochloride hydrate 
(MBTH) 
o 15 mL DI 
o 15 mg MBTH 
2. Mix: 
 125 L of buffer 
 125 L of L-methionine solution  
 200 L of enzyme sample (dilutions in buffer) [Note: blank with buffer 
only] 
3. Incubate the mixture at 37°C for 10 min. 
4. Add 62.5 L of 50 % (w/v) trichloro-acetic acid to terminate the reaction of 
Methioninase  
5. Centrifuge at maximum speed for 2 min. 
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6. Mix in transparent 96-well plate 
 65.8 L of the supernatant  
 131.6 L of sodium acetate 
 52.6 L of MBTH 0.1% (= 1 mg/ml MBTH).  MBTH reacts with the 
ketobutyrate to produce the color change that we measure. 
7. Incubate at 50°C for 30 min (PCH-2 Peltier Cooler/Heater, Grant-bio). 
8. Add 250 µL of sample to 96 well plate and measure the absorbance at 320 nm 
against the blank using a microtiter plate reader.  
 
 
Figure 67.  Standard curve for methioninase assay using α-ketobutyrate 
and MTBH. 
 
Definition of unit: One unit of enzyme is defined as the amount that catalyzes the 
formation of 1 μmol of  α-ketobutyrate per minute. Specific activity is expressed as 




(               )(       )




Chromogenic Limulus Amebocyte Lysate Endotoxin Assay 
The principle used to determine endotoxin quantities is the following:  Step 1: a 
proenzyme is converted to an enzyme by the endotoxin.  Step 2: the enzyme converts a 
substrate + water to a peptide and p-nitroaniline.  The p-nitroaniline is then measured at 
405 nm, and an endotoxin concentration can be calculated from a standard curve made 
using known amounts of E. coli endotoxin.   
 
1. Reconstitute 1 vial containing lyophilized Limulus Amebocyte Lysate using 1.4 
ml reagent water/vial of LAL.  Once reconstituted, it is stable up to 1 week 
when stored at -20
o
C immediately following reconstitution.  Thaw and use only 
once.  Keep in a dark place.  
2. Reconstitute the E. coli endotoxin vial using 1.0 ml of LAL Reagent Water 
warmed to room temperature.  Prior to use, vigorously mix for 15 minutes 
because the endotoxin tends to attach to glass.  Our kit contained 30 EU of 
lyophilized endotoxin.  Once reconstituted, it is stable for 4 weeks when stored 
at 4
o
C.  Keep in a dark place. 
3. Reconstitute the chromogenic substrate by adding 6.5 ml of LAL Reagent Water 
to obtain a final concentration of roughly 2 mM.  Once reconstituted, it is stable 
for 4 weeks when stored at 4
o
C.  Keep in a dark place. 
4. Prepare the stop reagent => 10 g Sodium Dodecyl Sulfate (SDS) in 100 ml of DI 
Water.   
5. Prepare the endotoxin sample dilutions that will be used to construct the 
standard curve.  Make dilutions in glass tubes.   
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1.0 0.1 ml - (30-1)/10 ml = 
2.9 ml 
0.5 - 0.5 ml 0.5 ml 
0.25 - 0.5 ml 1.5 ml 
0.1 - 0.1 ml 0.9 ml 
 
* NOTE: the bottom 3 standards are made from the 1.0 EU/ml solution made 
first.   Vigorously vortex each dilution for at least 1 minute before proceeding to 
the next dilution.  Also 30 EU is variable depending on the kit received – check 
literature with product for proper value to use.   
 
6. Using a clear 96-well plate, add 50 µl of each standard and diluted sample into 
appropriate wells (running all samples in triplicate).   Starting dilution is 1:10 
dilution of each sample, followed by 1:100 and 1:1000.  The BLANK wells 
should receive 50 µl of LAL Reagent Water in place of sample.  When adding to 
wells, use the same pattern of addition throughout the assay to be consistent.   
7. Add 50 µl of LAL to each well and then tap on the side of the plate to facilitate 
mixing.   
8. Incubate for 10 minutes at 37oC. 
9. Add 100 µl of substrate solution (pre-warmed to 37oC) to each well.  Tap the 
side of the plate to facilitate mixing. 
10. Incubate for 6 minutes at 37oC. 
11. Add 50 µl of stop reagent (SDS).  Tap the side of the plate to facilitate mixing.   




1. Dissolve biotin (SureLINK Chromophoric Biotin) in anhydrous DMF 
immediately prior to use at 20 mg/ml. 
2. Using a 60-fold molar excess of biotin for conjugation, add the appropriate 
volume of 20 mg/ml SureLINK Chromophoric Biotin to the protein solution 
(should be at 0.2-5.0 mg/ml). 
Note:  % DMF of total reaction volume should be < 5% 
3. Incubate at 4oC for 4 hours with gentle agitation. 
4. Remove the unconjugated biotin by dialysis using a 3.5-5.0 kDa membrane in 
2L 1X modification buffer. Run dialysis for 4 hours. Change dialysate and run 
another dialysis for 4 hours.  Change dialysate and run another overnight.  Done 
at 4
o
C with gentle stir. 
 Dialysis Buffer (2 L) 
o 100 mM sodium phosphate dibasic ( use 28.392 g) 
o 150 mM NaCl (use 17.532 g) 
 pH to 7.3 
5. Flash freeze in liquid nitrogen and store at -80oC in the dark.      
Determine Degree of Biotinylation 
6. Perform Bradford assay to determine [biotinylated protein] (mg/ml) and 
calculate molar concentration. 
a. [Protein] = (mg/ml)/MW 
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7. Measure absorbance of biotinylated protein at 280 and 354 nm in plate reader 
(must be between 0.05 and 2 – dilute if necessary). 
8. Calculate biotin concentration. 
a. [Biotin] = (D*A354)/(29000*L) 
b. 290000: molar extinction coefficient 
c. L: pathlength (1) 
9. MSR = [Biotin] / [Protein] 
 
DyLight 680 Conjugation 
1. To protect reagents from moisture, allow DyLight NHS Esters and DMF to 
equilibrate to room temperature before opening the vials. 
2. Add 100 μL of DMF to the DyLight NHS Ester. Pipette up and down or vortex 
until it is completely dissolved. 
Note: Allow the dye to completely dissolve for 5 minutes and then vortex again.  
3. Suspend fusion protein in 0.05 M sodium borate buffer, pH 8.5 (or 0.1 M 
sodium phosphate, 0.15 M NaCl, pH 7.2-7.5) to be in the range of 1-10 mg/mL.   
4. Transfer the appropriate amount of reagent (based on calculations) to the 
reaction tube containing the protein. Mix well and incubate at room temperature 




Calculate the amount (mg) of DyLight NHS Ester Dye to be added to the 
labeling reaction:  
   
                        (  )
             
                                 
=  
                      
Ex: .5 mg/ 330000 g/mol * 10 * 950 g/mol * 100 µL/mg = 1.4 µL 
[Dylight 680 has a molecular weight of 950 g/mol] 
  
Calculate the microliters of NHS-ester dye solution to add to the reaction:  
                     (                         )  
      
   
  
=  
      µL                 -                          
 
5. Remove non-reacted reagent from the protein by dialysis against 2 L of 20 mM 
sodium phosphate dibasic pH 7.4, using a 12-14k MWCO dialysis membrane 
for 4 hr at 4
o
C.  (5.678 g for 2 L DI H2O). 
Note: Wrap the beakers being used for dialysis to protect the DyLight 680 from 
the light. 








8. Remove labeled protein sample from dialysis cassette.  Store at 4oC protected 
from light or lyophilize to powder and store at -80
o
C.   
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In Vitro Studies 
Binding Stability Assay 
1. [Day -1] Seed 5 x 104 cells in wells on 4 plates and grow until 70-80% confluent 
(using growth medium).  Create 3 blanks (just media). 
2.  [Day 0] Add 300 µL FP suitable medium with 100 nM biotinylated FP to three 
wells on each plate. 
3. Incubate for 2 hours at 37°C. 
4. Wash 3 times with 250 µL FP suitable medium  (standard growth medium with 
supplemental 2 mM Ca
2+
). 
5. Add 1 mL FP suitable medium. 
6. [Day 0, 1, 2, 3] Take one plate (6 wells), remove medium and replace with 300 
µL FP suitable medium. 
7. Perform Alamar Blue assay 
a. Add 10% (30 uL) Alamar Blue. 
b. Incubate for 4 hours at 37°C. 
c. Transfer 250 µL to opaque 96 well plate. 
d. Measure fluorescence ( 530 nm excitation, 590 nm emmision). 
8. Wash 3 times with 250 µL FP suitable medium. 
9. Fix cells. 
a. Add 150 µL FP suitable medium with 0.25% glutaradlehyde to each 
well. 
b. Incubate for 5 min at room temperature. 
c. Remove medium. 
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d. Add 150 µL FP suitable medium with 50 mM ammonium chloride. 
e. Incubate for 5 min at room temperature. 
f. Remove medium. 
10. Wash 3 times with 250 µL FP suitable medium. 
11. Add 300 µL Streptavidin/HRP (2 µg/mL – stored in glass fridge). 
12. Incubate for 1 hour at room temperature. 
13. Wash 3 times with 250 µL FP suitable medium. 
14. Add 300 µL of the chromogenic substrate O-phenylenediamine (OPD) to each 
well. (OPD is in -20
o
C freezer in aluminum foil coated tube).  The OPD solution 
is made with phosphate citrate buffer (1 capsule in 100 mL DI water).  Prior to 
use, add 40 µL of 30% H2O2.  Weigh out the desired amount of OPD with a 
concentration of 0.4 mg/ml.   
 OPD Solution – keep out of light and use immediately 
 Add one capsule of phosphate-citrate buffer to 100 mL DI in beaker 
and stir (no more than 30 min prior to use of OPD) 
 Weigh 0.4 mg/mL OPD and place in foil coated tube (6.4 mg for 16 
mL buffer) 
 Add 40 µL of 30% H2O2 (glass fridge) to buffer 
 Mix for 30 seconds 
 Add required amount of buffer to OPD (16 mL) (use within 5 min) 
 Mix by inversion 
15. Incubate for 30 minutes at room temperature and in the dark to minimize OPD 
color change.   
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16. Transfer 100 µL of the supernatant to 96-well plates and measure absorbance at 
450 nm. 
 
Binding Strength Assay 
1. Seed 5 x 104 cells in 48 wells on 2 plates (per protein) and grow until 70% 
confluent (using growth medium).   
2. Fix the cells in all wells by adding 200 µL/well PBS buffer containing 0.25% 
glutaraldehyde for 5 min.  Remove before proceeding.    
3. Quench excess aldehyde groups by incubating with 200 µL/well of 50 mM 
NH4Cl, diluted in PBS buffer for 5 min at room temperature.  Remove after 
incubation period. 
4. Dilute biotinylated FP conjugate in 0.5% BSA diluted in PBS buffer.  Add 300 
µL to wells in Sets 1 and 2, using triplicates of each concentration.  The blank 
for each set will receive no FP.  
 Set 2 (21 wells) gets PBS + BSA + 2 mM Ca+2 + FP (varying 
concentrations) 
 Blank (3 wells) gets PBS + BSA + 2 mM Ca+2 
 Set 1 (21 wells) gets PBS + BSA + 5 mM EDTA + FP (varying 
concentrations) 
 Blank (3 wells) gets PBS + BSA + 5 mM EDTA 
5. Incubate for 2 hours at 37oC, 5% CO2. 
6. Wash 3 times with 250 µL of 0.5% BSA diluted in PBS buffer.   
 Set 2 (21 wells) gets PBS + BSA + 2 mM Ca+2 
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 Blank (3 wells) gets PBS + BSA + 2 mM Ca+2 
 Set 1 (21 wells) gets PBS + BSA + 5 mM EDTA 
 Blank (3 wells) gets PBS + BSA + 5 mM EDTA  
7. Add 300 µL of Streptavidin-HRP (2 µg/mL) and incubate for 1 hour at room 
temperature. (Streptavidin-HRP is in 4
o
C glass fridge)  
8. Wash 4 times with 250 µL of PBS buffer.   
 Set 1 (21 wells) gets PBS + 5 mM EDTA 
 Blank (3 wells) gets PBS + 5 mM EDTA  
 Set 2 (21 wells) gets PBS + 2 mM Ca+2  
 Blank (3 wells) gets PBS + 2 mM Ca+2 
9. Add 300 µL of the chromogenic substrate O-phenylenediamine (OPD) to each 
well. (OPD is in -20
o
C freezer).  The OPD solution is made with phosphate 
citrate buffer (1 capsule in 100 ml DI water).  Prior to use, add 40 µL of 30% 
H2O2.  Weigh out the desired amount of OPD with a concentration of 0.4 mg/ml.   
 Add one capsule of phosphate-citrate buffer to 100 mL DI in beaker 
and stir (no more than 30 min prior to use of OPD) 
 Weigh .4 mg/mL OPD and place in foil coated tube (6.4 mg for 16 
mL buffer) 
 Add 40 µL of 30% H2O2 (glass fridge) to buffer 
 Mix for 30 seconds 
 Add required amount of buffer to OPD (16 mL) (use within 5 min) 
 Mix by inversion 
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10. Incubate for 30 minutes at room temperature and in the dark to minimize OPD 
color change.   
11. Transfer 100 µL of the supernatant to 96-well plates. 
12. Measure absorbance at 450 nm.   
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Fixed Cell Confocal Microscopy 
1. Plate cells on chambered slide or coverslip in petri dish. 
2. Fix cells  
a. Fix the cells in all wells by adding 200 µL/well PBS buffer containing 
0.25% glutaraldehyde and 2mM Ca
2+
 for 5 min.  Remove before 
proceeding.    
b. Quench excess aldehyde groups by incubating with 200 µL/well of 50 
mM NH4Cl, diluted in PBS buffer for 5 min at room temperature.  
Remove after incubation period. 
3. Incubate the cells with 100 nM biotinylated FP/SWNT with calcium 
supplementation and 0.5% BSA. 
4. Rinse cells with PBS + Ca 
5. Add Streptavidin-Alexa 488 at 4 µg/mL (stored at 20 µg/mL) for 1 h 
6. Stain the cells with CellMask plasma membrane stain (stored at 10 µg/mL) at 2 
µg/mL.  Submerge in stain solution for 5 min at 37°C, rinse and repeat 3 times 
7. Stain cells with Hoechst 33258 for 30 min at 10 µg/mL. 
8. Wash cells with medium and allow to air dry. 
9. Attach coverslip to slide with fluorogel. 
10. Image with confocal Leica SP8 microscope. 
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Live Cell Confocal Microscopy 
1. Grow cells to 70% confluence in 35 mm petri dish under standard growth 
conditions. 
2. Add growth medium with 2 mM Ca2+ for fusion protein binding and 1 µM DAPI 
(membrane impermeable) to distinguish live and dead cells. 
3. Maintain 37°C using a Peltier stage and image prior to adding fusion protein. 
4. Add fusion protein conjugated to Dylight 680 to petri dish and continue imaging 
for 2 h. 
5. Wash cells 6 times with the calcium and DAPI supplemented growth medium. 




1. [Day -1] Seed cells on 24-well plates and grow them until they reach 70-80% 
confluence using growth medium. 
Note:  Methioninase systems require the separation of experimental groups on different 
plates to avoid effects of gaseous methylselenol. 
2. Incubate for 24 hours. 
3. [Day 0, 1, 2, 3] Replace growth medium with 300 µL of FP suitable medium (standard 
growth medium with supplemental 2 mM Ca
2+
).  Perform an Alamar Blue assay to 
determine cell viability. 
a. Add 10% (30 µL) of Alamar Blue. 
b. Incubate for 4 hours at 37°C. 
c. Transfer 250 µL to an opaque 96-well plate 
d. Read fluorescence: excitation – 530 nm; emission – 590 nm. 
e. NO CELLS well is blank, 0 µM on 2 plates without FP is 100% viability 
4. [Day 0] Wash 3 times using 300 µL of FP suitable medium. 
5.  [Day 0] Add 300 µL of FP suitable media containing 100 nM fusion protein to 21 
wells.   
6.  [Day 0] Incubate for 2 hours at 37°C. 
7. [Day 0, 1, 2, 3] Wash 3 times using 300 µL of FP suitable medium. 
8. [Day 0, 1, 2, 3] Remove medium from wells.  Add 300 µL /well of FP suitable medium 




In Vivo Studies and Follow-up Analysis 
Protein Specific Antibody Titers 
Sample collection 
1. Collect samples at week 0, 1, 2, 3. 
2. Collect 3 drops of blood (about 150 µL) from mice (submandibular bleed) and 
isolate plasma using capiject collection tubes. 
3. Store plasma at -80°C. 
Bioassay (Sandwich ELISA)  
1. Add 100 µL 20 ug/ml FP in 0.1 M carbonate coating buffer and incubate 
overnight at 4°C with plate cover. 
 Carbonate coating buffer 
o 0.08 g Na2CO3   
o 0.15 g NaHCO3 
o 25 mL DI 
 pH to 9.6 
2. Wash plate 2 times with 200 µL PBS. 
3. Block for 2 h at room temperature with 200 µL blocking buffer. 
 Blocking buffer 
o PBS 
o 10% FBS 
 pH to 7.4 
4. Wash plate 2 times with 200 µL PBS. 
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5. Add 100 µL of plasma samples (10x, 100x, etc. dilutions in PBS) and incubate 
overnight at 4°C. 
6. Wash plate 4 times with 200 µL PBS. 
7. Add 100 µL diluted goat anti-mouse IgG IgM conjugated to HRP and incubate 
for 1 h at room temperature. 
 HRP conjugated Rabbit anti-mouse IgG IgM (Jackson Immuno 315-035-
044) 
 Reconstitute lyophilized Ab with 1.5 mL DI and centrifuge if not 
clear 
 Dilute 1:25,000 for assay (2 µL in 50 mL PBS) 
8. Wash three times. 
9. Add 100 µL OPD, H2O2 solution and incubate for 30 min at room temperature 
in the dark. 
 Add one capsule of phosphate-citrate buffer to 100 mL DI in beaker 
and stir (no more than 30 min prior to use of OPD) 
 Weigh 0.4 mg/mL OPD and place in foil coated tube (6.4 mg for 16 
mL buffer) 
 Add 40 µL of 30% H2O2 (glass fridge) to buffer 
 Mix for 30 seconds 
 Add required amount of buffer to OPD (16 mL) (use within 5 min) 
 Mix by inversion 
10. Transfer 100 µL of the supernatant to 96-well plates. 
11. Measure absorbance at 450 nm.   
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Fusion Protein Plasma Clearance 
Sample Collection 
1. Biotinylate fusion protein. 
2. Inject 10 mg/kg IP into mice (t = 0 h controls do not receive injection). 
3. Perform cardiac draws at appropriate time (t = 0 h to 24 h). Use 3 mL 21 gauge 
needle for draw and collect in clot activating capiject blood collection vial. 
4. Allow 20 minutes for clots to form before centrifugation. 
5. Centrifuge at 3500 x g for 90 s. 
6. Remove serum with pipet and freeze (cryovial) at -80°C. 
 
Bioassay (ELISA) 
1.  Prepare biotinylated fusion protein samples for calibration curve (typically 
between 0 µg/mL and 10 µg/mL) and assay solutions. 
 Diluting Buffer (1 L) 
o 0.5 g Tween 20 (0.005%) 
o 2.5 g BSA (0.25%) 
o 1 L PBS 
 Wash Buffer 
o 5 g Tween 20 (0.05%) 
o 1 L PBS 
2.  Add 50 µL of each serum sample to wells.   Use streptavidin-coated 96 well 
plates. 
3.  Cover the plate with adhesive cover and incubate for 60 min at 37
o
C.   
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4.  Shake out the plates into a sink.  Wash the plates with wash buffer 4 times by 
adding 200 µL and shaking out the wash buffer into a sink.  Pat plates dry by 
inverting on paper towel.   
5.  Add 50 µL of Annexin V polyclonal antibody (rabbit) diluted to 1.25 µg/mL in 
diluting buffer to each well.   
6.  Cover the plate with adhesive cover and incubate for 60 min at 37
o
C.   
7.  Shake out the plates into a sink.  Wash the plates with wash buffer 4 times by 
adding 200 µL and shaking out the wash buffer into a sink.  Pat plates dry by 
inverting on paper towel.   
8.  Add 50 µL of anti-rabbit IgG-HRP conjugate (secondary antibody) diluted to 
1:1,000 (initially at about 1 mg/mL) using diluting buffer to each well. 
9.  Cover the plate with adhesive cover and incubate for 60 min at 37
o
C.   
10.  Shake out the plates into a sink.  Wash the plates with wash buffer 4 times by 
adding 200 µL and shaking out the Wash buffer into a sink.  Pat plates dry by 
inverting on paper towel.   
11.  Add 50 µL of OPD solution to each well. 
 Add one capsule of phosphate-citrate buffer to 100 mL DI in beaker 
and stir (no more than 30 min prior to use of OPD) 
 Weigh 0.4 mg/mL OPD and place in foil coated tube (6.4 mg for 16 
mL buffer) 
 Add 40 µL of 30% H2O2 (glass fridge) to buffer 
 Mix for 30 seconds 
 Add required amount of buffer to OPD (16 mL) (use within 5 min) 
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 Mix by inversion 
12.  Cover the plate with adhesive cover and incubate for 30 minutes at room 
temperature in the dark.   
13.  Read absorbance at 450 nm.   
 
Fluorescent Lung Metastasis Image Processing and Quantification 
An automated image processing macro was developed in ImageJ (National 
Institutes of Health) to clean up fluorescence images of whole lungs removed from 
BALB/cJ mice.  The macro code is included below.  Image cleanup first occurs through 
the subtraction of a Gaussian blur of the fluorescence image from the fluorescence 
image to highlight the high frequency information, particularly to separate fluorescence 
signal from background noise.  A median filter is then applied to remove speckling 
from the image.  User input is requested to select the region of interest, specifically to 
avoid analysis of lung boundary regions which are also high frequency information.  
User input is also requested to finalize the automated thresholding to ensure appropriate 
processing.  The “Analyze Particles” function in ImageJ (FIJI build) is then utilized to 
identify and quantify nodules based on size and circularity.   
//begin of ImageJ lung nodule processing macro 
//JJ Krais – July 21, 2014 
 
input = "enter input file path here (use’\\’ in place of ‘\’)"; 




//Go through image directory, apply 'action' to directory 
one at a time. 
list = getFileList(input); 
for (i = 0; i < list.length; i++) { 
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  current_image="";  
  print("processing image #" + i+1 + " of " + list.length);      
   image_cleanup(input, output, list[i]); 
  print("image cleanup complete"); 
   user_inputs(output); 
  print("beginning nodule analysis"); 





function image_cleanup(input, output, filename)   { 
     
    //Open file and apply Gaussian Blur 
    open(input + filename); 
    print("blurring..."); 
    run("Gaussian Blur...", "sigma=40"); 
    output_file = "blur " + filename; 
    saveAs("Tiff", output + output_file); 
    close(); 
     
 //Re-open images, this is necessary for image calculator       
to work. 
    open(input + filename); 
    open(output + output_file); 
    wait(100); 
     
    //Subtract blurred image from original 
    print("subtracting blur..."); 
    imageCalculator("Subtract create", filename,output_file); 
    selectWindow("Result of " + filename); 
    current_image = filename + "-background subtracted"; 
     
    //Save and close all images 
    saveAs("Tiff", output + current_image); 
    close(); 
    selectWindow(filename); 
    close(); 
    wait(100); 
    selectWindow(output_file); 
    close(); 
 
    //reopen and apply median filter 
   print("removing speckling..."); 
   open(output + current_image + ".tif"); 
   run("Median...", "radius=20"); 
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   selectWindow(current_image +".tif"); 
   current_image=current_image + "-despeckled"; 
   saveAs("Tiff", output + current_image); 
   wait(100); 
   close(); 
    } 
 
function user_inputs(output) { 
  open(output + current_image + ".tif"); 
 
//user selects region of interest and it is cleared 
   print("waiting on user selection..."); 
   setTool("freehand"); 
   run("Invert");     
  beep(); 
   waitForUser("Select region of interest. \nClick OK when 
complete."); 
   run("Clear Outside"); 
    
   //thresholding 
   print("waiting on user thresholding..."); 
   run("Threshold..."); 
   waitForUser("Adjust threshold value. \nClick OK when 
complete."); 
   run("Convert to Mask"); 
 
   //save 
   current_image=current_image + "-thresh"; 
   saveAs("Tiff", output + current_image); 
   wait(100); 
   close(); 
} 
 
function analyze_nodules()  { 
  open(output + current_image + ".tif"); 
 
 //analyze particles 
   run("Analyze Particles...", "size=50-Infinity 
circularity=0.20-1.00 Nothing display clear summarize add 
in_situ"); 
   roiManager("Show All with labels"); 
   roiManager("Show All"); 
   saveAs("Results", output + 
current_image+"_datafile.xls"); 
   close(); 
} 
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Immunohistochemistry Image Processing and Quantification 
An automated image processing macro was developed in ImageJ to quantify 
DAB staining on immunohistochemistry stained tumor sections counter stained with 
hematoxylin.  The macro code is included below.  The background is first subtracted 
with the ImageJ background subtraction function, and then the hematoxylin and DAB 
stains are separated using a color deconvolution.  Masks of the DAB and hematoxylin 
images are generated using a user applied threshold.  DAB positive and hematoxylin 
positive cells are quantified using the “Analyze Particles” function of ImageJ (FIJI 
build). 
//begin of ImageJ DAB quantification macro 
//JJ Krais – July 21, 2014 
 
input = "enter input file path here (use’\\’ in place of ‘\’)"; 
output = "enter output file path here (use’\\’ in place of ‘\’)"; 
var current_image=""; 
 
//Go through image directory, apply 'action' to directory one at a time. 
list = getFileList(input); 
for (i = 0; i < list.length; i++) { 
  current_image="";  
  print("processing image #" + i+1 + " of " + list.length);      
  subtract_background(input, output, list[i]); 
  print("background subtracted"); 
   
  separate_stains(output);  
  print("stains separated"); 
   
  print("beginning DAB thresholding..."); 
  stain_file=output + current_image + " DAB.tif"; 
  generate_masks(stain_file); 
  print("beginning H thresholding..."); 
  stain_file=output + current_image + " H.tif"; 
  generate_masks(stain_file); 
   
  window_name=current_image+" DAB.tif mask"; 
  mask_file=output+window_name; 
  print("quantifying DAB positive cells..."); 
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  quantify_cells(mask_file, window_name); 
  window_name=current_image+" H.tif mask"; 
  mask_file=output+window_name; 
  print("quantifying H positive cells..."); 
  quantify_cells(mask_file, window_name); 
   
  selectWindow("Summary"); 
  saveAs("Text", output + "summary.xls"); 
 
  outline_file=current_image + " DAB.tif mask outlines"; 
  create_overlay(outline_file); 
   print("file #" + i+1 + " processing is complete");  
} 
 
print("Processing complete, saving data..."); 
print("Data saved."); 
 
function subtract_background(input, output, filename)   { 
    //Open file 
    open(input + filename); 
   
    //Subtract background 
    run("Subtract Background...", "rolling=50 light separate"); 
     
    //Save and close all images 
    current_image=filename +"-bg"; 
    saveAs("Tiff", output + current_image); 
    close(); 
  } 
 
function separate_stains(output){ 
open(output + current_image + ".tif"); 
run("Colour Deconvolution", "vectors=[H DAB]"); 
selectWindow(current_image + ".tif-(Colour_3)"); 
run("Close"); 
 
selectWindow(current_image + ".tif-(Colour_2)"); 
saveAs("Tiff", output + current_image + " DAB"); 
close(); 
 
selectWindow(current_image + ".tif-(Colour_1)"); 
saveAs("Tiff", output + current_image + " H"); 
close(); 
 















 print("waiting on user thresholding..."); 
 run("Threshold..."); 
 waitForUser("Adjust threshold value. \nClick OK when complete."); 
 run("Convert to Mask"); 
 









run("Analyze Particles...", "size=75-Infinity circularity=0.30-1.00 
show=[Bare Outlines] display clear summarize"); 
 
selectWindow("Drawing of " + window_name +".tif"); 
saveAs("Tiff", mask_file + " outlines"); 
close(); 
 














run("Enhance Contrast", "saturated=0.35"); 
 
saveAs("TIff", output+current_image+" DAB selection overlay.tif"); 
close(); 
 




Quantification of Regulatory T Cells in Spleen 
1. Mechanically separate spleen in petri dish using a syringe (3 mL) plunger. 
2. Add 7 mL FACS buffer (PBS, 10% FBS, 0.1% NaN3 Sodium Azide; make 
ahead of time – alternatively use FACS buffer in kit). 
3. Pass cells through cell strainer (70 µm) and rinse strainer with 3 mL FACS 
buffer. 
4. Centrifuge 5 min at 1100 x g at 4°C and discard supernatant. 
5. Wash cells with 1 mL flow cytometry staining buffer, count cells, centrifuge. 
6. Resuspend cells in 1 mL flow cytometry staining buffer to get ~10 million 
cells/mL  (Should be about 1mL). 
7. Add 0.5 µg anti-mouse CD16/CD32 to 50 µL sample in flow cytometry staining 
buffer for blocking and incubate for 20 min at 4°C  
8. Make anti-CD4 and anti-CD25 mix solution using 0.125 µg CD4 and 0.06 µg 
per sample in 50 µL per sample and add 50 µL antibodies to 50 µL cells 
9. Vortex gently to mix and incubate at 4°C for 30 min. 
10. Wash cells twice in flow cytometry staining buffer.  Add 1 mL staining buffer, 
centrifuge 1100 x g for 5 min, discard supernatant, and repeat. 
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11. Discard supernatant and gently pulse vortex the pellet to cause dissociation of 
the pellet. 
12. Add 1 mL Foxp3 fixation/permeabilization working solution to each tube and 
pulse vortex. 
 Dilute Foxp3 fixation/permeabilization concentrate with Foxp3 
fixation/permeabilization diluent  in 1:3 ratio to get working solution  
13. Incubate 1 h at 4°C in dark. 
14. Add (do not wash) 1 mL 1x permeabilization buffer. 
 Dilute 10x concentrate with DI 
15. Centrifuge at 1100 x g for 5 min. 
16. Resuspend pellet in 100 µL 1x permeabilization buffer (usually the remaining 
volume). 
17. Add (do not wash) 0.5 µg (2.5 µL) anti-Foxp3 (or isotype control PE) to each 
sample and incubate in dark for 30 min at room temperature. 
18. Add 1 mL 1x permeabilization buffer to each tube. 
19. Centrifuge at 1100xg for 5 min and discard supernatant. 
20. Add 1 mL 1x permeabilization buffer to each tube. 
21. Centrifuge at 1100 x g for 5 min and discard supernatant. 
22. Add 1 mL flow cytometry staining buffer. 
23. Centrifuge at 1100 x g for 5 min and discard supernatant. 
24. Resuspend cells in flow cytometry staining buffer (add 350 µL to residual 
volume for total volume of 400-500 µL) and acquire data on flow cytometer. 
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Appendix C: Fusion Gene Construction 
PNP-AV Primers 
PNP and AV Amplification Primers 
PNP gene sense primer: 
5’-GAC GAC GAC AAG ATG CCC GCT ACC CCA CAC ATT AAT GCA G-3’ 
 
PNP gene antisense primer: 
5’-CGC G|GA TCC AGA ACC GGA GCC CTC TTT ATC GCC CAG CAG AAC-
3’ 
 
Annexin V sense primer: 
5’-CGC G|GA TCC GCA CAG GTT CTC AGA GGC-3’ 
 
Annexin V antisense primer: 
5’-GA GGA GAA GCC CGG TTA GTC ATC TTC TCC ACA GAG C-3’ 
 
Legend:  Gene complementary region, BamHI restriction site (cut indicated |), linker 
segment 
 
PNP-AV Fusion Primers 
 
Fusion gene sense primer: 
5’-CGC T|CT AGA ATG GCT ACC CCA CAC ATT AAT GCA G-3’ 
 
Fusion gene antisense primer: 
5’-CGC C|TCGAG CGG ACC CTG GAA CAG AAC TTC CAG GTC ATC TTC TCC 
ACA GAG CAG C-3’ 
 
Legend:  Gene complementary region, Xba1 (sense) restriction site (cut indicated |) or 


































Legend:  PNP, linker, AV, HRV-3C protease site, 6X His-tag 
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Legend:  PNP, linker, AV, HRV-3C protease site, 6X His-tag 
 













Legend:  PNP, linker, AV 
 
PNP-AV NCBI BLAST Results 
Table 22.  NCBI BLAST Result Summary for PNP-AV 
Protein Species Ident Accession 
Annexin A5 Homo sapiens 100% NP 001145.1 




Mutant CGL Sequences 
Engineered Mouse and Human CGL Sequence Comparison 
Table 23.  mCGL and hCGL NCBI BLAST Results and Sequences with 
Highlighted Site of Mutation 
Protein Species Ident Accession 
Cystathionine γ-lyase Mus musculus 
Homo sapiens 
99% NP 666065.1 
AAB24700.1 
    
 Identities Positives Gaps 
 340/397 (86%) 364/397 (91%) 0/397 (0%) 
Query (mCGL; wild type) 
Subjct (hCGL; wild type) 
 
   
Query  2    
QKDASLSGFLPSFQHFATQAIHVGQEPEQWNSRAVVLPISLATTFKQDFPGQSSGFEYSR  61 
EKDASSQGFLPHFQHFATQAIHVGQDPEQWTSRAVVPPISLSTTFKQGAPGQHSGFEYSR  62 
Sbjct  3 
     
Query  62   
SGNPTRNCLEKAVAALDGAKHSLAFASGLAATITITHLLKAGDEIICMDEVYGGTNRYFR  121 
SGNPTRNCLEKAVAALDGAKYCLAFASGLAATVTITHLLKAGDQIICMDDVYGGTNRYFR  122 
Sbjct  63    
 
Query  122  
RVASEFGLKISFVDCSKTKLLEAAITPQTKLVWIETPTNPTLKLADIGACAQIVHKRGDI  181 
QVASEFGLKISFVDCSKIKLLEAAITPETKLVWIETPTNPTQKVIDIEGCAHIVHKHGDI  182 
Sbjct  123   
 
Query  182  
ILVVDNTFMSAYFQRPLALGADICMCSATKYMNGHSDVVMGLVSVNSDDLNSRLRFLQNS  241 
ILVVDNTFMSPYFQRPLALGADISMYSATKYMNGHSDVVMGLVSVNCESLHNRLRFLQNS  242 
Sbjct  183   
 
Query  242  
LGAVPSPFDCYLCCRGLKTLQVRMEKHFKNGMAVARFLETNPRVEKVVYPGLPSHPQHEL  301 
LGAVPSPIDCYLCNRGLKTLHVRMEKHFKNGMAVAQFLESNPWVEKVIYPGLPSHPQHEL  302 
Sbjct  243   
 
Query  302  
AKRQCSGCPGMVSFYIKGALQHAKAFLKNLKLFTLAESLGGYESLAELPAIMTHASVPEK  361 
VKRQCTGCTGMVTFYIKGTLQHAEIFLKNLKLFTLAESLGGFESLAELPAIMTHASVLKN  362 
Sbjct  303   
 
Query  362   
DRATLGINDTLIRLSVGLEDEQDLLEDLDRALKAAHP  398 
DRDVLGISDTLIRLSVGLEDEEDLLEDLDQALKAAHP  399 
Sbjct  363   
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Mutant mCGL Sequence and NCBI BLAST Results 
Table 24.  Mutant mCGL NCBI BLAST Results and Sequence with Highlighted 
Mutations 
Protein Species Ident Accession 
Cystathionine γ-lyase Mus musculus 99% NP 666065.1 
    
 Identities Positives Gaps 
 395/398 (99%) 395/398 (99%) 0/398 (0%) 
Query (mutant) 
Subjct (wild type) 
 
   
Query  1    
MQKDASLSGFLPSFQHFATQAIHVGQEPEQWNSRAVVLPISLATTFKQDFPGQSSGFNYS  60 
MQKDASLSGFLPSFQHFATQAIHVGQEPEQWNSRAVVLPISLATTFKQDFPGQSSGFEYS  60 
Sbjct  1 
 
Query  61   
RSGNPTRNCLEKAVAALDGAKHSLAFASGLAATITITHLLKAGDEIICMDEVYGGTNLYF  120 
RSGNPTRNCLEKAVAALDGAKHSLAFASGLAATITITHLLKAGDEIICMDEVYGGTNRYF  120 
Sbjct  61 
 
Query  121  
RRVASEFGLKISFVDCSKTKLLEAAITPQTKLVWIETPTNPTLKLADIGACAQIVHKRGD  180 
RRVASEFGLKISFVDCSKTKLLEAAITPQTKLVWIETPTNPTLKLADIGACAQIVHKRGD  180 
Sbjct  121   
 
Query  181  
IILVVDNTFMSAYFQRPLALGADICMCSATKYMNGHSDVVMGLVSVNSDDLNSRLRFLQN  240 
IILVVDNTFMSAYFQRPLALGADICMCSATKYMNGHSDVVMGLVSVNSDDLNSRLRFLQN  240 
Sbjct  181 
   
Query  241  
SLGAVPSPFDCYLCCRGLKTLQVRMEKHFKNGMAVARFLETNPRVEKVVYPGLPSHPQHE  300 
SLGAVPSPFDCYLCCRGLKTLQVRMEKHFKNGMAVARFLETNPRVEKVVYPGLPSHPQHE  300 
Sbjct  241   
 
Query  301  
LAKRQCSGCPGMVSFYIKGALQHAKAFLKNLKLFTLAVSLGGYESLAELPAIMTHASVPE  360 
LAKRQCSGCPGMVSFYIKGALQHAKAFLKNLKLFTLAESLGGYESLAELPAIMTHASVPE  360 
Sbjct  301   
 
Query  361   
KDRATLGINDTLIRLSVGLEDEQDLLEDLDRALKAAHP  398 
KDRATLGINDTLIRLSVGLEDEQDLLEDLDRALKAAHP  398 







mCGL Fusions Gibson Fragments 
The mCGL fusion proteins, mCGL-AI and mCGL-AV, were each constructed 
via Gibson Assembly using three fragments each and assembled directly into the vector 
(pET-30 Ek/LIC).  The first fragment consists exclusively of the vector overlap and 
mCGL and therefore was able to be used for both fusions.  Underlined regions indicate 
overlapping sections of fragment, either with the adjacent fragment or vector sequence.  
Fragment overlaps were designed at 40 bp according to manufacturer recommendations 




mCGL-AI Gibson Fragments 
















































mCGL-AV Gibson Fragments 
















































mCGL Fusions Sequencing Primers and Sequences 
Sequencing primers are indicated with underlines on the fusion gene to indicate 
the sequencing approach.  In addition to the underlined primers indicated below, the 
sequencing facility at Oklahoma Medical Research Foundation provided T7 promoter 
and T7 terminator primers.  All primers are oriented in the forward direction for 
simplicity of analysis, with the exception of the T7 terminator primer.  Primer spacing 
was optimized to 350-500 base pairs to ensure accuracy and maximize reuse of primers 
for mCGL-AI and mCGL-AV.  Primers were designed using Gene Designer software 
(DNA 2.0; Menlo Park, CA) and analyzed with OligoAnalyzer 3.1 (Integrated DNA 
Technologies) to the following specifications: melting temperature of 55-50°C, length 
of 18-24 base pairs, no hairpins with a melting temperature >50°C, no self-dimers with 









































































































Legend:  6X His-tag,  HRV-3C protease site, mCGL, linker, AV  


















Legend:  6X His-tag,  HRV-3C protease site, mCGL, linker, AI  
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Legend:  mCGL, linker, AV 





















mCGL-AV NCBI BLAST Results 
For details regarding 99% identity, see the mutations outlined in Table 24, also 
in Appendix C: Fusion Gene Construction. 
Table 25.  NCBI BLAST Result Summary for mCGL-AV 
Protein Species Ident Accession 
Cystathionine-γ-lyase Mus musculus 99% NP 666065.1 
Annexin A5 Mus musculus 100% NP 033803.1 
 
mCGL-AI NCBI BLAST Results 
For details regarding 99% identity, see the mutations outlined in Table 24, also 
in Appendix C: Fusion Gene Construction. 
Table 26.  NCBI BLAST Result Summary for mCGL-AI 
Protein Species Ident Accession 
Cystathionine-γ-lyase Mus musculus 99% NP 666065.1 
Annexin A1 Mus musculus 100% NP 034860.2 
 
 
 
